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The unicellular parasite of the genus Trypanosoma infects a number of mammalian species 
including livestock and humans. In sub-Saharan Africa three main parasitic species cause 
disease: Trypanosoma brucei, T. congolense and T. vivax. The lack of sensitive diagnosis 
and increased drug resistance leaves an avenue in trypanosome research for exploring 
novel virulence factors as diagnostic and chemotherapeutic agents. The work reported in 
this dissertation involved investigation of the identified virulence factor, the Major Surface 
Protease (MSP), of African trypanosomes. The MSPs comprise a group of metalloproteases 
which have been found in over 13 Leishmanian species, T. cruzi, T. brucei and 
T. congolense as well as other Kinetoplastids.  
In this study, putative M8 metalloprotease sequences were also identified in the T. vivax 
genome. These putative sequences were grouped into four classes of protein, TvMSP-A, -C, 
-D and -E by phylogenetic comparison with other MSPs. Three-dimensional modelling 
showed high structural identity with leishmanolysin from Leishmania major. The T. vivax 
MSP sequences were used, in conjunction with T. brucei and T. congolense sequences, to 
select immunogenic peptide regions to produce anti-peptide antibodies. Three peptides were 
selected with the intention to 1) detect both TbMSP-B and TcoMSP-B (peptide 
Tb/TcoMSP:303-314, cross-species), 2) detect only TbMSP-C (peptide TbMSP:400-412) 
and 3) detect only TvMSP-C (peptide TvMSP:686-697). They were used to generate two 
types of detection molecules: complete IgY anti-peptide antibodies and single chained 
fragments (scFvs), with the capability to detect the peptide in an ELISA format. Single scFv 
expressing E. coli colonies were successfully selected and shown to detect two 
(Tb/TcoMSP:303-314 and TbMSP:400-412) of the three peptides. The anti-peptide 
antibodies, produced in chickens, were used to successfully detect native MSP within 
T. brucei and T. congolense parasite lysates; however, cross-reactivity between species was 
seen. 
The T. brucei MSP-C class of protease was successfully cloned, expressed and purified, 
although, numerous truncated proteins and gene mutations occurred [truncated 
(t)TbMSP-C]. The expression constructs rTbMSP-C and rTcoMSP-C were hence 
synthesised. These two enzymes were successfully expressed and purified and were shown 
to form high molecular weight multimers. Furthermore, the enzymes were able to cleave the 
peptide substrate H-Suc-Leu-Tyr-AMC with acidic pH optima and activity was inhibited with 
metalloprotease inhibitors, EDTA and 1,10 phenanthroline.  
v 
 
The successful detection of rTcoMSP-C by T. congolense infected cattle sera was also 
observed. tTbMSP-C, rTbMSP-C and rTcoMSP-C were detected with the chicken anti-
peptide antibodies and it was again found that these antibodies cross-reacted with different 
species MSPs. The high identity shared between MSPs from all Trypanosoma species made 
selecting species-specific antibodies difficult. 
Further work to detect native MSP-C protease within infected sera or blood would give a 
definitive conclusion of its use in diagnostics. Moreover, antibodies that detect just T. brucei 
and T. congolense still need to be produced. Preliminary activity assays were performed on 
rTbMSP-C and rTcoMSP-C but, additional research on the kinetics of these proteases is still 
needed. 
In summary, it was shown that MSPs have the potential to be novel diagnostic markers 
especially for cross-trypanosomal species detection. Furthermore, activity of rTbMSP-C and 
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Chapter 1 Literature Review 
The Trypanosome Parasites and their Major Surface Proteases. 
1.1 History of Trypanosomiasis 
In the early 1900s two Congolese patients were shipped to London for observation and 
treatment of an unknown disease to which they succumbed. Mott conducted autopsies of 
their brains and identified many abnormalities including large abnormal plasma cells later 
known as the "morula cells of Mott" (Mott, 1908). This marks the first study done on humans 
suffering from human African trypanosomiasis (HAT-sleeping sickness); however, it took 
another four years to connect sleeping sickness with trypanosomes.  
In the mid 1800s trypanosome parasites were identified in frogs (Kudo, 1922) and trout 
(Valentin, 1841)  and in 1843, Gruby denoted the genus Trypanosoma (Gruby, 1843; Hoare, 
1964). It was not until 1901 that live parasites were identified in a man suffering from 
recurring fever in Gambia (Baker et al., 1902). Dutton identified the parasites as 
trypanosomes and in his publication in 1902 named them Trypanosoma gambiense (Dutton, 
1902).  
Only after Castellani’s 1903 studies on the parasites morphology was it determined that 
T. gambiense (from trypanosome fever patients) and the parasites (from sleeping sickness) 
are of the same genus (Manson et al., 1903; Steverding, 2008). These parasites were 
named T. ugandensis and Castellani hypothesised that sleeping sickness and trypanosome 
fever are the same disease.  
After large numbers of cattle deaths in Zululand in the late 19th century, Sir David Bruce was 
asked to investigate the cause of the disease. In 1894, he showed in a series of experiments 
that tsetse flies (Glossina spp.) were able to transfer the disease from an infected dog to a 
healthy dog and that all infected animals had small parasites in their blood (Bruce, 1895). He 
gave definitive proof that the disease was transferred by the insect vector. This parasite was 
later named Trypanosoma brucei brucei (Steverding, 2008).  
Bruce also did extensive comparisons of parasites from Uganda and Gambia and 
determined that they were identical proving finally that sleeping sickness and trypanosome 




1.2 Classification of Trypanosomes 
Trypanosomes are protozoan parasites that cause diseases in both humans and animals 
(Uilenberg, 1998). Generally, their life cycle involves stages in both insect vector and 
mammalian host. Trypanosome parasites belong to the order Kinetoplastida since they have 
collections of DNA that form kinetoplasts, in addition to the nucleus (Stevens et al., 2004). 
They fall under the family Trypanosomatidae which includes other parasites like those of the 
genus Leishmania and Crithidia (Figure 1.1). Leishmania is an intracellular parasite that 
causes leishmaniasis in Central and South America (Farrell, 2002), while Crithidia resides 
within a vector only (Smyth, 1994). The genus Trypanosoma is divided into two groups, 
depending on how the parasites are transmitted: Salivaria and Stercoraria (Lloyd and 
Johnson, 1924). Salivarian trypanosomes are transferred to the host via the bite of the 
infected vector  whereas, Stercorarian trypanosomes develop in the hindgut of the vector 
and are posteriorly transmitted i.e. via contact with excreted faeces (Enyaru et al., 2010). 
Salivarian trypanosomes also typically exhibit antigenic variation owing to the presence of 
variant surface glycoproteins (VSGs) on their surface (Stevens et al., 2004). Trypanosomal 
parasites are highly diverse and contain a number of subgenera, species and subspecies 
(Figure 1.1). In this review, some significant trypanosome species will be discussed in more 
detail. 
An important subgenus of the group Stercoraria, Schizotrypanum, contains a significant 
species, T. cruzi that causes Chagas disease in humans in South America and Asia 
(Stevens et al., 2004). A number of other species are included in this subgenus like 
T. rangeli, which is non-pathogenic to humans, domestic and sylvatic animals (Guhl and 
Vallejo, 2003) and T. dionisii and T. myoti, which are restricted to bats (Klimpel and 
Mehlhorn, 2014). Morphologically speaking, these species cannot be distinguished because 
they have a small bloodstream form size of 14-24 nm. Therefore, other methods such as 
isoenzyme analysis, randomly amplified polymorphic DNA (RAPD) and other genetic 
markers have been used to distinguish these species. In South America and Asia, T. cruzi is 
prevalent and is pathogenic to its hosts: humans, pigs, dogs as well as wild mammals. In 
humans, Chagas disease results in damage to the heart and central nervous system 
(Stevens et al., 2004). It is non-pathogenic to its vector, the sandfly, and has also been 
found in leeches and ticks (Vallejo et al., 2009; Telleria and Tibayrenc, 2010). 
3 
 
  Species 
















Trypanosoma  evansi 
T. equiperdum 
T. brucei 
  T. b. brucei 
  T. b. gambiensis 








Trypanosoma suis Trypanosoma vivax 


























Figure 1.1: Classification of trypanosomes (Stevens and Gibson, 1999; Stevens et al., 2004; Baral, 2010)  
Species of importance in this review are underlined 
1Figure 1.1: Classification of trypanosomes 
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Of the Salivaria, the subgenus Duttonella contains the trypanosome species, T. vivax, which 
shows rapid and distinctive movement within a wet blood film typical of this subgenus 
(Uilenberg, 1998). All these parasites develop within the vector’s proboscis only (Foil, 1999). 
T. vivax, infects domestic and wild ungulates and is one of the key trypanosome species 
causing AAT (Ashford, 2001). It is unique in its length averaging around 21-25 µm. Its 
subspecies T. v. viennei is thought to have spread to South America and the Caribbean with 
the importation of zebu cattle from West Africa (Stevens et al., 2004).  
Subgenus Nannomonas contains three species of parasite: T. congolense, T. simiae and 
T. godfreyi, of which, T. congolense is of most interest. They are characteristically small 
parasites (8-24 µm) that lack a free flagellum (Hoare, 1964). T. simiae and T. godfreyi 
infection is limited to suids while T. congolense infects a range of mammals including but not 
limited to bovines, equines, sheep, goats and pigs (Simpson and Casas, 2009). 
T. congolense is probably the most commonly encountered pathogen of African livestock 
and results in a fatal disease called N’gana (Namangala and Odongo, 2014). For this 
reason, T. congolense is of significant importance in sub-Saharan Africa, since, the death of 
cattle causes economic loss (Namangala and Odongo, 2014). 
Trypanozoon, another important subgenus of Trypanosoma includes three species T. brucei, 
T. evansi and T. equiperdum. They are morphologically indistinguishable but have unique 
pathological and genetic characteristics (Stevens et al., 2004). T. brucei, a polymorphic 
parasite (Uilenberg, 1998), is one of the most significant species occurring on the African 
continent. The two subspecies, T. b. rhodesiense and T. b. gambiense cause HAT or 
sleeping sickness (Namangala and Odongo, 2014). A third subspecies, T. b. brucei, infects 
cattle and other domestic mammals but is non-pathogenic (Smyth, 1994). T. evansi, 
occurring in North African, the Middle East, Asia and South America, is transmitted by biting 
flies and causes disease in both domestic and wild animals (Desquesnes et al., 2013; 
Namangala and Odongo, 2014). This species, unlike T. brucei, is monomorphic and only 
consists of long slender forms (Ashford, 2001). This parasite is able to infect a diverse 
number of mammalian hosts with varying degrees of severity. T. equiperdum is transmitted 
venereally between horses causing the disease dourine (Mohler and Schoening, 1920). The 
disease has largely been eradicated due to drug treatment, animal movement legislation and 
culling of infected individuals (Bowman, 2006).  
The present study concentrates on the African trypanosome species, T. brucei, 
T. congolense and T. vivax, in the context of their effects on humans and cattle in sub-
Saharan Africa.  
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1.3 Biology of the Trypanosome 
Although, the genus Trypanosoma is diverse, these species share common genetic and 
morphological features. What follows is a general discussion on the genome and 
morphology of this genus of parasites, with specific reference to African trypanosome 
species. 
 
1.3.1 The Genome of African Trypanosomes 
Trypanosome parasites’ genetic material is found in two organelles: the nucleus and the 
kinetoplast where DNA replication occurs simultaneously. The nuclear genome of T. brucei 
is around 35 million bp (Mb) in length with sizes varying between different isolates. This is 
expected to be the result of the presence of varying numbers of variant surface glycoprotein 
(VSGs) genes. The size of the nuclear genome of African trypanosomes is comparable with 
that of other parasites such as Leishmania major (32.8 Mb) and Crithidia fasciculata (32 Mb). 
The Trypanosoma genome contains 20 chromosomes (0.2 to 6 Mb) and >100 ~50 kb 
minichromosomes (Ersfeld and Gull, 1997). It is suspected that the genome is of low 
complexity because more than 50% of the genome contains single copy sequences (El-
Sayed et al., 2000). Uniquely, the VSG genes and expression sites are haploid, which is 
most likely due to the high degree of variety required in coding for the protein coat. The 
entire T. brucei genome has been completely sequenced (Berriman et al., 2005) as well as a 
large portion of the T. congolense and T. vivax genome.  
The kinetoplast, so named because it was originally thought to be involved in the movement 
of the parasite (kineto meaning movement), contains genomic material. Within the 
kinetoplast there are maxicircles (~50 copies/cell) and minicircles (~10 000 copies/cell) of 
DNA (Madison-Antenucci et al., 2002). The maxicircles encode mitochondrial proteins, 
whereas the minicircles contain guide RNAs which act as templates for the editing of 
maxicircle DNA (Liu et al., 2005). 
1.3.2 Morphology of Trypanosomes 
Trypanosomes are unicellular organisms and classification is based on the following 
morphological characteristics: presence of a single flagellum (be it free or not) and the 
presence of the kinetoplast (Hoare, 1964). These organisms contain general cellular 
components found in most eukaryotic cells: nucleus, cytoskeleton, endoplasmic reticulum, 
Golgi apparatus and mitochondria (Figure 1.2). Specifically, African trypanosomes show two 
morphological forms: the trypomastigote form (blood stream form within the mammalian 






















The polymorphic African trypanosomes are between 11-42 µm in length and 1-3 µm in width 
(Stevens et al., 2004). The different forms depend on what part of the life cycle the parasites 
are in and whether they are infective or not (see section 1.4). These parasites are designed 
for motility within plasma, blood and other tissues within the host and vector. For this reason, 
they are generally streamlined in shape and tapered at both ends. They also contain a highly 
polarised microtubule cytoskeleton (Figure 1.2) with minus ends placed anteriorly while plus 
ends are positioned posteriorly (Robinson et al., 1995). The single copy organelles are 
located specifically within this cytoskeleton. Parasites also contain a pellicle (thin layer of 
cells supporting the cell membrane) which has evolutionarily been designed to keep the 










Figure 1.2: Diagrammatical representation of the morphology of a trypanosome.  
 
A single flagellum, essential for parasite movement, is present which begins posteriorly from 
the flagellum pocket and travels along the length of the parasite (Bastin et al., 1998). It can 
protrude anteriorly as a free flagellum. Whether a parasite has a free flagellum or not and the 
length of it again depends on the species and the life cycle stage it is in (Vickerman, 1985). 
The flagellum pocket is the only site of endo- and exo-cytosis for the parasite (Figure 1.2) 
and hence plays an important role in cell survival (Overath et al., 1997). The pellicle and 
cytoplasm are pinched along the body of the parasite to form an undulating membrane. The 
kinetoplast is generally situated at the posterior end and is adjacent to the parabasal body 
[from where the flagellum arises; (Figure 1.2)]. This defining organelle can vary in size and 








1988). Characteristically, African trypanosomes (and all Salivaria) contain a variant surface 
glycoprotein (VSG) coat over their entire surface, except the flagellum pocket, during the 
trypamastigote forms (Stevens et al., 2004). Movement from mammalian host to insect 
vector occurs in conjunction with ‘coat shedding’ i.e. rapid removal of glycoproteins from the 
surface (Bülow et al., 1989). This allows for the development of the procyclin coat present 
during the insect vector life cycle stage.  
 
1.3.3 Antigenic Variation 
One of the most extraordinary processes African trypanosomes possess is their ability to 
change their coat proteins (VSGs) periodically during the trypomastigote forms (bloodstream 
form) to evade the host immune system. This is done via a process called antigenic 
variation, in which trypanosomes produce an enormous range of antigenically distinct VSGs 
(Taylor and Rudenko, 2006). These distinct VSGs have varying levels of expression. As the 
host immune response develops against a particular VSG coat, parasites containing a 
homologous coat will decline; however, those parasites that are heterologous will survive, 
divide and initiate another wave of parasitaemia within the infected individual (Barry and 
Carrington, 2004; Mugnier et al., 2016). This variation of the protein coat is based on the 
switching of expression between various VSG genes and is comparable to immunoglobulin 
population development in higher eukaryotes (Robinson et al., 1999). Due to this 
phenomenon, conventional vaccines against trypanosome infection have been unsuccessful 
and novel vaccine development methods are being researched (Black and Mansfield, 2016). 
1.4 Life Cycle of the African Trypanosome 
The trypanosome parasite life cycle involves the transmission from invertebrate vector to 
vertebrate host and back again and requires changes in morphology as part of a complex life 
cycle. This life cycle involves alternative proliferative and quiescent stages. The only stage 
capable of differentiation is the quiescent stage and, hence, is infective (Matthews, 1999). 
The infective quiescent metacyclic forms are found within the salivary glands of the tsetse fly 
[Figure 1.3; (Vickerman et al., 1988)]. During the insect bite, saliva is injected into the host 
which contains anti-thrombotic, anti-platelet aggregating and anti-coagulation activities that 
prevent blood clotting and induce vasodilation during the blood meal (Telleria et al., 2014). 
Infective trypanosome parasites are transferred and initially divide at the site of infection to 
form a chancre, after which, they are released directly into the bloodstream via lymph nodes 
and vessels (Vickerman, 1985). 
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Once in the bloodstream, T. brucei undergoes differentiation from a metacyclic form to a 
proliferative trypomastigote form (Vickerman, 1985). This form is generally long and slender 
and divides rapidly within the blood where it is able to spread to different organs within the 
host (Figure 1.3). Subsequently, these proliferative forms differentiate into a quiescent 
trypomastigote form which is infective and are ingested by tsetse flies feeding on an infected 
host. This non-dividing blood stream form of the parasite is generally short and stumpy 
[Figure 1.3; (Matthews, 2005)]. 
Parasites are now in the midgut of the fly where they differentiate into the procyclic form 
(Figure 1.3) via rapid VSG coat shedding performed by a GPI-anchor specific phospholipase 
C (GPI-PLC) and a major surface metalloprotease (LaCount et al., 2003; Gruszynski et al., 
2006; Grandgenett et al., 2007). Procyclic parasites develop a procyclin coat within the 
insect vector (Matthews et al., 2004). At this point crucial adjustments of enzyme systems 
used by the parasite take place so that different nutrients can be used at the different 
temperatures within the vector and host. One of the most significant changes is the 
development of a functioning mitochondrion to provide energy via oxidiative 
phosophorylation. In comparison, the bloodstream form of the trypanosome uses glycolysis 









Figure 1.3: Schematic representation of the life cycle of T. brucei.  Proliferative forms      , Grey 
circle within the parasite represents the nucleus; note how its position changes with different life cycle 
stages [Adapted from Wheeler (2010)]. 
 
After ingestion by the tsetse fly, many parasites begin to die and this may lead to elimination 
of infection in some flies (Fenn and Matthews, 2007). Parasites that survive within the fly 
undergo differentiation and migration.  
3Figure 1.3: Schematic representation of the life cycle of T. brucei. 
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In the case of T. brucei, procyclic forms migrate to salivary glands and differentiate into 
epimastigote forms which become attached to the microvilli within the gland [Figure 1.3; 
(Vickerman et al., 1988)]. Within the salivary glands, epimastigotes differentiate into the 
metacyclic form which is characterised by the redevelopment of the VSG coat (Vickerman et 
al., 1988). Once the VSG coat has developed fully, parasites detach from the cell wall of the 
tsetse fly salivary glands and are able to infect the host; thus, perpetuating the life cycle 
(Figure 1.3). 
By contrast, T. congolense develops into the procyclic form once it has migrated to the 
insect proboscis and after differentiation it enters the salivary glands while T. vivax develops 
entirely in the proboscis and no differentiation occurs within the midgut or the salivary gland 
(Matthews et al., 2004). 
1.5 African Trypanosomiasis 
African trypanosomiasis (both HAT and AAT) is endemic in 36 African countries and a study 
published in 2011, which examined the risk factor over a ten year period, concluded that in 
central Africa about 3.5 million people are at risk of contracting HAT (Simarro et al., 2011). 
The decline of HAT over the last decade has promoted the World Health Organisation 
(WHO) in conjunction with Pan African Tsetste and Trypanosomiasis Eradication Campaign 
(PATTEC) to implement eradication strategies and at the beginning of 2014 announced that 
they hope to completely eliminate T. b. gambiense by 2020 (this is less than 1 case per 
10000 people in at least 90% of all endemic areas).  
Within central and northern Africa, livestock farming especially cattle plays an important role 
in the lives of people as a source of food, income and stature (Herrero et al., 2013). It has 
been known since the re-emergence of the disease in the 1980s, that the problem with 
animal trypanosomiasis needs to be resolved to ensure the economic development of Africa. 
The loss caused by this disease for the cattle industry within Africa is estimated as US$ 1.3 
million annually (Maitima, 2007).  
The presence of the tsetse fly and the disease generally overlaps geographically on the 
African continent (Figure 1.4). However, cattle farmers often migrate with their livestock into 
and out of tsetse fly areas where cattle become infected and carry the disease with them. It 
is here where the fact that biting flies (tabinids) can also carry the disease becomes 
important because, they aid in the spread of the disease even in tsetse fly free zones 
(Stevens et al., 2004).  
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A study conducted to map the economic benefit of treatment and prevention of bovine 
trypanosomiasis determined that due to high costs and high chance of re-infection, only 
farmers that are geographically located on the fringe of infection zones will be likely to profit 
(Shaw et al., 2014). Current assessment of sub-Saharan African communities, with 
prevalence of AAT, suggests that locally-adapted treatment and control programmes are 
required for the successful management of the disease (Holt et al., 2016).  
1.5.1 Pathogenesis 
T. brucei rhodesiense and T. b. gambiense HAT, manifest differently within human patients 
as either an acute or chronic form. The biggest difference being that T. b. rhodesiense HAT 
may be fatal within a few months of infection (acute), due to heart damage, while 
T. b. gambiense HAT may be present for years after initial infection (chronic) with death 
resulting from other causes, such as, central nervous system damage and opportunistic 
infections (Pentreath and Kennedy, 2004).  
The infections leading to HAT are divided into two stages: early and late. Early 
haemolymphatic stage trypanosomiasis begins with the formation of a chancre at the bite 
site. This is often considered to be a boil and disregarded by the infected patient (Kennedy, 
2004). Five to twelve days after a tsetse fly bite, the parasite has invaded the blood which is 
associated with symptoms such as fever, headache and joint pain (Pentreath and Kennedy, 
2004). At this point, a difference in the number of parasites in the blood for 
T. b. rhodensiense and T. b. gambiense infected patients is observed. High levels of 
T. b. rhodensiense parasites are found (105/ml); whereas, T. b. gambiense has low numbers 
and often goes undetected. Parasites also invade the lymphatic system and fever cycles are 
observed every seven to ten days.  
The late encephalitic stage of HAT is when the parasite invades the central nervous system 
(CNS) and cerebrospinal fluid (Kennedy, 2004). The acute form of the disease sees 
parasites invading the CNS within a couple of weeks following the initial infection and 
patients may die before this invasion even occurs. The chronic form is slower and symptoms 
like personality changes, insomnia and irritability are indicative of CNS invasion. Death by 
the chronic form of HAT is usually the result of opportunistic infections.  
A range of animal species are susceptible to AAT or N’gana caused by a variety of 
trypanosome species that could be described as ‘haematic’ where the parasite stays within 
the blood vessels of the host (T. congolense) or ‘humoral’ where the parasite invades other 
tissue [T. vivax and T  b. brucei; (Uilenberg, 1998)]. Pathogenesis of trypanosomiasis within 
animals is similar to that in humans. Generally, cattle become chronically ill and infection is 
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accompanied by a loss of milk production, emaciation and eventually death (Taylor and 
Authié, 2004). It should be noted that most African trypanosome species are able to infect 
wild animals with no effect on their health, hence, they serve as a reservoir of parasite to 
replenish the life cycle and continue to infect host animals (Steverding, 2008). This is one of 














Figure 1.4: HAT prevalence (A) and the overlap of cattle and tsetse fly distribution (B) in Africa. 




Diagnosis of trypanosomiasis, especially in humans, follows three general steps; screening, 
diagnostic confirmation and staging (Chappuis et al., 2005). Diagnostic techniques can be 
either direct or indirect. Direct diagnostic methods involve either clinical or parasitological 
methods that detect the parasite in blood, lymph or cerebrospinal fluid (CSF) samples 
(Büscher and Lejon, 2004) while indirect diagnostic methods involve detection of factors 
produced either by the parasite or in response to it, such as antigens or antibodies.  
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There are specific approaches to developing diagnostic methods because of the different 
species and strains causing the disease, due to antigenic variation and the fact that the 
disease is most common in third world African countries with rudimentary infrastructure and 
depressed economy. The epidemiology of this disease has resulted in adapting WHO 
“ASSURED” criteria (Affordable, Sensitive, Specific, User‐friendly, Rapid and robust, 
Equipment‐free and Deliverable to end‐users) for the development of diagnostic methods 
(Peeling et al., 2006).  
Direct clinical diagnosis is an unreliable method because symptoms of trypanosomiasis 
resemble those of other tropical diseases such as babesiosis and theileriosis which can 
result in misdiagnosis. Even so, it remains one of the most widely used methods of diagnosis 
of AAT because often physical assessment is the only means available (Eisler et al., 2004). 
In the case of HAT, this method has low sensitivity especially in identifying T. b gambiense 
which generally has low parasitaemia (Uilenberg, 1998). To increase sensitivity, various 
methods to concentrate parasite numbers have been developed such as removal of red 
blood cells using anion exchange chromatography (Nantulya, 1990), quantitative buffer coat 
technique (Bailey and Smith, 1994) and microhaematocrit centrifugation (Woo, 1970). These 
methods remain the most simple and inexpensive techniques.  
Indirect methods of diagnosis include serological and molecular tests. Some serological 
tests are the Card Agglutination Test for Trypanosomiasis (CATT), indirect 
immunofluorescent antibody (IFA) test, and indirect and direct enzyme-linked 
immunosorbent assays (ELISAs). The CATT has been an important development in the 
diagnosis of T. b gambiense. This simple agglutination test detects T. b. gambiense specific 
antibodies from patients’ blood or plasma (Magnus et al., 1978). It contains lyophilised 
variable antigen type LiTat 1.3. antigens (Chappuis et al., 2005). False negatives for this test 
can result if trypanosomes causing infection do not express the LiTat 1.3 gene; however, 
other tests like LATEX includes three different variant antigen types and has shown to have 
higher specificity (Penchenier et al., 2003). However, it has lower sensitivity when compared 
to CATT. Both IFA and ELISA testing have shown promising diagnostic results because they 
have high sensitivity and specificity especially when antigens can be supplied at low cost 
and in high quantity (Uilenberg, 1998). However, these methods require sophisticated 
equipment which limits field use.  
Lateral flow tests have also been developed that use a parasitic antigen for the detection of 
serum antibodies and include HAT SERO K-SeT (detects patient serum antibodies against 
T. b gambiense VSGs LiTat 1.3 and 1.5), HAT Sero-Strip (detects patient serum antibodies 
against T. b. gambiense VSGs LiTat 1.3 and 1.5), SD BIOLINE HAT (detects patient serum 
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antibodies against T. b. gambiense VSGs LiTat 1.3 and 1.5) and Surra SERO K-SeT 
[detects animal serum antibodies against T. evansi VSGs Rotat 1.2; (Büscher et al., 2014; 
Birhanu et al., 2015; Jamonneau et al., 2015)]. A potential lateral flow test against the p310 
invariant surface glycoprotein (ISG) antigen, for T. vivax, has given promising preliminary 
results (Fleming et al., 2016). A disadvantage of antibody detecting serological tests is that 
cured or previously infected individuals may give positive results, if antibodies are still 
present (Garcia et al., 2000; Solano et al., 2002). Therefore, further research into antigen 
detecting serological tests is still required to distinguish between past and present infections.  
Molecular tests involve various techniques to detect parasite DNA or RNA often with the use 
of polymerase chain reaction (PCR) or nucleic acid labelled probes. Advantages of these 
techniques are higher sensitivity and specificity even to subspecies level; however, 
sophisticated equipment is often required. Development of a PCR-oligochromatography 
dipstick has shown promising results since it is able to distinguish between T. b. gambiense 
and T. b. rhodesiense (Deborggraeve et al., 2006; Büscher et al., 2013). The 18S ribosomal 
RNA gene is a favourite in the detection of parasites using PCR diagnostics because of the 
high number of copies as well as the uniqueness of the genetic code (Desquesnes et al., 
2001). A two-year study published in 2011 by Deborggraeve et al. showed that PCR on 
blood and CSF may be a non-invasive technique to diagnose infected individuals with better 
or equal performance compared to other methods. 
Diagnostic methods for the detection of African trypanosomiasis is continually being 
improved because of the regions where this disease occurs (Brun et al., 2010). Also, current 
diagnostic techniques are often only effective in 95% of cases and as trypanosome 
infections drop below 5% of the population, more sensitive diagnostic methods are required 
(Chappuis et al., 2005). It is clear that new diagnostic targets and techniques need to be 
developed to continue the fight against this disease that is a prominent burden in third world 
Africa.  
1.5.3 Treatment and Control of Trypanosomiasis 
1.5.3.1 Treatment  
Treatment for HAT is stage specific; i.e., a different treatment is used for the early haematic 
and late CSF stages; although even today, there are only a few drugs available for HAT 
treatment.  
Two main drugs used for early stage treatment are pentamidine and suramin (Brun et al., 
2010). Pentamidine is used in the treatment of T. b. gambiense HAT and is a general 
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anti-protozoal agent which is thought to disrupt nuclear metabolism by inhibiting DNA, RNA, 
lipid and protein synthesis (Nguewa et al., 2005). Suramin, on the other hand, is used to 
treat first stage T. b. rhodesiense HAT and is a polyanionic compound that contains six 
electronegative sites and is thought to act by binding many important enzymes involved in 
respiration and glycolysis of the parasite (Hanau et al., 1996; Barrett et al., 2007).  
Melarsoprol and eflornithine are used for the treatment of late stage AAT. Eflornithine is the 
only drug released in the last 25 years (released in 1990) for the treatment of late stage 
T. b. gambiense (Brun et al., 2010). Nifurtimox, originally developed for the treatment of 
Chaga’s disease, has been tested in combination with eflornithine for treatment of late stage 
T. b. gambiense as well (Priotto et al., 2009). Melarsoprol can be used in the treatment of 
both chronic and acute HAT and is an arsenic-based anti-parasitic agent that binds thiol 
groups. Binding of thiol groups inhibits the action of many enzymes including those required 
for glycolysis (Hanau et al., 1996) which are important in the production of adenosine 
triphosphate (ATP) and therefore energy within the parasite. It has also been shown to bind 
trypanothione, which provides a defence against damage by oxidants (Fairlamb et al., 1989). 
Eflornithine specifically inhibits ornithine decarboxylase (ODC) within the parasite. This 
enzyme is important in the production of polyamines which play a significant role in growth, 
differentiation and cellular replication by actively participating in nucleic acid and protein 
synthesis (Van Bogaert and Haemers, 1989).  
Diminazene aceturate, homidium (bromide and chloride), isometamidium chloride, 
quinapyramine (sulfate and dimethylsulfate), suramin and melarsomine dichlorohydrate are 
used either as chemoprophylaxis or chemotherapeutic agents for AAT (Holmes et al., 2004) 
caused by T. vivax, T brucei, T. evansi and T. simiae. Prophylactic drugs are used as a 
preventative measure against infection in livestock. Diminazene has been shown to inhibit a 
trypanosome serine protease, oligopeptidase B (OPB), whereas isometamidium targets the 
kinetoplast DNA. Suramin was shown to inhibit OPB as well (Morty et al., 1998). On the 
other hand, homidium interferes with glycosomal functions (Holmes et al., 2004). 
New drugs can be developed by looking at commercially available drug libraries that have 
chemical structures with the potential to be optimised against trypanosomiasis. Katiyar et al. 
(2013) identified kinases as new drug targets within trypanosomes and determined that 
current drugs such as 4-anilinoquinazoline and pyrrolopyrimidines have good scaffolds for 
further optimisation to develop new anti-trypanosomal drugs. However, drug development 
and testing is lengthy process that often ends in failure.  
Since no new drugs have entered the market in the last 25 years, drug resistance has 
become a serious problem for the treatment of trypanosomiasis (Brun et al., 2010). 
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Resistance against suramin for HAT is rare; however, it is seen for AAT. Resistance against 
melarsoprol and pentamidine has increased throughout Africa as well. Melarsoprol 
resistance occurred because the uptake of the drug is dependent on the P2 aminopurine 
transporter and resistant parasites have lost this transporter (Barrett et al., 2007). A similar 
resistance mechanism is seen for pentamidine as well. Therefore, new pathogenic and 
virulence factors need to be identified within trypanosomes and a better understanding of the 
life cycle and differentiation of the parasite is required before new drug targets can be 
developed.  
1.5.3.2 Control 
Due to antigenic variation of trypanosomes and their immunosuppressive effect on the host 
immune system, conventional vaccination has been unsuccessful. Therefore, vector control 
is of utmost importance and numerous techniques and methods have been employed in sub-
Saharan Africa to reduce risk and spread of the disease. Methods include aerial and ground 
spraying, artificial baits (Rayaisse et al., 2010), insecticidal treatment of animals (Bouyer et 
al., 2009) or insecticide-treated insect targets (e.g. Harrison trap) and the sterile insect 
technique (Vreysen, 2000). Tsetse flies are susceptible to most insecticides from the groups 
of organochlorines, organophosphate, carbamate, natural pyrethrum and synthetic 
pyrethroids. For over 40 years, the insecticide dichlorodiphenyltrichloroethane (DDT) was 
used throughout Africa from spraying against tsetse flies; however, it was later found that the 
long-lasting ability of this chemical was detrimental to the environment and was banned 
(Allsopp and Hursey, 2004). Aerial spraying is highly effective over large areas but may 
leave small areas untreated from where tsetse flies proliferate and spread. Ground spraying 
is labour-intensive and governments may not be able to afford the manpower for this method 
to be viable (Allsopp and Hursey, 2004).  
Artificial baiting technologies, such as, odour or visual cue containing traps that contain 
insecticides have been shown to decrease tsetse fly populations. However, a study 
conducted by Rayaisse et al. (2010) showed that current traps employed in the Ivory Coast 
only kill ~50% of the tsetse flies attracted to the area. In an assessment of AAT vulnerability 
within sub-Saharan Africa, areas that show high vulnerability to the disease reported few 
traps or targets (Holt et al., 2016). Since this method of control is much cheaper compared to 
the spraying of insecticide, it would be expected to have higher prevalence; however, traps 
require maintenance and are labour-intensive which could have had a negative impact on 
their availability. Improvements of these traps or targets are required, to have a significant 
effect on the tsetse fly population.  
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Animals can be treated with pour-on insecticide and/or repellent to avoid being bitten which 
has also been shown to be an effective vector control method and it minimises chemical 
spread to the environment (Bouyer et al., 2009). However, in high density tsetse fly areas 
the efficacy of this method is diminishing. The need to supply farmers with dip that is 
inexpensive enough to be viable can also be a challenge. Synthetic and natural repellents 
(identified from wild animals that are generally not bitten by the tsetse fly) have been 
identified and are undergoing validation (Gikonyo et al., 2003; Bett et al., 2010). 
Sterile insect technique when sterilised males are released into an area which slows 
population growth until it stops and starts to die out (Vreysen, 2000), has shown moderate 
success. Sterilised flies have to be continually released to counteract fertile males being 
born in the new generation. There has been successful use of this technique in eradicating 
the tsetse fly from the island Zanzibar (Vreysen et al., 2000), as well as, for other insect 
species like the screwfly from North America and Libya (Lindquist et al., 1992). Doubts have 
been expressed as to whether it will work over such large areas as in the case of the 
Glossina species habitat. It has potential in smaller pockets, such as, northern 
KwaZulu-Natal, where its use is in the planning stage. 
1.5.4 Trypanotolerance 
Animals that do not show symptoms of trypanosomiasis despite being infected are termed 
trypanotolerant. This is thought to be genetically predetermined due to the evolution of 
animal species with the parasite over thousands of years (Murray et al., 2004). Wild animals 
such as zebra, buffalo, wildebeest and waterbuck are able to resist infection but are still 
carriers and act as reservoirs for the continuation of the life cycle of the parasite (Njiokou et 
al., 2006). However, there are also species of cattle, like the N’Dama cattle, which are 
trypanotolerant (Murray et al., 2004).  
Trypanotolerant animals are able to reduce parasitaemia levels and self-cure and it has 
been shown that β2-microglobulin plays an important role in this resistance. Hill et al. (2005) 
showed that during high parasitaemia increased expression of β2-microglobulin, MHC-1 
lymphocyte antigen and protein kinase C could all be important in the observed tolerance.  
This resistant N’Dama cattle breed is, however, smaller than general cattle farming breed 
like Zebu cattle and therefore, the use of susceptible cattle is more common and widespread 
throughout Africa. Cross-breeding to select for resistant larger breeds should be considered 




Whether trypanotolerance occurs in humans is a question that still needs to be answered. 
Older literature reported sleeping sickness in self-curing patients but these studies used 
diagnostic tests that lack the advancements we have today and have been deemed 
unreliable (Jamonneau et al., 2012). However, a 15 year follow-up study reported that ten 
out of eleven patients that refused treatment showed reduced parasitaemia as observed with 
microscopy and PCR, as well as, some showing reduced serological responses becoming 
negative for trypanosome variable antigens over time (Jamonneau et al., 2012). Even more 
recently, it has been determined that pro-inflammatory cytokines are involved in this 
observed ‘tolerance’ with high levels of IL8 being associated with serologically negative 
patients while those with high levels of IL10 and low levels of TNF-α have higher risk of 
developing sleeping sickness (Ilboudo et al., 2014). This may mean that the disease could 
follow an alternate progression of tolerance rather than being 100% fatal every time. 
1.6 Leishmania, a Trypanosomatidae Parasite 
There are many other parasitic species that fall under the family Trypanosomatidae. These 
species all have different mechanisms of infection, different vectors and different hosts. In 
the discussions that follow, Leishmania is included for comparitive purposes.  
Leishmania causes the disease leishmaniasis which infects mainly vertebrate hosts like 
rodents and humans (Dedet, 2002). Its vector, the sandfly of the genus Lutzomyia, is found 
in subtropical and tropical countries of South America and South-East Asia. The parasite 
causes two types of disease within humans; cutaneous leishmaniasis, which causes sores 
and nodules on the skin, and visceral leishmaniasis, which infects different tissues of 
important organs such the liver or bone marrow (Dedet, 2002). Like Salivaria, parasites are 
injected by sandflies into the human host during a blood meal. Conversely, Leishmania are 
intracellular parasites that invade or are engulfed by macrophages within the host (Dedet, 
2002). African trypanosomes are exclusively extracellular, while Leishmania is comparable 
to T. cruzi which is also intracellular. It must be noted here that the Major Surface Protease 
(the main focus of the present study) was first identified in this species of Trypanosomatidae 
and its function is to allow parasites to invade macrophages and gives them resistance 





1.7 Major Surface Proteases (MSPs) in African Trypanosomes 
1.7.1 Genomic Organisation of MSP Genes 
The Major Surface Protease (MSP) or Glycoprotein 63 (gp63) was first discovered in the 
1980s in Leishmania mexicana amazonensis (Chaudhuri and Chang, 1988) and identified as 
a pathogenic and virulence factor (Oliver et al., 2012). Later on, homologs were found in 13 
other Leishmania species, as well as, Crithidia fasciculata and Herpetomonas samuel 
pessoai (Etges, 1992). Genes identified as LmMSP homologs were reported in both African 
and American trypanosomes (El-Sayed and Donelson, 1997a; Cuevas et al., 2003; Marcoux 
et al., 2010), as well as Cryptobia salmositica (Jesudhasan et al., 2007) of the order 
Kinetoplastida (Thomas and Woo, 1991). The presence of MSPs on the T. brucei cell 
surface proteosome was recently confirmed (Shimogawa et al., 2015). Within many of the 
species shown to have MSP genes, each have a distinct number of classes which have 
been shown to differ primarily in the C-terminal coding regions and 3′ untranslated regions 
[UTRs; Ramamoorthy et al. (1992); Voth et al. (1998)]. In most cases, differential expression 
during the life cycle was observed (Ramamoorthy et al., 1992; Voth et al., 1998) and, for 
T. brucei MSP, this expression was regulated by the 3’-UTRs (Helm et al., 2009). 
The genomic organisation of MSP genes of Leishmania major will be compared to that of 
Trypanosoma brucei, T. congolense and T. cruzi. To date seven MSP genes have been 
found in the L. major genome and were originally called gp63 1-7. The first five MSP genes 
are highly conserved tandem repeats on chromosome ten (Ivens et al., 2005). The 8-10 kb 
downstream genes six and seven are less conserved compared to the first five (Figure 1.5). 
Later, they were re-named MSP-L1-5, MSP-C (gene six) and MSP-S [(gene seven); Roberts 
et al. (1993); Voth et al. (1998)] and each have varying levels of expression at different life 
cycle stages of the parasite. For example, MSP-L is expressed only in promastigotes while 
MSP-C is expressed in both promastigotes and amastigotes (Ramamoorthy et al., 1992). It 
has also been concluded that the different isoforms of MSP, within Leishmania, have unique 
pIs which are related to the biological function of the protease (Hsiao et al., 2008).  
By chance, in an experiment to compare genome survey sequencing (GSS) and expressed 
sequence tag (EST) shotgun sequencing techniques, El-Sayed and Donelson (1997b) 
discovered Trypanosoma brucei sequences that were similar to genes that code for L. major 
MSP (gp63). Subsequently, cDNA libraries were used to identify T. brucei homologs to 




As seen in Figure 1.5, three gene classes were discovered; namely, TbMSP-A, -B and -C 
(LaCount et al., 2003). TbMSP-A gene class consists of five closely related copies (1-5) and 
is located on chromosome 11 (LaCount et al., 2003; Berriman et al., 2005; El-Sayed et al., 
2005). The TbMSP-B class consists of four tandem genes located on chromosome eight of 
the T. brucei genome (LaCount et al., 2003; Berriman et al., 2005; El-Sayed et al., 2005) 
while the TbMSP-C class consists of a single gene found at the end of a high gene density 
collection on chromosome 10 (LaCount et al., 2003). Interestingly, MSP-B mRNA is found in 
both the blood stage and procyclic form of the parasite while both MSP-A and MSP-C mRNA 
is only found in the blood stage form (LaCount et al., 2003). 
Several genes were identified in the T. congolense genome as homologous to both T. brucei 
and L. major MSP genes. Marcoux et al. (2010) discovered a total of six full-length 
homologues and after extensive sequence analysis of each they were identified as MSP-A, 
-B1, -B2, -C, -D and -E. MSP-B1 and B2 were grouped together, because, both genes 
showed high sequence identity to TbMSP-B with low genetic distance. Genes encoding 
MSP-D and -E were found to have low sequence identity to all TbMSP gene classes and 
with high genetic distance were grouped on their own as separate gene classes. TcoMSP-D, 
-A and-E, similarly to TbMSP-A, all occur on chromosome 11 and cluster between 270 kb 
(Figure 1.5). TcoMSP-C, like TbMSP-C, occurs on chromosome 10 (Figure 1.5) within the 
genome while TcoMSP-B2 and -B1 may occur on chromosome 8 like TbMSP-B. However, 
this remains to be confirmed. Putative Major Surface Protease genes within T. vivax were 
identified and are discussed in full in Chapter 2.  
In total, eight major surface protease genes have been identified in the T. cruzi genome 
(Grandgenett et al., 2000) which have been separated into two groups: I and II (Cuevas et 
al., 2003). It was also shown that within group I two members were detected; namely, a and 
b (Cuevas et al., 2003). Perusing the phylogenetic tree constructed by Marcoux et al. (2010) 
shows that these two groups can be MSP-B and MSP-C with the likelihood that members a 
and b correspond to MSP-B1 and B2 as seen within the T. congolense genome (Figure 1.5). 
The fact that these two groups show identity with T. brucei and T. congolense MSP could 
mean that they occur on corresponding chromosomes within the genome. However, this also 
remains to be determined. There is uncertainty which class contains tandem repeats and on 
which chromosomes these genes reside. More information will come to light when more of 


















Figure 1.5: Genomic organisation of Major Surface Proteases within various Trypanosomatidae species. Arrangement of different MSP classes on 
corresponding chromosomes within the genomes of specific species is shown. ? denotes unknown information. *name according to phylogeny constructed by 
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1.7.2 Classification of Proteases 
A protease is a unique enzyme because it recognises the carboxyl side of an amino acid 
residue regardless of the protein it belongs too (Garcia-Carreon and Del Toro, 1997). 
Mechanisms by which proteases cleave the peptide bonds are used to determine to which 
class they belong. There are seven classes of proteases identified to date: serine, cysteine, 
threonine, aspartic acid, metallo, glutamic acid and asparagine peptide lyases. Classification 
depends on residues within the active site of an enzyme and how they affect the cleavage of 
a protein. Some common proteases from each types are; chymotrypsin (serine), papain 
(cysteine), proteosome (threonine), pepsin (aspartic), thermolysin (metallo), scytalidopepsin 
(glutamic) and nodavirus coat protein [asparagine; (Rawlings et al., 2014)]. Proteases are 
grouped into families because of their evolutionary relationships. As classification continues 
from family to subfamily followed by clan and subclan, evolutionary distance and difference 
between peptidases becomes less and less (Rawlings et al., 2014). Classification into clans 
includes analysis of secondary and tertiary structures. 
All serine proteases contain a catalytic serine residue in their active site with the hydroxyl 
group acting as the nucleophile involved in peptide cleavage. Cysteine and threonine 
catalytic types are the only other two groups that use an amino acid residue to act as a 
nucleophile rather than a water molecule. The most common catalytic mechanism of serine 
proteases involves a His, Asp and Ser triad which was previously known as clan SA 
(Rawlings and Barrett, 1993). However, after more analysis of the secondary and tertiary 
structure of these proteases it was found that there are a number of cysteine proteases with 
similar folds and cleavage mechanisms and so they were grouped in subclan PA (S) for 
serine and (C) for cysteine (Barrett et al., 2004). There is an assortment of different catalytic 
sites which includes diads to tetrads of varying types of residues and these are grouped into 
separate clans.  
Cysteine peptidases contain a catalytic cysteine residue in their active site and the sulfhydryl 
group acts as the nucleophile that attacks the scissile peptide bond (Erez et al., 2009). The 
cleavage mechanism, in this case, is similar to that of serine proteases in that a nucleophile 
and a proton donor (general base) are required (Barrett et al., 2004). Papain was the first 
clearly recognised cysteine protease with a catalytic tetrad: Gln, Cys, His and Asn and this 
forms the foundational requirements for clan CA (Rawlings and Barrett, 1993). Again, 




The threonine protease family was first identified following the three-dimensional 
construction of the proteosome from yeast (Barrett et al., 2004). The proteosome contains a 
number of different catalytic activities grouped together in one super-enzyme (DeMartino 
and Slaughter, 1999) and those are called N-terminal nucleophile peptidases. Three families 
of threonine peptidases exist (T1-3) and are grouped in subclan PB (T) with PB (C-cysteine) 
and (S-serine) (Barrett et al., 2004). In this case, the N-terminal nucleophile is a threonine.  
Aspartic proteases require a water molecule to act as the nucleophile that attacks the 
scissile peptide bond (Berg et al., 2002). These proteases are called aspartic, not because 
of the amino acid residues involved in catalysis, but because Asp residues are ligands of the 
activated water molecule (Barrett et al., 2004). Interestingly, all characterised enzymes from 
this group are endopeptidases. There are five clans of aspartic proteases with general 
ligation of the water molecule involving two Asp residues (Barrett et al., 2004). Clans AC and 
AD have no proteases where the crystal structure has been derived and so classification for 
these may change as more understanding of their structure becomes known.  
Glutamic proteases have been reclassified as a sixth catalytic type from the A4 group of 
aspartic proteases (Sims et al., 2004) and consists of the families G1 and G2 (Rawlings et 
al., 2014). Scytalidoglutamic peptidase from Scytalidium lignicolum is the founding member 
of the G1 family (Pillai et al., 2007). These proteases have a unique Glu-Gln catalytic dyad in 
which the glutamic acid acts to activate the nucleophilic water molecule while the glutamine 
acts to stabilise the tetrahedral intermediate (Sims et al., 2004; Pillai et al., 2007; Jensen et 
al., 2010). These proteases also contain a novel β-sandwich domain. Glutamic proteases 
have been identified in fungi, bacteria, viruses and animal species and over 350 putative 
protease sequences (Rawlings et al., 2014).  
In 2011, a seventh protease family was identified: the asparagine peptide lyases (Rawlings 
et al. 2011). In this family five clans have been identified: NA-E consisting of a total of eight 
subclans (N1-8) (Rawlings et al., 2011; Rawlings et al., 2014). Clan NA is the largest 
consisting of over 900 putative sequences within bacteria and viruses only. There are 
putative sequences within plants and animals for these lyases as well (Rawlings et al., 
2014). These proteases all contain an Asn within their catalytic site which acts as the 
nucleophile during catalytic processing (Rawlings et al., 2011). This shows that not all 
proteolytic enzymes are peptidases.  
Metalloproteases are one of the largest groups of proteases containing about 50 families 
(Rawlings et al., 2014). Like aspartic proteases, they use a water molecule to act as a 
nucleophile for the hydrolysis of the peptide bond (Barrett et al., 2004). They differ from all 
other proteases in that they require a divalent metal cation as a cofactor to activate the water 
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molecule and perform cleavage (Barrett et al., 2004). The most common cofactor is zinc 
while other protease families use other cofactors such as copper, magnesium or nickel. The 
zinc dependant proteases have the ability to use other cations in zinc deficient environments 
(Holmquist and Vallee, 1974). The metal ions are held in place by amino acid ligands. A 
significant amount of research has been done to further class the large number of various 
zinc metalloproteases known using techniques that involve analysis of primary to tertiary 
structure, mechanism of peptide substrate cleavage and zinc binding site residues (Hooper, 
1994; Stocker and Bode, 1995; Stocker et al., 1995; Rawlings et al., 2014). The general zinc 
binding site motif is HEXXH (where X is any amino acid) and all proteases that contain this 
site are grouped together in the class called the zincins (Bode et al., 1993) or clan MA 
(Barrett et al., 2004). Proteases that do not contain the HEXXH motif are grouped in clans 
MC-H and MJ-N. Examples of variations include HXXEH (inverzincins), HXXE and HXH.  
The zincin class is then further split into two super-families: gluzincins or subclan MA(E) 
(Hooper, 1994; Barrett et al., 2004) and metzincins (Bode et al., 1993) or subclan MA(M)  
(Barrett et al., 2004). Proteases are allocated a family according to the third zinc ligand 
consensus sequence which is conserved in each case. Gluzincins, named because of their 
fifth zinc ligand being a glutamic acid residue, consists of the thermolysin, endopeptidase 24-
11, angiotensin converting enzyme and aminopeptidase families (Hooper, 1994). The other 
superfamily is the metzincins, so called due to the presence of a much longer zinc binding 
consensus sequence HEXXHXXGXXH and a conserved methionine-containing turn [Met-
turn; Bode et al. (1993); Hooper (1994); Barrett et al. (2004)]. Four main families that belong 
to this superfamily are the astacin, serratia, reprolysin and matrixins, which are further 
divided into sub-families M6-8, M10-12, M35, M43, M46, M57, M64 and M72. In this case, 
proteases are separated into corresponding families by determining which residue follows 
the third histidine zinc binding ligand and the residues surrounding the methionine in the 
Met-turn. This Met-turn is present in all metzincins and so must be important for the 
functioning of the enzymes (Tallant et al., 2010). 
Astacin, a digestive enzyme found in crayfish (Hopsu-Havu et al., 1997) is the exemplar 
enzyme for the astacin family. Enzymes that belong to this group come from diverse sources 
including matrix metalloendopeptidase and developmental regulation proteases (Bond and 
Beynon, 1995). They have a conserved glutamic acid following the third histidine 
(HEXXHXXGXXHE). Zinc ligation involves the three histidines within the zinc binding motif, 
the fourth being water and uniquely a fifth tyrosine residue within the Met-turn which results 
in a pentacoordinated trigonal-bipyramidal geometry of zinc binding (Stocker et al., 1993).  
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The serralysin family consists of proteases that are secreted into their environment by 
various pathogenic bacteria of the genera Serratia (Nakahama et al., 1986), Pseudomonas 
(Duong et al., 1992) and Erwinia (Dahler et al., 1990). A conserved proline follows the third 
histidine (HEXXHXXGXXHP) within the longer zinc binding consensus sequence (Mock and 
Yao, 1997) and as in the astacin family, a tyrosine within the Met-turn acts as the fifth zinc 
binding ligand (Bond and Beynon, 1995). 
The reprolysin family, which consists of a number of snake venom toxins (Bjarnason and 
Fox, 1995), has a conserved aspartic acid residue following the third histidine within the zinc 
binding motif (HEXXHXXGXXHD). Unlike astacin and serralysin protease families, reprolysin 
proteases lack a fifth zinc binding ligand which results in a tetrahedral geometry of zinc 
binding (Cirilli et al., 1997; Gomis-Rüth, 2003). 
Lastly, the matrixin family which mainly consists of mammalian matrix metalloprotease 
(Visse and Nagase, 2003; Nagase et al., 2006) has a conserved serine following the zinc 
binding motif (HEXXHXXGXXHS). Like reprolysin, no tyrosine residue is present in the 
Met-turn resulting in a similar zinc binding topology. 
Of all the Major Surface Proteases discovered only leishmanolysin from Leishmania major 
has been classed into a metalloprotease clan and family. Since it contains the HEXXH motif 
it belongs in the zincin or MA clan under the M8 peptidase family (Barrett et al., 2004). 
Three-dimensional analysis showed that it contains the conserved Met-turn and hence 
belongs to the subclan, metzincin [(MA(M)); (Schlagenhauf et al., 1998)], but determination 
as to which family it belongs or if it needs to be grouped into a family of its own is still 
uncertain. Further discussion on this aspect will be found in Section 1.7.3.3.  
 
1.7.3 Structure of MSPs 
None of the trypanosomal Major Surface Proteases have been crystallised but molecular 
modelling, using various bioinformatics programs, has been done. The structure of one of 
the Leishmania Major Surface Proteases, leishmanolysin, has been successfully 
determined. However, primary and secondary structure for the various proteases will be 
analysed first.  
 
1.7.3.1 Primary Structure of MSPs 
The amino acid sequences for all T. brucei, T. congolense, and T. cruzi MSPs was aligned 
with the amino acid sequence for leishmanolysin, using BioEdit, for the purpose of this 
discussion (Appendix 1, Figure A1).  
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A basic trend observed in sequence identity is that each class of protease shares highest 
identity; of example, TbMSP-B shares approximately 55% identity with TcoMSP-B and 44% 
with TcMSP-B (Appendix 1, Table A1). Also, in general, higher sequence identity is 
observed between proteins from T. brucei and T. congolense compared to those from 
T. cruzi which is expected since T. cruzi is a South American Trypanosoma species. 
Leishmanolysin gave low sequence identities ranging between 20-30%. Highest identity for 
leishmanolysin was seen between the MSP-B protein sequences of all species. Interestingly, 
30% identity was seen between leishmanolysin and TcoMSP-B2 (Appendix 1, Table A1).The 
sequence identity also reinforces the deduction that Tcgp63-Ia, -Ib and II indeed belong to 
the family MSP-B1, B2 and C, respectively (Appendix 1, Table A1). 
From the full alignment (Appendix 1, Figure A1), conserved regions were schematically 
mapped as seen in Figure 1.6. In total, 18 conserved cysteine residues and 12 semi-
conserved proline residues (11 or more of the sequences contain a proline at that position) 
are present which means that the secondary and tertiary structure of these proteins is likely 
to be conserved. The conservation of important amino acid residues throughout different 
species shows that the basic function of the protein has not changed. This conservation 
again suggests these proteins are of importance within the various parasites (LaCount et al., 
2003). It is observed that all sequences contain a truncated zinc binding site HEXXHXXGF 
instead of the full HEXXHXXGXXH motif found in other metzincin metalloproteases (Figure 
1.6). The truncated form is due to the approximately 40-60 amino acid insert present 
between the glycine and the ‘third’ histidine (Figure 1.6). The C-terminal domain contains 
few conserved regions (Figure 1.6) which corresponds to literature that shows that different 
classes of Major Surface Protease are either GPI-anchored or not (Cuevas et al., 2003; 
LaCount et al., 2003; Grandgenett et al., 2007; Marcoux et al., 2010). 
Evaluation of the number of amino acid residues in each sequence showed that on average 
the MSP protein is ~595 amino acid residues (65 kDa). If the different classes of MSPs of 
Trypanosoma are compared, the sizes MSP-A, -C, -D and -E were similar which correspond 
with sequence identities and may be related to where they are found within parasites 
(Appendix 1 and 2). Greatest variation in size is observed between members of the MSP-B 
family (Appendix 2, Figure A2.1).  
The analysed sequences included the propeptide of the protein (Figure 1.6). It has been 
shown that in leishmanolysin a cysteine residue bound to the zinc cofactor is expected to 
block the active site resulting in protease inhibition (Macdonald et al., 1995). 
Interestingly, catalytically active leishmanolysin is unable to cleave the propeptide of inactive 
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this cysteine zinc complex which then allows the enzyme to autocatalytically remove its 
propeptide. This has been shown to occur, within leishmanolysin, between two valine 
residues downstream from the cysteine (Button and McMaster, 1988). There is a conserved 
cysteine in all other MSPs studied (not present in TcoMSP-B1) which may indicate that the 
propeptide inhibits protein functioning in a similar manner to leishmanolysin (Figure 1.6). All 
of T. cruzi’s MSPs, TbMSP-A and TcoMSP-E contain a valine dyad downstream from the 
conserved cysteine (Figure 1.6). These five MSPs homologues may remove their peptide in 
a similar manner to leishmanolysin but since a large number do not contain this dyad, 










Figure 1.6: Schematic representation of conserved regions within MSPs. C, cysteine residue 
suspected to be involved in peptide inhibition; VV - valine-valine dyad where propeptide is removed 
(arrow); HEXXHXXGF, conserved active site motif; H, third histidine ligand; M, Met-turn methionine. 
From G (Gly) to H (His) a 40-60 amino acid insert is present. The solid line shows the three His (H) 
ligands bound to the zinc (Zn) cofactor while the dotted line shows interaction of Cys with Zn for 
protease inhibition. N- and C-termini are indicated. GPI-anchor signal peptide* is only present in 
MSP-A, -B and -E (as predicted).  
 
1.7.3.2 Secondary Structure of MSPs 
Various prediction programmes are available to predict the secondary structure of proteins. 
Since the structures of all Trypanosoma MSPs are unknown, we used the Quick2D 
bioinformatics tool (http://toolkit.tuebingen.mpg.de/quick2_d) to predict the secondary 
structures discussed here. 
For simplicity, only TcoMSP-B2 and TcMSP-B2 (gp63-Ib) were used in secondary structure 
analysis. When all MSP outputs were examined, it was observed that all these proteases 














following, 50-90 residues later, the 1,4 Met-turn and a third relatively prominent helix 
(examples in Appendix 3). These helices may correspond to helix A, B and C, respectively, 
which are seen in a number of gluzincins and metzincins like thermolysin (Matthews et al., 
1972), astacin (Gomis-Rüth et al., 1993) and leishmanolysin (Schlagenhauf et al., 1998). 
The C-terminal domain is dominated by β-sheets with few helices which is also seen in 
leishmanolysin (Schlagenhauf et al., 1998). Interestingly, TcoMSP-D does not contain the 
1.4 Met-turn methionine that is conserved in all the other MSPs and no methionine is in that 
vicinity either (Appendix 1). 
The Quick2D analysis also showed that all the MSPs contain a signal peptide and signal 
peptide cleavage site which is indicative of being exported from the cell (Kapp et al., 2009). 
An additional prediction program, PredGPI (http://gpcr2.biocomp.unibo.it/gpipe/pred.htm), 
was used to determine the likelihood that the MSP classes have a glycosyl-
phosphatidylinositol (GPI) anchor or not (Appendix 4). It was found that all MSP-As and 
MSP-Bs are highly likely to have a GPI-anchor. All MSP-Cs and MSP-Ds are highly unlikely 
to have a GPI-anchor. On the other hand, the MSP-E class has a probable chance of having 
a GPI-anchor like classes MSP-A and -B. Taking into account both the presence of a signal 
peptide and a GPI-anchor and if prediction corresponds to biological function, it would seem 
that classes MSP-A, MSP-B and MSP-E are all located via a GPI-anchor to the surface of 
the parasite while MSP-C and MSP-D families are either secreted by the parasite or 
anchored to the surface in an alternative manner. This conclusion corresponds to a study 
done by Grandgenett et al. (2007) who showed that VSG cleavage and coat shedding in 
T. brucei is performed by a zinc metalloprotease on the surface of the parasite. Furthermore, 
the recent analysis of the T. brucei cell surface proteome places both MSP-A and MSP-B on 
the surface of the parasite, confirming these predictions (Shimogawa et al., 2015). It has 
been shown that GPI-anchored proteins can act as activator antigens within the immune 
system which may suggest that these proteases cause immune responses in their host and 
may be a good diagnostic target (Brown and Waneck, 1992). 
The sequences were also subjected to predictions on whether transmembrane domains 
were present using DAS-TMfilter (http://mendel.imp.ac.at/sat/DAS/DAS.html). Generally, 
GPI-anchored proteins do not contain transmembrane domains but are rather synthesised 
with a transmembrane tail which is removed after attachment to the GPI-anchor (Brown and 





It was found that the MSP-D family and TbMSP-C are unlikely to have a transmembrane 
domain (Cserzo et al., 2002, 2004) and unlikely to be GPI-anchored (Appendix 4) and so 
could be secreted by the parasite. TcoMSP-C and TcMSP-C are both unlikely to have GPI-
anchors but likely to have transmembrane domains (Appendix 4). 
By comparison, leishmanolysin has a predominant β-sheet secondary structure (Figure 1.7) 
and the C-terminus contains the GPI-anchor used for surface attachment via an asparagine 
residue (Schlagenhauf et al., 1998). In total; there are nine disulfide bridges which help in 
the formation and stabilisation of the tertiary structure. There are three major helices named 
A, B, and C as well as the tight 1,4 Met-turn, represented in all metzincin metalloproteases 
(Gomis-Rüth, 2009). It is also observed that leishmanolysin has a number of extra amino 
acids between helices and disulfide bridges that result in a number of flaps which are not 
seen in other zincin proteases (Schlagenhauf et al., 1998).  
Overall, the MSP proteins seem to contain a number of secondary structure similarities to 
leishmanolysin as well as other metzincins so the tertiary structure and mechanism of 
cleavage employed by these metalloproteases are likely to be similar to those of 
leishmanolysin. 
1.7.3.3 Tertiary Structure of MSPs 
Since high similarity was observed between the MSPs of Trypanosoma species and that of 
Leishmania major, an analysis of the tertiary structure of leishmanolysin, solved by 
Schlagenhauf et al. (1998), was done highlighting both similarities and differences it has with 
other zincin metalloproteases.  
Other than the short HEXXH zinc binding motif, leishmanolysin shows little sequence identity 
with other metalloproteases, other than the homologs occurring in Trypanosoma (El-Sayed 
and Donelson, 1997a; Grandgenett et al., 2000; Marcoux et al., 2010), Crithidia and 
Herpetomonas (Etges, 1992). After crystallisation of leishmanolysin by Schlagenhauf et al. 
(1998), insight into the mechanism of cleavage and similarities to other zinc 
metalloendoproteinases was possible. The overall structure consists of three domains: 
N-terminal, central and C-terminal (Figure 1.7). The N-terminal domain consists of helices A 
and B (Figure 1.7) found on one side of a five-stranded β-sheet complex, which is also 
present in both gluzincin and metzincin families (Matthews et al., 1972; Gomis-Rüth et al., 
1993; Gomis-Rüth et al., 1994). The HEXXH motif is located within helix B of the N-terminal 
domain where the two histidines bind the zinc cofactor (Figure 1.7). The predicted secondary 
structure of other MSPs showed that the second prominent helix contained the zinc ligation 
29 
 
motif (Appendix 3). Leishmanolysin also has two 35 and 40 residue flaps which cover the 
opposite side of the β-sheet. 
The central domain consists of compact anti-parallel helices and an anti-parallel β-sheet. In 
other metzincins, the glycine within the full HEXXHXXGXXH motif causes a tight turn at the 
end of the active site and results in the third histidine being in position for zinc ligand binding 
(Stocker et al., 1995). However, as shown in Figure 1.6, a truncated form of the consensus 
sequence is present in the MSPs which results in the third histidine ligand in leishmanolysin 
being about 60 residues further away compared to other metzincins (Figure 1.7). The 
truncated form of the metzincin zinc binding motif results in an active site geometry which is 
different from other metzincins known to date. 
Schlagenhauf et al. (1998) results show that the conserved histidine is still the third zinc 
ligand and that leishmanolysin has a pentacoordination of zinc binding similar to the astacin 
family. However, instead of the water molecule and tyrosine within the Met-turn being the 
fourth and fifth ligand respectively, a different setup is observed. After electron density 
studies on leishmanolysin and comparison to astacin and matrix metalloproteases, it was 
found that a glycine’s amino nitrogen is in a similar position to the catalytic water of these 
enzymes while the glycine’s carboxyl oxygen is orientated like the phenolic oxygen of 
tyrosine in astacin. So overall, three histidines represent the first three zinc ligands while a 
glycine molecule’s amino nitrogen and carboxyl oxygen form the fourth and fifth ligands, 
respectively. A similar conformation of N-O zinc ligation has been found in stromelysin-1 
matrix metalloprotease (Gomis-Ruth, 1997). Moreover, all the MSPs have a conserved 
glycine residue C-terminal from the active site motif (Appendix 1, Figure A1) 
The Met-turn and helix C is present in the central domain of leishmanolysin (Figure 1.7). The 
function of the Met-turn within leishmanolysin (since it is unlikely to be used for zinc binding) 
and whether these proteases actually need it is uncertain. Since MSP-D of trypanosome 
species do not contain the Met-turn, suggests that it is not essential.  
The C-terminal domain consists mostly of β-sheets and minimal helices are present which is 
comparable to the predicted secondary structure of other MSPs (Appendix 3). It also 
contains six of the nine disulfide bridges present within the entire molecule (Figure 1.7). 
From its N-terminus to its C-terminus the structures are as follows: two-stranded β-sheets, 
two short helices and a six stranded anti-parallel β-sheet sandwich (Figure 1.7) followed by 
two short helices which are attached to a GPI-anchor on the surface of the parasite.  
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Since the truncated form of the metzincin motif is present in all trypanosoma MSPs it is 
probable that similar residues and pentacoordinate geometry of zinc ligation may be used in 


























Figure 1.7: Crystal structure of leishmanolysin. The published structure was edited using Cn3D. 
The N-terminal domain is shown in purple, central domain in blue and C-terminal domain in brown. 
The grey sphere represents zinc binding and red lines represent the disulfide bonds. N- and C-termini 
are labelled.  Yellow represents the HEXXH motif, third histidine ligand (H) and the Met-turn (M). Helix 
A, B and C are labelled. The six-stranded anti-parallel β-sheet sandwich is also labelled. Adapted 
































1.7.4 Mechanism of Substrate Cleavage 
With knowledge of how the zinc cofactor is ligated and the different use of a nucleophile 
within leishmanolysin, the cleavage of the peptide bond by MSPs can be considered. 
Thermolysin is a common zinc metalloprotease and its mechanism of cleavage is illustrated 


















Figure 1.8 General mechanism of catalytic cleavage by thermolysin zinc metalloprotease 
(Pelmenschikov et al., 2002).  
 
The active site of the free thermolysin enzyme contains the zinc cofactor bound by three 
amino acid ligands. A water molecule is also associated with the zinc cofactor and a 
glutamate residue is the near vicinity (1. Free enzyme; Figure 1.8). On peptide entry, the 
carbonyl oxygen polarises with the zinc atom causing the water molecule to associate with 
the glutamate (2. Michaelis complex; Figure 1.8).  
8 Figure 1.8 General mechanism of catalytic cleavage by thermolysin zinc metalloprotease 
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This complex then undergoes nucleophilic attack by a water molecule which results in the 
amino nitrogen of the peptide bond associating with glutamate (3. Tetrahedral complex; 
Figure 1.8). The tetrahedral complex is stabilised by a tyrosine and a histidine held in 
position by an asparagine. The water molecule donates its hydrogen to the amino nitrogen 
causing the peptide bond to break and the release of the amine product. The glutamate is 
also freed. The carboxylate region of the peptide remains attached to the zinc atom (4. 
Enzyme carboxylate complex; Figure 1.8). Addition of a water molecule causes the release 
of the carboxylate product and regeneration of the active site.  
This is the general mechanism of cleavage and there are a number of variations. As 
described before, leishmanolysin is unlikely to use a water and glutamate but rather the 
amino nitrogen and carbonyl oxygen from a glycine in its cleavage (Schlagenhauf et al., 
1998). This is also likely for other MSPs.  
The general substrate specificity for leishmanolysin is -Ala-Tyr↓Leu-Lys-Lys- (Bouvier et al., 
1990) from P2-P3′ (Schechter and Berger, 1967). Studies have shown that P2 can contain a 
Leu as well (Schomburg and Stephan, 2012). Since tyrosine contains a benzene ring as well 
as a hydroxyl group in the R-chain, the S1 site of leishmanolysin must be large to 
accommodate this. The S2’ and S3′ sites have been shown to favour the lysine dyad and, 
therefore, must be able to accommodate their long side chains (Bouvier et al., 1993).  
1.7.5 Function of Major Surface Proteases 
Proteases within parasitic protozoa have been identified to play an important role in these 
unicellular organisms. Identifying different proteases and understanding the way they 
function within the life cycle of parasites have helped to understand how the parasite 
functions, as well as giving insight to vaccine development and diagnostics especially, in 
cases where these organisms infect and cause disease (Klemba and Goldberg, 2002).  
Isoforms of leishmanolysin are expressed in both the promastigote and amastigote stages of 
the life cycle of the parasite and is likely to have different functions within different stages 
(Frommel et al., 1990). One of the most important functions of leishmanolysin is that it is 
able to bind to complement component C3 which the parasite encounters on injection by the 
sand fly vector into the mammalian host (Russell, 1987). Leishmanian parasites expressing 
wild type leishmanolysin on their surface act as primary acceptors of C3b and are involved in 
its conversion into a molecule that contains iC3b. It then uses this to bind Mac-1 receptors 
for cell invasion enabling the parasites to use complement factors without being affected by 
their lytic properties (Brittingham et al., 1995). This aids the parasites’ engulfment by 
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macrophages where they reside within the mammalian host (Russell, 1987; Wilson and 
Hardin, 1988). More recently, it has been shown that leishmanolysin is able to inhibit the 
recruitment of LC3 to phagosomes via the down-modulation of VAMP8 (endocytic SNARE 
protein associated with phagolysosome biogenesis and function), protecting the parasite 
from the antimicrobial activity of the host (Matte et al., 2016). Furthermore, leishmanolysin 
has been identified as a virulence factor for the parasite where it acts, in conjunction with 
cysteine peptidase B, to regulate the trafficking of VAMP3 and VAMP8, two endocytic 
SNARE proteins (Casgrain et al., 2016). Cysteine peptidase B mutant parasites, lack 
expression of leishmanolysin and the ability to regulate the two SNARE proteins (Casgrain et 
al., 2016).  
Other roles that have been suggested for this protease are that they are able to protect 
liposomal contents of the parasite from degradation (Chaudhuri and Chang, 1988) and may 
have an important function in avoiding antimicrobial peptides within the host and vector 
(Kulkarni et al., 2006).  
The discovery of MSP genes within African trypanosomes was a surprise since these 
parasites already have an efficient and effective way of evading the immune system, i.e. 
antigenic variation of their VSG type, which enables different generations of parasite to 
express different surface proteins and therefore evade the immune system (Pays et al., 
2004). Also, African trypanosomes do not contain an intracellular stage of their life cycle, like 
Leishmania does, and so the function of MSPs to aid parasite entry into macrophages or 
other host cells does not apply either (Vickerman et al., 1988). It was concluded that either 
these proteases have novel functions in trypanosomes which do not apply in leishmanian 
species or they have functions that have not yet been discovered in Leishmania.  
Of the small amount of research done on MSPs in T. brucei, it has been shown that 
TbMSP-A and -C are only expressed in blood stage parasites while TbMSP-B is expressed 
in both blood stage and procyclic forms (El-Sayed and Donelson, 1997a; LaCount et al., 
2003; Grandgenett et al., 2007). Expression of MSP-B in the procyclic form is higher 
compared to in the blood stage form. For this reason, LaCount et al. (2003) decided to do an 
in depth study on TbMSP-B. Their study showed that knockout of the TbMSP-B coding gene 
had no effect on growth of parasites at either the procyclic or blood stream stage of 
development and is, therefore, not essential for parasite survival (LaCount et al., 2003). In 
1997, Bang et al. showed that VSGs are exported to the parasite surface with a 
phosphatidylinositol-specific phospholipase C-resistant GPI-anchor and that these VSGs are 
released into the culture medium during parasite differentiation into the procyclic form.  
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This release of VSG is dependent on a zinc metalloprotease since addition of 1,10-
phenanthroline, a common metalloprotease inhibitor, stops this process of protein release 
(Bangs et al., 1997). It was found later that TbMSP-B functions in this coat shedding by 
parasites since RNAi knockout of the gene inhibits release of VSG during parasite 
differentiation (LaCount et al., 2003). TbMSP-B may also be used to ensure that VSG and 
other unwanted procyclin proteins do not accumulate on the surface of the parasites. This 
ability of T. brucei to rapidly shed its VSG coat has now been shown to be due to both 
MSP-B and GPI-PLC activity (Grandgenett et al., 2007). Since TbMSP-A and -C are only 
expressed in the blood stage form of the parasite, these proteases may have life cycle stage 
specific functions.  
After the discovery of homologues for MSP in T. congolense, a study was conducted to 
determine the functioning of TcoMSP-D. TcoMSP-D was studied since conservation with 
T. cruzi and Leishmania MSP was considerable and it is likely to be secreted (Marcoux et 
al., 2010). After recombinant expression of the amino terminus of the protein, mice were 
immunised and then subjected to parasitic infection. It was found that mice immunised 
against TcoMSP-D became more susceptible to parasitic infection and, therefore, TcoMSP-
D is in fact a virulence factor (Marcoux et al., 2010).  
A very interesting study was done by Bangs et al. (2001) using existing metzincin 
metalloprotease inhibitors, known to inhibit Leishmania MSP, on in vitro growing T. brucei 
parasites. Excitingly, four inhibitors were found to reduce proliferation and differentiation of 
blood stage form of the parasite and it was concluded that metalloprotease have an 
important function in the life cycle of trypanosomes. Therefore, this may open a new avenue 
for drug development and therapy (Bangs et al., 2001).  
T. cruzi MSPs are expressed at different life-cycle stages, specifically most abundantly in 
amastigote parasites (Cuevas et al., 2003; Kulkarni et al., 2009). Since T. cruzi has an 
intracellular life cycle stage like Leishmania, it is suspected that its MSP proteases function 
in host cell invasion (Cuevas et al., 2003; Kulkarni et al., 2009). Also, like T. brucei, T. cruzi 
is required to shed its VSG coat during cell differentiation and so its MSP proteases may 
function here as well.  
It has also been shown that a recombinant form of T. carassii gp63 is able to significantly 
reduce expression of inducible nitric oxide synthase, TNFα-1 and -2 within macrophages 
and internalisation of recombinant Tcagp63 was observed by goldfish macrophages 
(Oladiran and Belosevic, 2012). This MSP is grouped together with T. brucei and T. cruzi 
MSPs in phylogenetic analysis. 
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Considering that it has been shown that leishmanolysin is able to protect the parasites from 
antimicrobial peptides found within its mammalian host (Kulkarni et al., 2006), it is possible 
that its trypanosome homologues could have the same function. Leishmanolysin does this 
by rapidly cleaving these peptides so they become ineffective (Kulkarni et al., 2006). 
Antimicrobial peptides have been designed to avoid MSP cleavage which has been 
successfully shown to have anti-leishmanian properties (Kulkarni et al., 2014). This could 
then be applied to Trypanosoma species as an anti-parasitic treatment since African 
trypanosomes have already been shown to be susceptible to antimicrobial peptides in vitro 
(McGwire et al., 2003b). 
Also, a zinc metalloprotease was identified in crude lysate from T. brucei blood stream form 
parasites (de Sousa et al., 2010). Although, it is uncertain whether this protease is part of the 
MSP family or not, it was suggested that it may play a role in crossing the blood brain barrier 
and invading the central nervous system since it was able to degrade collagen, fibronectin 
and laminin, all of which are important vascular matrix components (de Sousa et al., 2010). 
Could it then be possible that MSP plays a similar role? 
Clearly there are still a number of questions involving the function of these proteases that 
need to be answered. Also, they have been identified as virulence factors and, hence, 
important but whether they open up new avenues for diagnostics and treatment of 
trypanosomiasis is still uncertain. Knowledge of their biochemical properties could further 
this investigation. 
 
1.8 Objectives of the Study 
Major Surface Proteases (MSPs) have been identified in the African trypanosomes, T. brucei 
and T. congolense but not in T. vivax. The first aim of the study was to analyse protein 
databases to identify putative T. vivax MSPs and attempt to classify the proteins found. 
Additional bioinfomatic analyses were also done and are presented in Chapter 2. 
Once MSPs were identified in all African trypanosomes, each protease was analysed to 
determine conserved and nonconserved regions. The second aim was therefore to use 
these regions to produce anti-peptide antibodies with differing detection abilities. Three 
peptides were selected with the intention to 1) detect TbMSP-B and TcoMSP-B 
(Tb/TcoMSP:303-314), 2) detect TbMSP-B and TbMSP-C (TbMSP:400-412) and 3) detect 
T. vivax (Tv) MSP-C (TvMSP:686-697). They were used to generate two-types of detection 
molecules: full IgY antibodies and single chain variable fragments (scFvs). This would give 
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insight into the possibly of these proteases as diagnostic markers and these results are 
reported in Chapter 3. 
Of all the MSP classes, MSP-C was of most interest because it is found in all African 
trypanosome species, is expressed in the blood stage form of the parasite and is highly 
unlikely to be GPI-anchored to the surface of the parasite. It, therefore, may be a secreted 
protease. Since these trypanosomes are extracellular, this protease would be secreted 
directly into the host blood stream. This suggests that they could be detected in a diagnostic 
test or may have adverse effect on the host. The last aim was to clone, express and 
characterise the protease under non-denaturing condition. The ability of MSP-C, from 
T. brucei and T. congolense, to hydrolyse the fluorescent substrate H-Suc-Leu-Tyr-AMC, the 
effect of this hydrolysis in the presences of metalloprotease inhibitors and the pH optima of 
the enzymes were also assessed. Furthermore, the detection of recombinant protease by 




Major Surface Proteases in Trypanosoma vivax:  
A Bioinformatics Analysis 
2.1 Introduction 
Numerous Major Surface Proteases (MSPs) have been identified in a number of 
trypanosomal and leishmanial species including the African trypanosomes, T. brucei and 
T. congolense, whereas little has been reported on the T. vivax MSPs. Putative MSP gene 
and protein sequences for T. vivax exist on a number of databases; however, these 
sequences have not been organised into the MSP classes A to E. Therefore, before any 
study can be undertaken on the T. vivax proteases, putative gene and protein sequences 
need to be analysed in comparison with other MSP sequences for their classification as 
MSP-A, B, C, D or E. The National Centre for Biotechnology Information (NCBI-
www.ncbi.nlm.nih.gov/) has the largest collection of sequence information in a single site 
and it was used to search for putative T. vivax MSPs.  
When the metabolic requirement of a gene product is in high demand, gene duplication, 
which can result in multiple copies of a gene, can fulfil this requirement (Ohno, 2013). It is 
known that TbMSP-B has four tandemly repeated genes while there are two classes of 
TcoMSP-B (LaCount et al., 2003; Marcoux et al., 2010). TbMSP-A has five tandemly 
repeated genes (LaCount et al., 2003) which suggests that these proteases are required in 
significantly large amounts by these parasites. However, posttranslational regulation also 
affects protein concentration within a particular cell and it is not solely based on mRNA 
levels [reviewed in Brockmann et al. (2007)].  
Determining the conserved regions within an enzyme’s primary structure can suggest 
similarities in function and substrate specificity. Amino acid residues such as cysteine and 
proline indicate conserved secondary and tertiary structure as mentioned in Chapter 1. 
There are 18 cysteine and 12 proline residues conserved in all MSP sequences (Appendix 1, 
Figure A1) which led to the deduction that these proteases have conserved structural 
characteristics. 
Open source structure prediction programmes were used to determine the possible 
secondary and tertiary structures of putative T. vivax MSPs. The I-TASSER 
(Iterative Threading ASSEmbly Refinement; Figure 1.2) program, used to predict the three-
dimensional structures of each T. vivax MSPs, was selected based on its rating, its 
accessibility and its ease of use.  
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Rating of protein prediction software is conducted by the community-wide Critical 
Assessment of Structural Prediction (CASP) experiments for which I-TASSER has been 
rated top for a number of years running (2007-2011). Tertiary protein prediction programs, 
such as MODELLER, which is rated as one of the best software, requires program download 
and an understanding of programming language, while I-TASSER is completely web-based 
and results are sent to the user after modelling is complete. It was for these reasons that this 















Figure 2.1: Schematic diagram of I-TASSER hierarchical method of three-dimensional protein 
modelling. The protocol is based on the use of protein structure categorisation using secondary 
structure profiling. Sequences are threaded through profile-profile alignments (PPA) until all regions 
are aligned with known structures which allows for the development of template structural fragments. 
All possible fragments are grouped together in such a way to form a number of full length structural 
models which are compared to known structures. The models that cluster together with known 
structures are then used to undergo profile-profile alignment again as well as using the structural 
alignment program called TM-align. This then allows for structural reassembly where those models 
with the lowest E-values are selected for the addition of rotamers (or N, C, O backbones) to produce a 
final model. The newer versions of I-TASSER also include function prediction but it was not included 
























The I-TASSER method of modelling is based on hierarchical protein structure categorisation 
using secondary structure profiling (Figure 2.1). Sequences are threaded through a number 
of secondary structure profiles until all regions are aligned with the primary and secondary 
structures of proteins with known tertiary structure (Zhang, 2008). Regions that show gaps or 
a low level of alignment are designated as separate domains and multiple domains are then 
determined. This allows for modelling of both full length protein and separate domains giving 
a more complete final model (Zhang, 2008). Finally, domains are docked together to form a 
final full length protein which is superimposed with the most closely related protein that has a 
known three-dimensional structure. Five models are produced and users then decide which 
best represents the protein’s structure. The full outline of I-TASSER method of protein 
modelling is explained by Roy et al. (2010). 
The results described in this chapter include the identification of putative gene and protein 
sequences from NCBI for a number of T. vivax MSP classes. These sequences were 
subjected to secondary and tertiary structural bioinfomatic investigations in an attempt to 
show conservation of key characteristics of this family of proteases. This analysis was done 
in parallel to the Marcoux et al. (2010) modelling study on MSPs in T. congolense. 
2.2 Materials and Methods  
2.2.1 Selection of T. vivax MSP Sequences 
The methods used within this Chapter are outlined in Figure 2.2 below. The NCBI database 
(www.ncbi.nlm.nih.gov/) and Basic Local Alignment Search Tool for protein (BLASTp- 
www.ncbi.nlm.nih.gov/BLAST/) were used to find putative MSP sequences within the T. 
vivax genome. The NCBI protein database was searched using these specific phrases: 
‘Trypanosoma vivax gp63′, ‘Trypanosoma vivax major surface protease’, ‘Trypanosoma 
vivax putative M8 peptidase’. Six sequences comprising 400-700 amino acid residues were 
selected as putative MSP sequences. BLASTp was then used to localise sequences from 
T. vivax with all T. brucei and T. congolense MSP sequences. Two additional putative MSPs 
comprising  400-700 amino acid residues were found. Eight putative T. vivax MSP protein 
sequences were identified (Accession numbers: CCC52269.1, CCC53317.1, CCC53338.1, 
CCD18177.1, CCD18122.1, CCD19977.1, CCD21328.1, CCD20103.1). ClustalW 
(www.ebi.ac.uk/Tools/msa/clustalw2) was used in an alignment of all MSPs from T. brucei, 
T. congolense, T. cruzi and leishmanolysin. This alignment was used to construct an 
unrooted phylogenetic tree. The sequences that shared the same clade with each class (A, 
B, C, D or E) of MSP were selected as putative TvMSPs.  
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The genomic organisation of the identified proteases, within the T. vivax genome, was done 
by finding the corresponding gene for each selected protease as well as the size and 
chromosome on which each gene resides, using the NCBI nucleotide database.  
2.2.2 Primary Structural Analyses  
Primary structural analysis was done by using ClustalW within the BioEdit platform to align 
the selected sequences with other MSPs. The alignment was then used to identify 
conserved amino acid residues, such as histidine and cysteine, which are known to have 
important functions. Sequence identity and theoretical sizes of TvMSPs were used to assess 
the similarities between each MSP class and within each trypanosome species, in 
comparison with the analyses outlined in Chapter 1. 
2.2.3 Secondary Structural Analyses 
T. vivax MSPs were analysed in four secondary prediction programmes: Quick2D 
(http://toolkit.tuebingen.mpg.de/quick2_d), PredictProtein (https://www.predictprotein.org/), 
PSIPred (http://bioinf.cs.ucl.ac.uk/psipred/) and Scratch Protein Predictor 
(http://scratch.proteomics.ics.uci.edu/). The resulting information was tabulated for 
comparison and identification of important structural characteristics. The sequences were 
also subjected to GPI predictions software: PredGPI (http://gpcr.biocomp.unibo.it/predgpi/). 
2.2.4 Tertiary Structural Analyses 
Each T. vivax MSP was submitted for three-dimensional structure modelling using the 
software I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/). The method with 
which this software designs three-dimensional models is explained in Section 2.1. The 
program outputs five of the best tertiary models in protein data bank (.pdb) format. Those 
with the highest confidence score were then converted to Cn3D format (.cn3) using VAST 
search (http://www.ncbi.nlm.nih.gov/Structure/VAST/vastsearch.html) for their manipulation 
in the Cn3D software (downloadable from the NCBI structure database). Cn3D-converted 
models produce structures highlighting individual domains. Model one of TvMSP-A and -E 
with the highest confidence score from the I-TASSER server, gave three domains as seen 
for leishmanolysin and these models were therefore used. Model one of TvMSP-C and -D 
with the highest confidence scores gave domain outlines that were incomparable to 
leishmanolysin and so model two from the I-TASSER server was used. The models were 
compared to the known leishmanolysin structure and the addition of a zinc atom was done to 
help with the orientation of each model. All editing of the models was done within the Cn3D 






















Figure 2.2: Flow diagram outlining the methods used in the work reported in this chapter. 
NCBI, National Centre for Biotechnology Information; BLAST, Basic Local Alignment Search Tool; aa, 
amino acid residues; MSP, Major Surface Protease; GPI, Glycosylphosphatidylinositol; and 
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2.3.1 Selection of T. vivax Protein Sequences and Genomic Organisation 
The NCBI protein and BLASTp databases were searched to find a total of eight ‘full length’ 
MSP protein sequences (400-700 aa) for T. vivax (Jackson et al., 2012). A multiple 
sequence alignment was done using ClustalW (Larkin et al., 2007) with these MSP 
sequences and used to construct an unrooted phylogenetic tree (Figure 2.3). An unrooted 
tree was used because the ancestry of these proteases is uncertain and since evolutionary 
distance is not considered in this study, a rooted tree is not required. The tree was used to 
simply give visual representation of which sequences group together. In Figure 2.3 (panel 
A), CCC52269.1 is grouped in the same clade as TbMSP-A and TcoMSP-A and is named 
TvMSP-A in further analyses. Sequence CCC53317.1 is grouped in the same clade 
TcoMSP-D and is named as TvMSP-D. Sequence CCC53338.1 is grouped in the same 
clade as TcoMSP-E and is named TvMSP-E. Sequence CCD18177.1 is grouped in a 
subclade of TbMSP-C and TcoMSP-C and is named TvMSP-C. None of the sequences 
found were grouped in the same clade as TbMSP-B, TcoMSP-B or TcMSP-B and therefore 
no protein sequence for MSP-B were identified for T. vivax. All the other sequences are a 
branch of CCD18177.1 (TvMSP-C). As shown in Section 1.7, MSP-C and -D, and MSP-B 
and -E show higher sequence identity with each other while the MSP-As are grouped on 
their own (Figure 2.3, panel A). Leishmanolysin is grouped in the same clade as TcoMSP-D 
which was unexpected as its sequence identity is highest with TcoMSP-B (Appendix 1).  
Corresponding nucleotide sequences, for each protein sequence, were found and the 
genomic organisation is shown in Figure 2.3 (panel B). The TvMSP-A nucleotide sequence 
occurs on chromosome 10, which is unlike other MSP-A genes from other Trypanosoma 
species where it resides on chromosome 11. MSP-C from T. congolense and T. brucei 
reside on this chromosome instead. However, like TcoMSP-D and -E, TvMSP-D and -E also 
resides on chromosome 11 approximately 38 kb apart. The size of TvMSP-D and TcoMSP-D 
are the same (2 kb), while the size of TvMSP-E (1.64 kb) is similar to TcoMSP-E (1.7 kb). 
TvMSP-A (1.8 kb) is similar to TbMSP-A (1.9 kb) and TcoMSP-A (1.7 kb), as well. The 
chromosome on which the TvMSP-C gene resides could not be determined and its size 



















Figure 2.3: Phylogenetic representation and genomic organisation of T. vivax MSP protein 
sequences in relation to MSP classes from T. brucei, T. congolense, T. cruzi and 
leishmanolysin. (A) Phylogenetic tree showing selected sequences for each class of TvMSP. Note 
that no sequence was found to be in the same clade as MSP-B. (B) Arrangement of different TvMSP 
genes on corresponding chromosomes within the T. vivax  genome. ? denotes unknown information. 
(Saitou and Nei, 1987; Larkin et al., 2007). 
 
2.3.2 Primary Structure Analyses 
For primary structural analysis the sequence alignment shown in Appendix 1 and the 
schematically mapped conserved regions were shown (see Figure 1.6). The primary 
structure of T. vivax MSPs contains all conserved cysteine residues and all semi-conserved 
proline residues (Appendix 1) which is indicative of conserved secondary and tertiary 
structure (LaCount et al., 2003). All TvMSP sequences included the HEXXHXXGF truncated 
motif, and ~60-70 amino acid residues C-terminal to this motif the ‘third’ histidine ligand 
(conserved in all sequences). 
Interestingly, TvMSP-A shares the highest identity with TbMSP-A but TvMSP-C, -D and -E 
have highest identity with TcoMSPs of the corresponding classes (Appendix 1). Overall, T. 
vivax MSPs at ~70 kDa are generally larger in size compared to all other MSPs with TvMSP-
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T. vivax MSPs show highest variability in size between each class of protein (Appendix 2). 
All T. vivax sequences also contain the conserved cysteine residue within their propeptide 
(Figure 1.6), like leishmanolysin, which suggests a similar mechanism of enzyme inhibition. 
TvMSP-E is the only T. vivax sequence that contains a valine dyad where leishmanolysin 
cleaves its pro-region to become fully activated (Button and McMaster, 1988). 
2.3.3 Secondary Structure Analyses 
Secondary structure analysis was done by comparing four prediction programs: Quick2D, 
PredictProtein, PSIPred, and Scratch Protein Predictor and is presented in Appendix 5. All 
TvMSP sequences for all predictions show three prominent helixes which are called helix A, 
B and C as seen in leishmanolysin and other metzincin and gluzincin proteases (Matthews 
et al., 1972; Gomis-Rüth et al., 1993; Gomis-Rüth et al., 1994). There are highly variable 
regions N-terminal from helix A, in all TvMSPs, which is most likely due to the presence of a 
propeptide. TvMSP-C has the largest propeptide with helix A starting at the 200th residue 
compared to the ~120th residue for the other TvMSPs. 
All contain the HEXXH motif within helix B as seen for all zincin proteases (Bode et al., 
1993) and the amino acid insert before the ‘third’ histidine seen only in MSPs. C-terminal to 
the ‘third’ histidine ligand is the 1, 4 Met-turn (which gives metzincins their name) present in 
all TvMSPs, except the D class, and almost all MSPs (Appendix 1). Both TvMSP-D and 
TcoMSP-D lack this methionine residue. Comparable to all metzincin proteases, helix C 
follows shortly after the Met-turn for all TvMSPs (Barrett et al., 2004). Within the C- terminal 
regions the predicted number of β-sheets exceeds the number of α-helices by greater than 
10 for all classes of the TvMSP proteases.  
Leishmanolysin has three main domains: N-terminal, central and C-terminal. Helices A and 
B, including the HEXXH motif, are present in the N-terminal domain, the third histidine 
ligand, Met-turn and helix C are in the central domain with a β-sheet sandwich within the C-
terminal domain. The domain predictions for TvMSPs show no correlation to the 
leishmanolysin domains. None correspond to the pattern seen with helices A and B in 
domain one; third ligand, Met-turn and helix C in domain two followed by domain three. 
However, C-terminal regions of all the proteases are dominated by β-sheets, which are 
comparable to that of leishmanolysin. 
All TvMSP are unlikely to be transmembrane proteins as expected (Appendix 5). These 
proteases are suspected to be attached by a GPI-anchor to the surface of the protein as 
seen for TbMSP-B (LaCount et al., 2003; Grandgenett et al., 2007). 
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Further analysis using the pred-GPI program showed that TvMSP-A and -E are highly likely 
to be GPI-anchored to the surface of the parasite while TvMSP-D is highly unlikely to be 
GPI-anchored, like all other MSPs. In contrast to other MSP-C classes, TvMSP-C is highly 
likely to contain a GPI-anchor comparable to TvMSP-A and -E (Appendix 5). GPI-anchor 
prediction was also done on the unused sequences (CCD18122.1, CCD19977.1, 
CCD21328.1, CCD20103.1) from the T. vivax genome and it was found that two were 
weakly probable to have an anchor while two were highly probable to have an anchor 
comparable to TvMSP-C (CCD18177.1).  
2.3.4 Tertiary Structural Analyses 
I-TASSER was used to predict the three-dimensional structure of the four putative TvMSPs 
(Figures 2.4-2.7). Each model is shown with a zinc atom used for their orientation in 
comparison with leishmanolysin shown previously (Figure 1.7). 
Models for TvMSP-A and –E have similar structures to each other and to leishmanolysin 
while models constructed for TvMSP-C and -D are similar to each other but contain a 
number of extra loops and flaps particularly N- and C-terminally. The core structure, 
however, is highly comparable to that of leishmanolysin as seen in Figure 1.7 with each 
containing an observed helix A, helix B (with the truncated HEXXH active motif), followed by 
a third histidine ligand, Met-turn, helix C and a β-sheet sandwich. The domain prediction 
follows the expected pattern in most cases. All modelled structures contain a predicted 
propeptide which is not seen in the active leishmanolysin three-dimensional structure (Figure 
1.7).  
The predicted propeptide TvMSP-As (Figure 2.4), shown in yellow, is tightly coiled and 
remains atop the structure. The propeptide contains the conserved cysteine residue and 
forms a ‘lid’ with possible blocking of the putative active site which may prevent entry of 
larger substrate entry (Figure 2.4). The leishmanolysin propeptide is suspected to act using 
the cysteine switch mechanism in which a highly conserved cysteine residue forms a 
complex with the zinc cofactor in the active site (Macdonald et al., 1995). In this case, the 
conserved cysteine residue would be in the correct orientation to form a complex with the 
zinc atom.  
The N-terminal domain of the protein, shown in purple, has a compacted C-terminal ‘tail’ and 
two extra helices (C-terminal to helix B) not seen in the N-terminal domain of leishmanolysin 
(compare Figure 2.4 to Figure 1.7). This domain, however, contains conserved structures 
such as helices A and B (with the HEXXH motif). Conversely, helix A is separated into two 





N– Terminal Domain 







C– Terminal Domain  
β – sheet 
sandwich 
The central domain, shown in blue, containing the third histidine ligand, Met-turn and helix C 
(Figure 2.4), is very similar to the leishmanolysin central domain. It can also be seen that the 
HEXXH motif and the third histidine ligand are in a similar position to that of leishmanolysin 
which is optimal for zinc binding (shown in Figure 2.4 with a grey sphere). Shown in brown is 
the C-terminal domain which has the same orientation as in leishmanolysin with two anti-



















Figure 2.4: TvMSP-A modelled by I-TASSER modelling program. Purple indicates predicted N-
terminal domain, blue-central domain and brown-C-terminal domain. N- and C- termini are labelled. 
Yellow indicates predicted pro-region of the enzyme while the HEXXH motif, third histidine ligand (H), 
Met-turn (M) and helices A, B and C are indicated on the structure. Red lines indicate suspected 
disulfide bonds. The grey sphere represents the possible positioning of the zinc atom as in 
leishmanolysin (added after modelling and used for orientation). 
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The comparison of modelled TvMSP-A to modelled TcoMSP-A (Marcoux et al., 2010) shows 
similarity in zinc atom orientation with a helical structure (assumed to be helix B) and a 
second helical structure in close proximity (assumed to be helix A). However, differences 
seen between the two include a reduced number of helices and β-sheets and the lack of a β-
sheet sandwich. 
The propeptide of modelled of TvMSP-C (indicated in yellow) is longer in length and its 
orientation does not block the putative active site in any way that is visible (Figure 2.5). The 
N-terminal domain, shown in purple, contains helices A and B with the HEXXH motif as 
expected (Figure 2.5). Helix A is a single long helical region as seen in leishmanolysin 
(Figure 1.7) but unlike TvMSP-A (two separate helices; Figure 2.4). Overall, the 
conformation of this domain resembles that of leishmanolysin including the compacted 
β-sheets; loop regions and the C-terminal tail (compare Figure 1.7 to Figure 2.5). It also 
does not contain any extra helical structures like those in TvMSP-A.  
The central domain, shown in blue, has an arrangement of the third conserved histidine 
ligand, Met-turn and helix C that resembles those of leishmanolysin and seem to be 
conserved throughout all classes of the protease. Again, helix B and the third histidine ligand 
are in optimal positioning for zinc binding as compared with leishmanolysin (Figure 2.5, grey 
sphere).  
The C-terminal domain was predicted to have two separate domains (brown and grey) but 
when grouped together and compared to leishmanolysin’s C-terminal domain (compare 
Figure 1.7 to Figure 2.5), the grey (extra domain) resembles the N-terminus of the domain 
with the same two anti-parallel β-sheets. The domain shown in brown contains the 
C-terminal β-sheet sandwich. Unlike leishmanolysin, this protein is predicted to have an 
extra C-terminal loosely folded tail. This region is not found in any other family of MSPs and 
may take into account the larger size of TvMSP-C compared to its homologues (Appendix 
2).  
Modelling of TcoMSP-C by Marcoux et al. (2010) shows the zinc atom orientation to be 
similar to that in TvMSP-C again with a prominent helix as well as a loop region (assumed to 
























Figure 2.5: TvMSP-C modelled by I-TASSER modelling program. Purple indicates predicted N-
terminal domain, blue-central domain and brown-C-terminal domain. N- and C- termini are labelled. 
Yellow indicates predicted pro-region of the enzyme, while the HEXXH motif, third histidine ligand (H), 
Met-turn (M) and helices A, B and C are indicated on the structure. Red lines indicate suspected 
disulfide bonds. The grey sphere represents the possible positioning of the zinc atom as in 
leishmanolysin (added after modelling and used for orientation). 
 
The MSP-D class of proteins is only present in T. congolense and T. vivax. In the model 
shown in Figure 2.6, the propeptide is coloured yellow and contains an extra helical structure 
which corresponds with predicted secondary structure (Appendix 5), but is not seen in other 
TvMSPs. Orientation of the propeptide, which again contains the conserved cysteine residue 
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13Figure 2.5: TvMSP-C modelled by I-TASSER modelling program. 
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The N-terminal domain is shown in purple (Figure 2.6) and contains helix A and B as well as 
the HEXXH motif. Helix A is also shown as a single long helical region rather than two 
separate smaller ones, comparable with TvMSP-C and leishmanolysin. This domain does, 
however, contain two extra N-terminal helical regions which are not present in 
leishmanolysin (N-terminal domain dominated with β-sheets and helix A and B are the only 
two present: compare Figure 1.7 to Figure 2.6). This is comparable to TvMSP-A; however, 
the two extra helical structures of TvMSP-D are more C-terminal (compare Figure 2.4 to 





















Figure 2.6: TvMSP-D modelled by I-TASSER modelling program. Purple indicates predicted 
N-terminal domain, blue-central domain and brown-C-terminal domain. N- and C- termini are labelled.  
Yellow indicates predicted pro-region of the enzyme, while the HEXXH motif, the third histidine ligand 
(H) and helices A, B and C are indicated on the structure. No Met-turn is present within D classes of 
the protein. The predicted structure shows no disulfide bonds. The grey sphere represents the 
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The MSP-D class lacks the conserved methionine (Figure 1.6) which is characteristic of 
metzincin metalloproteases and is present in all other MSPs studied thus far. Thus, unlike 
leishmanolysin and other TvMSPs, the central domain, shown in blue, lacks this feature. 
However, it does contain the third histidine ligand and helix C in the same conformation as 
other TvMSPs and leishmanolysin which results in a similar folding compared to other 
central domains. The histidine ligands are in the correct orientation for zinc binding which is 
necessary for enzyme activity.  
Like TvMSP-C, TvMSP-D’s C-terminal domain consists of two separate domains shown in 
brown and grey (Figure 2.6). However, the first brown domain resembles the entire 
leishmanolysin C-terminal domain and the ‘fourth’ grey domain represents an extra 
C-terminal region of the protein. The predicted structure does contain the two anti-parallel β-
sheets leading to the compacted β-sheet sandwich, like all other TvMSPs and 
leishmanolysin. The extra domain is incomparable to the extra region seen in TvMSP-C 
which is more a tail rather than an individual domain. The sizes of TvMSP-D (75 kDa) and 
TvMSP-C (77 kDa) are relatively similar which may indicate that TvMSP-C might have extra 
loops and flaps within the actual protein structure rather than excess N- and C-terminal 
regions only. Whether this extra fourth domain in TvMSP-D has a functional role in this 
protein class is unknown. 
The TcoMSP-D model (Marcoux et al., 2010) shows the same zinc orientation as seen for all 
other MSPs modelled to date including the expected helix A and helix B. However, it is 
lacking a number of β-sheets in the N-terminal domain that TvMSP-D and leishmanolysin 
contain, as well as the full β-sheet sandwich seen in all TvMSPs. It does not have the extra 
C-terminal domain seen in TvMSP-D either. 
The MSP-E class of proteins, like MSP-Ds, are also found in T. congolense and T. vivax 
only, but show most sequence identity with MSP-A. The propeptide of TvMSP-E, shown in 
yellow, is predicted to lie atop the main protein structure (Figure 2.7) and like TvMSP-A 
forms a ‘lid’ over the active site. It also contains the conserved cysteine residue which, in this 
orientation, would be able to form a complex with the zinc cofactor.  
The N-terminal domain, shown in purple, contains the same helix A and B with the HEXXH 
motif (Figure 2.7). It resembles TvMSP-D since it lacks the C-terminal tail observed in the 
N-terminal domain of TvMSP-A, -C and leishmanolysin (compare Figure 2.7 to Figure 1.7); 
however, its helix A is separated into two smaller helical regions like TvMSP-A. It does not 
contain the extra two helices as is the case for TvMSP-A and -D which is comparable with 
leishmanolysin and TvMSP-C.  
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The central domain, shown in blue, resembles all other classes containing the third histidine 
ligand, Met-turn and helix C (Figure 2.7). Helix B and the third His ligand are also in optimal 
positioning for zinc binding (Figure 2.7, grey sphere). The C-terminal domain, shown in 
brown, contains the two anti-parallel β-sheet regions leading to the β-sheet sandwich. This 
domain closely resembles TvMSP-A.  
The zinc atom orientation of the TcoMSP-E model’s (Marcoux et al., 2010) is incomparable 
to that of TvMSP-E with no helix B being present for binding. There is also no β-sheets and 





















Figure 2.7: TvMSP-E modelled by I-TASSER modelling program. Purple indicates predicted N-
terminal domain, blue-central domain and brown-C-terminal domain. N and C termini are labelled.  
Yellow indicates predicted pro-region of the enzyme, while the HEXXH motif, third histidine ligand (H), 
Met-turn (M) and helices A, B and C are indicated on the structure. Red lines indicate suspected 
disulfide bonds. The grey sphere represents zinc atom expected positioning as in leishmanolysin 
(added after modelling and used for orientation). 
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The modelling software (Figures 2.4-2.7) and the Scratch Protein Predictor (Appendix 5) 
showed various numbers of disulfide bonds in each TvMSP, however, since all TvMSPs 
contain the 18 conserved cysteine residues found within leishmanolysin and other 
trypanosoma MSPs (Figure 1.6, Figure 1.7 and Appendix 1), it is suspected that all contain 
nine disulfide bonds. Similar to leishmanolysin though, all disulfide bonds were predicted to 
be in the C-terminal domain for all four TvMSPs (Figure 2.4-2.7). 
All protein sequences selected to represent the T. vivax MSP classes have key 
characteristics which shows that they belong to this group of metalloproteases. However, 
each individual protein also has unique features which shows why they are in different 
classes of MSPs. 
2.4 Discussion  
The NCBI database was searched for putative MSP sequences within the African 
trypanosome, T. vivax for which eight sequences were found ranging in size from 400-700 
amino acid residues. After phylogenetic comparison of all eight sequences with all other 
MSP proteases from T. brucei, T. congolense, T. cruzi and leishmanolysin, four were 
selected to represent classes MSP-A, -C, -D and -E. These four T. vivax MSP sequences 
then were subjected to a number of secondary and tertiary structure bioinfomatic analyses. 
They showed key characteristics within their predicted structures that are conserved and are 
comparable with leishmanolysin and metalloprotease of the metzincin family. Each class 
also contained unique features explaining the presence of individual classes of the protease. 
The evidence provided here again shows how these proteases are conserved across 
species, genera and families which could suggest that their function has some importance in 
these parasites (Chaudhuri and Chang, 1988; Etges, 1992; Ramamoorthy et al., 1992; El-
Sayed and Donelson, 1997a; Cuevas et al., 2003; Jesudhasan et al., 2007; Marcoux et al., 
2010; Oladiran and Belosevic, 2012).  
No protein sequence was found to be phylogenetically grouped with the MSP-B class and for 
the remainder of this study, this protein class was omitted. TvMSP-C, when subjected to 
phylogenetic construction with the omission of all other subsequences listed in Figure 2.3, 
appears as a parent sequence to the other MSP-Cs (data not shown). This sequence was 
also the only MSP-C protein that was predicted to be GPI-anchored to the surface of the 
parasite, unlike other MSP-Cs which are unlikely to be GPI-anchored [Marcoux et al. (2010) 
and the points described in Chapter 1]. GPI-anchor prediction was also done on the unused 
sequences (CCD18122.1, CCD19977.1, CCD21328.1, CCD20103.1) from the T. vivax 
genome and it was found that two were weakly probable to have an anchor while two were 
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highly probable to have an anchor (data not shown) comparable to TvMSP-C (CCD18177.1). 
These characteristics of TvMSP-C (and sequences CCD20103.1 and CCD21328.1) 
resemble MSP-Bs from other species and so it is hypothesised that ‘TvMSP-B’ may have 
higher identity with possible TvMSP-Cs. Sequences CCD18122.1 and CCD19977.1 would 
then represent the true MSP-C class from T. vivax which is unlikely to be GPI-anchored as 
expected. This is, however, speculative and it is uncertain whether the T. vivax genome 
contains an MSP-B gene at this point.  
All the sequences selected were predicted to include the propeptide of the protein. 
Leishmanolysin has been shown to have latent activity which is activated by the treatment 
with organomercurials (Macdonald et al., 1995). The activated enzyme is unable to cleave 
latent enzyme into its fully activated form which means that leishmanolysin is not 
autocatalytic (McGwire and Chang, 1996). Treatment by organomercurials, as a means to 
activate the enzyme, is commonly observed with activation of matrix metalloproteases and 
the cysteine switch mechanism (Stricklin et al., 1983). Matrix metalloproteases all contain 
the consensus sequence ‘PRCGVPDV’ which includes this cysteine residue (Park et al., 
1991). The theory is based on the binding of the sulfhydryl group of a conserved cysteine 
residue with the zinc cofactor of the enzyme thereby blocking the active site (Van Wart and 
Birkedal-Hansen, 1990). Organomercurials are able to break this bond which then allows 
removal of the propeptide. Mercury chloride has been shown to fully activate leishmanolysin 
(Macdonald et al., 1995). A conserved cysteine residue is found in all MSP sequences and a 
number contain the ‘RC’ dyad seen in the matrix metalloprotease consensus sequence 
(Park et al., 1991).  
Orientation of the propeptide shown in the modelling of TvMSP-A and -E forms a ‘lid’ over 
the active site and is in prime position for cysteine interaction with the zinc cofactor within the 
putative active site. This folding would explain the latent activity in leishmanolysin, before 
activation, since the active site is not completely blocked and may still allow low levels of 
substrate cleavage. TvMSP-C and -D propeptide modelling showed the active site open and 
exposed.  
Since I-TASSER bases its modelling on predicted domains and because TvMSP-A and -E 
both have the ‘RC’ dyad within their propeptide, modelling of this region for these two 
sequences could have been based on known structures of modelled matrix metalloprotease 
propeptides such as procollagenase, transin (rat stromelysin) and human stromelysin 
(Stricklin et al., 1983; Park et al., 1991; Gomis-Ruth, 1997). TvMSP-C and -D do not contain 
the ‘RC’ dyad and perhaps its propeptide modelling was based on a different known 
structure and would explain the differences seen here.  
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The T. congolense and T. vivax genomes contain the classes MSP-D and -E which are not 
present in T. brucei. These proteases are suspected to have similar roles to MSP-C and -B, 
respectively because they are either known (Grandgenett et al., 2007; Shimogawa et al., 
2015) or predicted to be GPI-anchored (MSP-B, -A and -E) or predicted not to be GPI-
anchored (MSP-C and -D). Since T. brucei has four tandemly repeated MSP-B genes while 
T. congolense has two classes of MSP-B (Figure 1.5), it may suggest that MSP-E in 
T. congolense acts like MSP-B when this protease is required in high amounts. This 
suggests different regulation of expression of these proteases within the two species. 
Furthermore, because T. vivax has both MSP-A and -E, that are suspected to have similar 
roles to MSP-B, it does not require this enzyme in such high quantities and the MSP-B class 
could have been lost from the T. vivax genome.  
The MSP-D class is unique because it does not contain the conserved methionine residue 
(Marcoux et al., 2010) found in all metzincin proteases (Bode et al., 1993). In studying the 
crystal structure of leishmanolysin, it was determined that due to the extra loops between the 
second and ‘third’ histidine ligand, the methionine turn which helped in zinc binding, loses its 
function (Schlagenhauf et al., 1998). Therefore, this class of protease is more than likely to 
have the same function as the other proteases. TvMSP-D does have ~10 extra amino acid 
residues between the second and ‘third’ histidine ligands which may help in ligand 
orientation in the absence of the methionine.  
Overall, four putative T. vivax MSP sequences were selected to represent classes A, C, D 
and E. These selected sequences underwent bioinformatic investigation to determine 
important key features of these proteases as well as unique features within each class. 
These identified sequences were used in conjunction with T. brucei and T. congolense 
sequences to identify immunogenic peptides for the production of anti-peptide antibodies 
(Chapter 3). This allowed for the exploration of these proteases as potential diagnostic 
markers. These proteases were also recombinantly expressed and purified, to give insight 
into their multimerisation and enzymatic function (Chapter 4). 
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Chapter 3  
Anti-peptide Antibody Production against  
T. brucei, T. congolense and T. vivax MSP-B and -C:  
IgY antibodies vs single chain Fv fragments (scFvs) 
3.1 Introduction  
Human African trypanosomiasis (HAT) and animal African trypanosomiasis (AAT) are two of 
the many neglected tropical diseases causing health, agriculture and economical burdens to 
the continent. To combat any disease, accurate diagnosis is required to ensure correct 
treatment and since the symptoms of tropical diseases are similar (Tiberti et al., 2013), direct 
clinical diagnosis is challenging and often unreliable. For HAT, disease transmission is 
suspected to be under control since the number of reported cases are on a decline, 
however, aspects of patient management still need improvement [reviewed in Tiberti et al. 
(2013)]. AAT control has been less effective with the disease being highly prevalent 
throughout countries of sub-Saharan Africa [reviewed in Odeyemi et al. (2015)]. AAT has 
also spread to previously trypanosomosis-free areas such as the Jos Plateau, Nigeria 
[occurred in the last two decades; Majekodunmi et al. (2013)]. A more recent publication 
showed that the Mayo Rey division of Cameroon’s cattle still have an annual prevalence of 
bovine trypanosomiasis of 55.2% (Abdoulmoumini et al., 2015). Furthermore, assessment of 
AAT susceptibility of cattle farming communities within sub-Saharan Africa showed that 
these communities can be clustered into groups of low to high vulnerability (Holt et al., 
2016). It was suggested that for effective control, specialised methods for each area of 
vulnerability is necessary (Holt et al., 2016). Therefore, new diagnostic and disease staging 
tools are required to continue the fight against both HAT and AAT. 
Synthetic peptides corresponding to immunogenic epitopes in proteins have been used to 
produce site-specific antibodies for their use in both diagnostic tests and vaccine 
development (Posnett et al., 1988; Gómara and Haro, 2007). These peptides provide a 
powerful tool for the production of antibodies that can be polyclonal, yet mono-specific. This 
would allow for the detection of an array of antigens to just a single antigen (Lee et al., 
2010). The generation of these types of antibodies involves the determination of 
immunogenic regions within the antigen using epitope prediction software. Whether the 
peptide is conserved between proteins of different species or unique to a protein from a 




Recently developed diagnostic tests for HAT and AAT that use parasite antigen for the 
detection of serum antibodies include HAT SERO K-SeT (detects patient serum antibodies 
against T. b. gambiense VSGs LiTat 1.3 and 1.5), HAT Sero-Strip (detects patient serum 
antibodies against T. b. gambiense VSGs LiTat 1.3 and 1.5), SD BIOLINE HAT (detects 
patient serum antibodies against T. b. gambiense VSGs LiTat 1.3 and 1.5) and Surra SERO 
K-SeT [detects animal serum antibodies against T. evansi VSGs Rotat 1.2; (Büscher et al., 
2014; Birhanu et al., 2015; Jamonneau et al., 2015)]. The identification of antigen p310 (an 
ISG) with the ability to specifically detect T. vivax infected cattle sera in a diagnostic setup, is 
in early stage field testing (Fleming et al., 2016). These detection systems are rapid, easy to 
use and field-applicable which is suitable for diagnosis in the sub-optimal, poor 
infrastructural environment found in sub-Saharan Africa where trypanosomiasis occurs. The 
tests are similar to more commonly used diagnostic tests, in both specificity and sensitivity, 
with most detecting trypanosomiasis with 95% accuracy (Büscher et al., 2014; Birhanu et al., 
2015; Jamonneau et al., 2015). As HAT infected cases decreases, diagnostic tests require 
increased sensitivity. Studies have shown that detecting more than one type of antigen 
within a single test may help solve this problem (Jamonneau et al., 2015). It has also been 
suggested that to distinguish between post and current infection an antigen detecting 
diagnostic test is better. 
The research reported in this chapter focused on the production of anti-peptide antibodies 
against Major Surface Proteases (MSPs) found in T. brucei, T. congolense and T. vivax. 
Two methods for anti-peptide antibody production were used; namely, antibodies produced 
in chickens and using scFv phage technology. Since MSP-A and MSP-B are known to be 
present on the surface of the trypanosome (LaCount et al., 2003; Shimogawa et al., 2015) 
and MSP-E is suspected to be additionally GPI-anchored in the trypanosome membrane, 
while, MSP-C and -D are suspected to be secreted into the mammalian host circulation, 
would infer that there are a high number of these genes within the trypanosome genome. 
This may result in a number of possible antigen targets for the development of a diagnostic 
test. Additionally, it has also been shown that GPI-anchored proteins are likely to induce an 
immune response (Brown and Waneck, 1992) which may result in serum antibodies 
available for diagnostic detection. Although, the expression level of these proteins by the 
parasites is unknown at present, they are highly conserved amongst Trypanosoma species. 
Therefore, a diagnostic assay based on MSPs could provide a pan-specific test for 
trypanosomes. 
The general structure of an antibody consists of two heavy chains and two light chains. A 
single heavy chain consists of a single variable (VH) and either three constant (CH) domains 
for IgG, IgA and IgD or four CH domains for IgM, IgE and IgY.  
57 
 
A single light chain consists of a single variable (VL) and a single constant (CL) domain 
(Figure 3.1). These heavy and light chains can be linked together to form smaller antibody 
types (Figure 3.1) that have different detection abilities (Skottrup, P 2010). One of these 
antibody fragments involves the joining of just the variable regions, VH and VL, to form 
fragment variable (Fv) which together still contains the antigen binding site (Skottrup, 2010). 
When recombinantly expressed with a linker region (Gly4Ser)3 that joins them together, 
these variable regions are called scFvs (Holliger et al., 1993). These recombinantly 
expressed scFvs have the ability to recognise and bind antigens and are produced using 






Figure 3.1: Schematic representation of a complete antibody and various antibody fragment 
types. CH1-3, constant heavy chain 1 - 3; VH, variable heavy chain; CL, constant light chain; VL, 
variable light chain; Fc, fragment crystallisable; Fab, fragment antigen binding; Fv, fragment variable; 
scFv, single chain fragment variable (Nelson, 2010). 
 
Phage display technology is a molecular technique that uses filamentous phage particles to 
express protein libraries, such as scFvs, and display them on their surface [reviewed in 
Azzazy and Highsmith (2002)]. Filamentous phages are viruses that are able to infect Gram 
negative bacteria (like Escherichia coli) where they use the bacteria to propagate the next 
generation of virus. The virus structure consists of five major and minor coat proteins (pIII, 






Figure 3.2: Schematic representation of the assembly of wild-type M13 phage coat proteins. 
























During bacterial infection, the ssDNA is injected and converted to double-stranded (ds) DNA 
that acts as a template for the production of the various viral coat proteins as well as more 
ssDNA for the next phage generation. These coat proteins are then expressed on the 
infected E. coli surface which allows for non-lytic blebbing of new viral particles or phage 
(Endemann and Model, 1995). Essentially, the virus that leaves the E. coli is a protein coat 
encapsulating the viral ssDNA (Figure 3.2). Coat proteins have functions in binding E. coli, 
injecting DNA into E. coli and general protection and encapsulation of its DNA. Phage 
display technology uses coat protein genes to attach foreign genes that code for the 
selected protein library (Smith, 1985).  
In the present study, the Nkuku® phagemid library, which codes for Fv regions originally from 
the chicken genome, was used (Van Wyngaardt et al., 2004). The phagemid is a vector of 
DNA that resembles a plasmid vector because it contains an origin of replication, a c-myc 
detection tag, ampicillin resistance gene, some restriction sites, an amber codon as well as a 
coat protein gene followed by a foreign gene (Hoogenboom et al., 1991). In the case of the 
Nkuku® phagemid library, the coat protein pIII’s gene was selected to attach the scFv gene 
which results in an expressed pIII-scFv coat protein. The genes inserted are an array of 
chicken immunoglobulin genes plus those that contain inserted mutations to give a library of 
possible scFvs which are transformed into E. coli TG1 cells (Figure 3.3). The phagemids’ 
DNA alone is ineffective at forming new viral particles, since, the pIII contains the scFv 
portion and the viral particle is thus unable to reinfect E. coli, which means it remains within 
E. coli cells where it replicates in a similar manner to a plasmid. In culture, the ampicillin 
resistant E. coli cells grow with pIII-scFv coat proteins displayed on their outer membrane 
(Figure 3.3). 
To allow for the reformation of phagemid viral particles, the full viral genome is required 
including wild-type pIII coat proteins. This is done by adding helper phage (wild type M13K07 
phage) which are able to infect E. coli cells, injecting the full viral genome. Infected E. coli 
TG1 cells produce all viral coat proteins including wild-type pIII and pIII-scFv, resulting in a 
heterogenous population, containing both phagemid genome and helper phage genome 
(Figure 3.3). M13K07 ssDNA has a kanamycin resistance gene while the phagemid has an 
ampicillin resistance gene; therefore, the E. coli cells are grown in the presence of both 
antibiotics to select for cells that contain both genomes. This results in the formation of a 
mosaic of viral particles that contain either phagemid genome or wild-type genome with 
either pIII-scFv only, wild-type pIII only or both pIII-scFv and wild-type pIII on their surface 
(phages: single copy of DNA, E. coli: more than one copy of DNA; Figure 3.3).  
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This mosaic population of phages are then purified and allowed to react with the antigen (in 
this case a peptide) which allows for selection of phages that contains scFvs that recognise 
the antigen. Phages that do not recognise antigen, as well as those only expressing pIII 
without the scFv fragment are lost. The phages that contain specific pIII-scFv fusion protein 
bound to antigen are then allowed to reinfect E. coli cells (with a loss of phage that do not 
contain wildtype pIII) and grown in ampicillin containing medium (selects for phagemid 
genome and loss of helper phage genome; Figure 3.3). This results in the selection of the 
phagemid genome that expresses scFvs specific for the antigen. This entire selection 
process is called panning which is repeated a minimum of four times and results in a 















Figure 3.3: Schematic representation of the use of phage display technology to select for scFv 
specific fragments. 1 - phagemid DNA containing gene coding for scFvs is transformed into E. coli 
to form a library of possible scFv fragments. 2 - pIII-scFv conjugate expressed on E. coli surface. 
Striped block represents c-myc tag. 3 - E. coli cells with phagemid DNA are Amp
r
 and are able to 
propagate. Phagemid DNA is also copied. 4 - phagemid DNA is rescued by the addition of helper 
phage which also infects E. coli cells. 5 - E. coli with both phagemid (Amp
r
 ) and helper phage (Kan
r
) 
genome are propagated in the presences of both Amp and Kan. 6 - blebbing of new phage particles 
results in mosaic population. 7 - phagemids allowed to react with antigen (need pIII-scFv to bind 
antigen). 8 - bound phagemid allowed to infect E. coli (need WT pIII to infect E. coli cells). 9 - E. coli 
cells have either phagemid genome (Amp
r
) or helper genome (Kan
r
). 10 - growth in ampicillin medium 
selects for cells with phagemid genome only. Amp
r 
- ampicillin resistance. Kan
r
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The polyclonal phagemid population can be used to select for monocolony scFv expressing 
clones (individual colonies that express a single scFv phenotype and detect a single 
epitope). The specific phagemid population derived finally is used to express scFvs in a 
soluble form via an amber codon selection process (Qi et al., 2012). This codon is present 
between the pIII and scFv gene in the phagemid genome (Figure 3.1). It can either act as a 
codon coding a glutamic acid or as a stop codon, depending on the strain of E. coli 
containing the DNA. The E. coli TG1 strain is unable to recognise the stop codon and so 
expresses a pIII-scFv fusion protein. However, strains of E. coli, such as TOP 10, are able to 
read the stop codon which results in expression of pIII and scFv as separate proteins (Qi et 
al., 2012). The scFv protein can then be affinity purified using anti-c-myc antibodies. 
The objective of the work described in this chapter was to produce antibodies and scFvs 
against three MSP peptides. Peptides were selected from protease MSP-B and -C from 
T. brucei, T. congolense or T. vivax with the objective that the anti-peptide antibodies would 
detect full length MSP proteins. Peptides were selected from only these two protease 
classes with the purpose of showing native MSP-B and MSP-C in parasite lysate. 
Comparison of antibody binding capacity of the two different scaffolds of antibody produced 
(complete antibody and scFvs) may result in a novel diagnostic detection system. These 
antibodies were used for the further analyses of recombinant MSP-C described in Chapter 4.  
3.2 Materials and Methods  
3.2.1 Materials 
All reagents used during the study were of analytical grade. Reagents Na2HPO4, NaH2PO4, 
NaN3, Ethylenediaminetetraacetic acid (EDTA), sodium dodecyl sulfate (SDS), NaCl, KCl, 
KH2PO4, NaOH, HCl, PEG (Mr 6000), Tween 20, H2O2, citric acid, tryptone, yeast extract, 
bacteriological agar, glycine and glycerol were purchased from Merck (Gauteng, RSA). 5,5'-
dithio-bis-[2-nitrobenzoic acid] (Ellman’s reagent), dimethylsulfoxide (DMSO) and 
dimethylformamide (DMF) were purchased from Sigma-Aldrich (USA). Tris-HCl was 
purchased from Melford (UK) and dithiothreitol (DTT) was purchased from ThermoScientific 
(USA). 
IgY antibody production and purification: Peptides were synthesised by GL Biochem 
(China) and SulfoLink® resin was purchased from ThermoScientific (USA). Freund’s 
complete and incomplete adjuvants, rabbit serum albumin (RSA), m-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS) and L-cysteine were purchased from Sigma-Aldrich (USA). 
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Phage Display Technology: M13K07 wild type phage, Nkuku® phagemid display library 
and E. coli TG1 cells were obtained from Prof. Dion du Plessis and Dr Jaenni Fehrsen, 
Immunology Division, Onderstepoort Veterinary Institute, South Africa. NUNC® ImmunoTM 
tubes were purchased from ThermoFisher Scientific (USA). Ampicillin was from Amresco 
(USA) and kanamycin was purchased from Life Technologies (UK). Sterile filters (0.22 µm 
and 0.45 µm) were purchased from PALL Life Sciences (USA) and sterile 96 well microtitre 
plates from Nest BioTech co (China). 
Enzyme-Linked Immunosorbent Assay (ELISA): Bovine serum albumin (BSA) and 2,2'-
azino-bis(3-ethylbenzothiazoline-6-sulphonic) acid (ABTS) were purchased from Roche 
(Germany). NUNC® Maxisorb non-sterile 96 well microtitre plates were purchased from 
ThermoFisher Scientific (USA) and non-fat milk powder from Elite (RSA). Goat anti-mouse 
IgG HRPO antibody was purchased from Jackson Immunochemical (USA), mouse anti-M13 
antibody from ThermoScientific (USA) and rabbit anti-chicken horse radish peroxidase 
(HRPO) antibody from Sigma-Aldrich (USA). 
Parasite Purification: DE-52 pre-swollen diethylaminoethyl (DEAE) cellulose resin was 
purchased from Sigma-Aldrich (Germany). 
3.2.2 Peptide Design  
T. brucei, T. congolense and T. vivax MSP-B and -C amino acid sequences were aligned 
using ClustalW (www.ebi.ac.uk/Tools/msa/clustalw2/) in BioEdit. Conserved and 
nonconserved regions were noted. Predict7 epitope prediction software (Cármenes et al., 
1989) was used to calculate the hydrophilicity (Kyte and Doolittle, 1982), surface probability 
(Chothia and Janin, 1975), flexibility (Karplus and Schulz, 1985) and antigenicity (Welling et 
al., 1985) of each protease and prediction plots were constructed in MS Excel. Using both 
the alignment and Predict7 plots, peptides were selected to produce anti-peptide antibodies. 
Peptide Tb/TcoMSP:303-314 was selected since it shares high identity (>55%) with both 
T. brucei and T. congolense MSP-B which would result in an antibody that can detect both 
species. Peptides were also designed that are unique to T. brucei (TbMSP:400-412) and T. 
vivax (TvMSP:686-697), respectively. This was done by selecting peptides with sequence 
identity of less than 50% in comparison with full length proteases from other species. The 
peptides selected were used to produce antibodies in chickens (Section 3.2.3) and used to 
select scFvs from the Nkuku® phagemid library (Section 3.2.6). 
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3.2.3 Coupling Peptide to Carrier Protein and Chicken Immunisation  
Four milligrams of each peptide was weighed out and dissolved in 50 µl of 100% (v/v) 
DMSO to which 450 µl reducing buffer [100 mM Tris-HCl, 1 mM EDTA, 0.02% (w/v) NaN3, 
pH 8.0] was added. DTT (10 mM) was added to make a final volume of 1 ml. The solution 
was incubated at 37oC for 90 min before loaded onto a Sephadex G-10 (1.5 cm x 11 cm) 
column equilibrated with 5 column volumes of MEC buffer [100 mM NaH2PO4, 0.02% (w/v) 
NaN3, pH 7.0]. The eluted fractions (25 x 500 µl fractions) were collected and tested for 
reduction of peptide using Ellmans reagent [100 mM Tris-HCl , 1 mM EDTA, 0.1% (w/v) 
SDS, pH 8.0 supplemented with 2 mg Ellmans reagent]. Each fraction (10 µl) was mixed 
with Ellmans reagent (10 µl) and reduced peptide resulted in a yellow colour. All fractions 
that gave a yellow colour were pooled.  
Rabbit serum albumin (RSA) was used as a carrier protein for attachment to each peptide 
via a terminal cysteine residue using MBS. Ratio of reduced peptide to rabbit albumin (RA) 
carrier used was 40:1 while the ratio of rabbit serum albumin to MBS was 1:40. The following 
equations were used to calculate the amount of carrier and MBS required for coupling:  
                             
                  
             
 
 
                         
              
         
 
                                  *Mw: Molecular Weight  
 
RSA was dissolved in 500 µl phosphate buffered saline (PBS; 10 mM Na2HPO4, 1.8 mM 
KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.2) while MBS was dissolved in 200 µl DMF and 
300 µl PBS. The two solutions were mixed together and incubated at room temperature (RT) 
for 30 min before loaded on to a Sephadex G-25 (1.5 cm x 13 cm) column equilibrated with 3 
column volumes MEC buffer. Fractions were collected (20 x 1 ml fractions) and absorbance 
at 280 nm was measured using a Nanodrop spectrophotometer (Thermoscientifc, USA).  
Fractions with absorbance at 280 nm of greater than 0.3 were pooled. The reduced peptide 
fractions and MBS-activated RSA fractions were then mixed together and incubated at RT 
for 3 h. The peptide-RSA conjugate was aliquoted and stored at -20oC until required for the 
immunisation of chickens. 
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The use of all animals for research was approved by the Biomedical Research Ethics 
Committee (053/15/Animal) at the University of KwaZulu-Natal. Two chickens per peptide 
were used to produce IgY antibodies. Each chicken was injected twice intramuscularly (once 
per breast; 400 µl per site) every two weeks, four times in total. The first immunisation was 
done using Freund’s complete adjuvant followed by boosters using Freund’s incomplete 
adjuvant. For immunisation, 1.5 ml of coupled peptide was emulsified in 1.5 ml Freund’s 
complete/incomplete adjuvant. Each immunisation site was cleaned using 70% (v/v) ethanol 
and 750 µl of emulsified peptide adjuvant mixture was injected using a 2 ml syringe and 20G 
sterile needle. A non-immune egg was collected on the day of the first immunisation as a 
non-immune control. Eggs were collected daily for 16 weeks for the isolation of IgY 
antibodies. 
3.2.4 Purification of Anti-peptide Antibodies  
The purification of anti-peptide antibodies is divided into two steps: bulk isolation of all IgY 
antibodies from chicken egg yolk and affinity purification of specific anti-peptide antibodies. 
3.2.4.1 IgY Isolation from Chicken Egg Yolks 
The method used to isolate chicken IgY antibodies was done as described by Polson et al. 
(1985) and amended by Goldring and Coetzer (2003). Briefly, eggs were cracked open and 
all egg white removed by running the yolk under tap water. The yolk sac was punctured and 
the yolk volume determined. Working buffer [100 mM Na2HPO4, 0.02% (w/v) NaN3, pH 7.6] 
was used to dilute the yolk in a 2:1 ratio. PEG (Mr 6000) was added at a 3.5% (w/v) 
concentration, gently dissolved and centrifuged (4400 x g, 30 min at 4oC) to pellet the 
unwanted lipid fraction. The supernatant was filtered through cotton wool resulting in a clear 
filtrate. To the filtered supernatant 8.5% (w/v) PEG (Mr 6000) was added and dissolved to 
give a final concentration of 12% (w/v). To pellet precipitated proteins the solution was 
centrifuged (12000 x g, 10 min at 4oC) and the supernatant discarded. The pellet was 
dissolved in the yolk volume using working buffer and 12% (w/v) PEG (Mr 6000) was added 
and dissolved. This solution was centrifuged (12000 x g, 10 min at 4oC) and the final IgY 
pellet dissolved in 1/6 of the original yolk volume using final buffer [100 mM Na2HPO4, 0.1% 
(w/v) NaN3, pH 7.6]. This was called total IgY and it was further purified using affinity 
purification.  
3.2.4.2 Affinity Purification of Anti-Peptide IgY Antibodies 
SulfoLink® resin was used to link peptides, via the terminal cysteine residue (as indicated in 
Figure 3.4), to the resin. These peptide affinity columns would allow for antigen-antibody 
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interaction for the purification of anti-peptide antibodies. Eight milligrams of peptide was 
dissolved in 100 µl of 100% (v/v) DMSO and 400 µl general buffer (50 mM Tris-HCl -HCl, 50 
mM EDTA, pH 8.5). DTT (10 mM) was added as a reducing agent (500 µl) to the dissolved 
peptide and incubated for 90 min at 37oC. The Sephadex G-10 column, equilibrated with 
general buffer, was used to separate reduced peptide from excess DTT. Fractions were 
collected (25 x 500 µl fractions) from the column and tested for reduction using Ellman’s 
reagent as described in Section 3.2.3. The reduced peptide fractions were pooled and 
immediately added to 2 ml of resin (4 ml of the 50% slurry) and incubated at RT for 15 min 
on an end-over-end rotator, followed by 30 min without rotation. The column was washed 
with general buffer (3 x 5 ml). To block uncoupled reactive groups on the resin 50 mM L-
cysteine was added to the column and incubated at room temperature for 15 min on an end-
over-end rotator, followed by 30 min rotation. The column was then washed with general 
buffer (3 x 5 ml) and stored in phosphate buffer (100 mM Na2HPO4, pH 7.6) at 4
oC until used.  
The SulfoLink® resin was equilibrated with PBS (3 x 5 ml) and total IgY, isolated from 
immunised chicken egg yolks, was added and incubated at 4oC overnight. The resin was 
allowed to settle in the column and unbound IgY passed over the resin, by gravity, one more 
time. The column was then washed with PBS until the absorbance at 280 nm, read on the 
Nanodrop 6000 spectrophotometer (Thermoscientifc, USA), was less than 0.02. The bound 
anti-peptide antibodies were eluted by decreasing the pH with elution buffer [100 mM 
glycine, 0.02% (w/v) NaN3, pH 2.8] and 10 x 1 ml fractions, containing 100 µl of 
neutralisation buffer [1 M Na2HPO4, 0.02% (w/v) NaN3, pH 8.5], were collected  
The absorbance at 280 nm for each fraction was determined using the Nanodrop 
spectrophotometer and the final concentration calculated using the Beer-Lambert law and an 
extinction coefficient for IgY of ε = 1.25. Fractions containing an absorbance of 0.1-0.5, 0.5-
0.8 and greater than 0.8 were pooled and stored, in a final concentration of 0.1% (w/v) NaN3, 
at 4oC until needed. 
3.2.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
Microtitre plates were coated overnight with either 1 µg/ml or 5 µg/ml peptide at 4oC. The 
unoccupied sites were blocked with 200 µl/well of 0.5% (w/v) BSA-PBS for 60 min at 37oC. 
The plate was washed with PBS Tween-20 [PBS with 0.1% (v/v) Tween-20] using a Biotek 
ELx50 plate washer (3 x 300 µl/plate). Primary IgY antibody (100 µl/well) was added and 
incubated for 60 min at 37oC. The plates were again washed with PBS Tween-20 
(3 x 300 µl/plate) using the plate washer and incubated with rabbit anti-chicken IgY-HRPO 
(1:10000) for 60 min at 37oC (120 µl/well).  
65 
 
The last wash was performed as before and 150 µl/well substrate solution [0.05% (w/v) 
ABTS, 0.005% (v/v) H2O2 in 150 mM citrate-phosphate buffer, pH 5.5] added. Absorbance 
readings at 405 nm were taken either after 15 min, 30 min or 60 min using the FLUOstar 
Optima spectro-fluorometer (BMG Labtach, Germany). 
3.2.6 Phage Display and Anti-Peptide scFvs 
A number of steps (Figure 3.3) are used in phage display technology to obtain phagemids 
expressing specific anti-peptide scFvs which was shown by both polyclonal and monocolony 
ELISAs (Van Wyngaardt et al., 2004). All the work conducted was in a sterile environment. 
3.2.6.1 Culturing Escherichia coli TG1 cells 
E. coli TG1 cells were streaked onto TYE agar plates [10 g tryptone, 5 g yeast extract, 8 g 
NaCl per litre with 1.5% (w/v) bacteriological agar] and grown overnight at 37oC. A single 
colony was selected for growth in 2xYT medium (1.6% (w/v) tryptone, 1.0% (w/v) yeast 
extract, 86 mM NaCl) medium overnight at 37oC. The overnight culture was used to make a 
1:100 dilution with 2xYT medium and grown to an optical density (OD) of 0.5 at 600 nm 
(log phase). These cultures can be stored at 4oC for one week. 
3.2.6.2 Culturing and Titering M13K07 Helper Phage  
M13KO7 helper phage was cultured and titred and stored at 1 x 1012 pfu/ml. The helper 
phage stock was used to make serial dilutions (10-2 - 10-10) with 2xYT medium. Each phage 
dilution (100 µl) was incubated with log phase E. coli TG1 cells (100 µl) for 5 min at RT. The 
200 µl of now infected TG1 cells was added to pre-warmed 1.5% (w/v) 2xYT agar and 3 ml 
liquid 0.7% (w/v) 2xYT agar (kept warm between 44-47 oC) was added on top and levelled. 
The top agar was allowed to set and agar plates incubated at 37oC overnight.  
A single plaque was cut out of the agar plate and added to 4 ml 2xYT medium. TG1 cells 
grown overnight were added (40 µl). The culture was incubated at 37oC for 2 h at 100 rpm. 
This culture (40 ml) was used to inoculate 800 ml of fresh 2xYT medium and grown for 1 h 
(37oC, 100 rpm). The culture was supplemented with kanamycin (final concentration of 
50 µg/ml) and grown overnight (37oC, 100 rpm). The resulting culture was centrifuged 
(10800 x g, 15 min, 4oC) and the supernatant kept. Helper phage particles from the 
supernatant were precipitated by adding 1/4 supernatant volume of 20% (w/v) PEG (Mr 
6000) in 2.5 M NaCl and incubating on ice for 30 min. The solution was centrifuged 
(10800 x g, 15 min, 4oC) and the supernatant discarded. The pellet was centrifuged again 
(2000 x g, 2 min, 4oC) to remove any excess liquid and the final pellet resuspended in 6 ml 
PBS and sterile-filtered through 0.45 µm filter.  
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This resulting wild type phage was titred again, pfu/ml calculated and diluted to 
1 x 1012 pfu/ml using sterile PBS with a final concentration of 20% (v/v) glycerol. The helper 
phage was stored at -80oC, for use later in rescuing the phagemid library (Section 3.2.6.3). 
pfu/ml  
no.of plaques   dilution factor 
( .5    .1 ml)
 
 3.2.6.3 Culturing and Titering Nkuku® Phagemid Library  
The phagemid stock obtained from the Onderstepoort Veterinary Institute (Van Wyngaardt et 
al., 2004) was used to amplify the library and new stocks made and titred. Phagemid stock 
(250 µl) was added to 500 ml 2xYT medium containing 100 µg/ml ampicillin and 
2% (w/v) glucose. The initial OD of this culture at 600 nm should be 0.05. The inoculated 
medium was grown at 37oC until the OD was 0.5. A 100 ml aliquot of this culture (the rest of 
the culture was used to make glycerol stocks) was transferred to a clean flask and M13K07 
helper phage stock was added at a ratio of 20:1 (20 phage particles for 1 bacterial cell). An 
OD of 1 at 600 nm is equivalent to 8 x 108 bacterial cells/ml (Van Wyngaardt et al., 2004). 
This was incubated at 37oC for 30 min standing and 30 min shaking (100 rpm) and this 
procedure is called rescuing. The culture preparation was centrifuged (3300 x g, 15 min, 
4oC) to pellet the cells, resuspended in 1 L of 2xYT medium containing 100 µg/ml ampicillin 
and 25 µg/ml kanamycin. The resuspended pellet was grown overnight at 30oC (240 rpm). 
To make glycerol stocks, the rest of the culture was grown for another 3 h and cells were 
pelleted by centrifugation (3300 x g, 15 min, 4oC). The pellet was resuspended in 2xYT 
medium (1:100 of original volume) and used to make stocks by adding glycerol to a final 
concentration of 20% (v/v).  
After the rescued phages had grown overnight, the cells were pelleted by centrifugation 
(3300 x g, 20 min, 4oC) and discarded. The supernatant was used to precipitate phages as 
before by adding 1/4 (of original volume) 20% (w/v) PEG (Mr 6000) in 2.5 M NaCl on ice for 
1 h. The phagemid particles were pelleted by centrifugation (3300 x g, 30 min, 4oC) and the 
supernatant discarded. The pellet was centrifuged again (2000 x g, 2 min, 4oC) to remove 
any excess liquid and resuspended in 20 ml PBS (50 x concentrated) and centrifuged 
(11000 x g, 10-15 min, 4oC) to remove any insoluble components. The supernatant was then 
sterile-filtered through a 0.45 µm filter. This represents the full Nkuku® library phagemid 
stock which needs to be titred and used for panning.  
To titre the Nkuku® library, serial dilutions are made using 2xYT medium (10-2-10-10). Each 
dilution (100 µl) was incubated with log phase E. coli TG1 cells (100 µl) at RT for 5 min. 
Infected cells (200 µl) were plated onto TYE A/G agar. 
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Log phase TG1 cells (100 µl) and phagemid stock (100 µl) only were also plated as controls. 
Agar plates were incubated overnight at 37oC and cfu/ml is calculated as follows:          
cfu/ml  
no.of cells   dilution factor 
( .5    .1 ml)
 
This is used to determine how much phagemid stock to add during the first round of panning 
(Section 3.2.6.4).  
3.2.6.4 Biopanning  
To select for specific phagemids that express scFvs that recognise and bind the peptides 
designed earlier, biopanning was used. Immunotubes are coated with a decrease in peptide 
antigen (50, 25, 10 or 5 µg/ml) for all four rounds of panning overnight at 4oC. Decreasing 
concentrations of peptide per round of panning was used as a selection mechanism to 
ensure only those phagemids expressing scFvs that bind most efficiently are selected for. 
The immunotubes were then washed with PBS (3 x) and blocked using 2% (w/v) non-fat 
milk-PBS for 1 h at RT. The extra immunotubes were stored at 4oC in blocking solution until 
required. During the blocking step, the phagemid stock wass also incubated with non-fat 
milk-PBS to remove any phagemids expressing scFvs that recognise the blocking solution 
(blocked phagemid). This was done by incubation of 1012 - 1013 cfu of phagemid stock 
(isolated and titred as described in Section 3.2.6.3) with 2% (w/v) milk-PBS Tween-20 [PBS 
with 0.1% (v/v) Tween-20] for at least 30 min (3.5 ml). After the blocking step was 
completed, the immunotubes were washed twice with PBS and the ‘blocked’ phagemid stock 
added to the immunotubes which were allowed to stand for 30 min at RT and then rotated 
for 90 min at RT using an end-over-end rotator.  
Once the incubation step was completed, stringent washing was used to ensure only those 
phagemids expressing scFv with high binding efficiency remain. This was done by washing 
each immunotube 20 times with PBS Tween-20 followed by washing 20 times with PBS 
alone. To each immunotube, 3.5 ml log phase E. coli TG1 cells were added and incubated at 
37oC for a maximum of 30 min to allow the bound phagemid to infect the cells. The E. coli 
solution was immediately centrifuged (3300 x g, 10 min, 4oC) or kept on ice until it can be 
centrifuged. The pelleted cells were resuspended in 1 ml 2xYT medium and 3 x 333 µl were 
plated on three TYE A/G agar plates (E. coli TG1 cells alone were also plated to ensure cells 
were not infected). The plates were grown overnight at 30oC. Three plates were used for 
round one and two and only one plate was used for rounds three and four.  
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To a single plate 5-10 ml of 2xYT medium was used to loosen the colonies and ~500 µl was 
added to 50 ml 2xYT medium (containing 100 µg/ml ampicillin and 2% (w/v) glucose) to 
make a culture of OD at 600 nm of less than 0.05.  
This was grown at 37oC until log phase was reached (OD at 600 nm = ~0.5). Only 5 ml of 
this culture was used to rescue phagemids while the rest was used to make glycerol stocks 
(culture containing 20% (v/v) glycerol in 1 ml aliquots) and stored at -80oC. To the 5 ml 
removed from the log phase culture, M13K07 helper phage was added at a 20:1 ratio. 
Helper phage stocks made earlier were used and an OD at 600 nm of 1 was equivalent to 
8 x 108 bacterial cells/ml (Van Wyngaardt et al., 2004). Helper phage was allowed to infect 
the E. coli cells by incubating the culture for 30 min at 37oC with occasional agitation. At this 
stage some the E. coli cells contained both phagemid and helper phage DNA. They were 
pelleted by centrifugation (3300 x g, 10 min 4oC twice and supernatant discarded each time), 
resuspended in 25 ml 2xYT medium containing 100 µg/ml ampicillin and 25 µg/ml 
kanamycin and grown overnight at 30oC (240 rpm). Growth of the E. coli cells in both 
antibiotics selects for those that contain both phagemid and helper phage DNA.  
The overnight culture was centrifuged (10000 x g, 10 min, 4oC) and phages precipitated from 
the supernatant using 1/5 the volume 20% (w/v) PEG in 2.5 M NaCl at 4oC for 60 min. The 
precipitated phage preparation was pelleted by centrifugation (10000 x g, 10 min, 4oC) and 
the supernatant discarded. The pellet was resuspended in sterile PBS (1 ml) and centrifuged 
(11000 x g, 10 min, 4oC) to remove any insoluble precipitate. A volume of 0.5 ml was used 
for the next round of panning while the other 0.5 ml was stored at 4oC and used in a 
polyclonal ELISA. The steps listed above were repeated four times with the rest of the 
coated immunotubes.  
3.2.6.5 Polyclonal and Monocolony phagemid ELISA 
Polyclonal ELISA 
Microtitre plates were coated with 10 µg/ml of peptide overnight at 4oC. Unoccupied sites in 
the wells were then blocked with 2% (w/v) non-fat milk-PBS Tween-20 for 1 h at 37oC. The 
0.5 ml of precipitated phagemid from each round of panning, stored at 4oC, was diluted 1:10 
with 2% (w/v) milk-PBS Tween-20 and incubated at RT for at least 30 min (blocked 
phagemid). The full phagemid library was also included as a control in a separate well. 
Following the blocking step, plates were washed with PBS Tween-20 using the BioTek Elx50 
plate washer (3 x 300 µl/plate). Blocked phagemid (100 µl/well) were added to the plates 
and incubated at 37oC for 2 h. The plates were washed as before (3 x 300 µl/plate) and then 
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incubated with 1:8000 diluted mouse anti-M13 primary antibody in 0.5% (w/v) BSA-PBS at 
37oC for 1 h (100 µl/well). To washed plates (as before) 1:10000 diluted goat anti-mouse 
IgG-HRPO secondary antibody (120 µl/well) was added for 1 h at 37oC. Plates were washed 
as before and substrate solution [0.05% (w/v) ABTS, 0.005% (v/v) H2O2 in 150 mM citrate-
phosphate buffer, pH 5.5] added (150 µl). Absorbance readings were taken either after 15 
min, 30 min or 60 min using the FLUOstar Optima spectro-fluorometer at 405 nm. 
Monocolony ELISA 
Single colonies from round four of panning were used in a monocolony ELISA to select for 
clones that have the best binding efficiency and give the highest absorbance signal. First 
round four precipitated phage was serially diluted (10-2-10-10) with 2xYT medium and 200 µl 
plated on TYE A/G agar (as in Section 3.2.6.3). Colonies (96) were used to inoculate sterile 
microtitre plates which contained 100 µl/well 2xYT A/G medium. The inoculated plates were 
incubated at 30oC overnight (220 rpm). Each well from the overnight culture (5 µl) was used 
to inoculate a fresh sterile microtitre plate containing 150 µl/well 2xYT A/G medium and 
incubated at 37oC for 2.5 h (220 rpm). The rest of the culture within the plate was stored at 
-80oC after adding 20% (w/v) glycerol. 
After the new plate (containing 5 µl overnight culture with 150 µl fresh medium) was 
incubated at 37oC for 2.5 h, 50 µl of 2 x 109 pfu M13K07 helper phage was added and 
allowed to stand for 30 min at 37oC. The plates were centrifuged (600 x g, 10 min, 4oC) and 
supernatant removed. To each well 150 µl of 2xYT medium containing 100 µg/ml ampicillin 
and 25 µg/ml kanamycin was added and incubated at 30oC overnight (220 rpm). The 
overnight plate was centrifuged and the supernatant used to perform an ELISA as described 
for the polyclonal ELISA. The supernatant (50 µl) was incubated with 4% (w/v) milk-PBS 
Tween-20 (50 µl) before use in the ELISA. 
3.2.7 Parasite Purification and the Detection of MSP in Parasite lysate  
Cryopreserved T. brucei LiTat 1.3 and T. congolense IL3000 parasites were used to infect 
mice intraperitoneally. Tail pricks were used to monitor parasitaemia using heomocytometer 
under light microscopy (Olympus, Germany) until the parasite level was 5 x 104 cells/cm2. 
Cardiac puncture was performed on anaesthetised mice and blood samples used for 
parasite purification.  
All equipment used was sterile and the purification was done in a sterile environment. 
Parasite purification was adapted from the method outlined by Lanham and Godfrey (1970). 
A ~20 ml DE-52 column was set up using a 25 ml syringe with a plastic tap at the bottom.  
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Whatman no. 1 filter paper was used to plug the bottom of the syringe and a second disc 
placed on top of the resin. The column was washed with two column volumes sterile PBS 
and equilibrated with two column volumes sterile PBS with glucose (PSG; 57 mM Na2HPO4, 
3 mM NaH2PO4, 42 mM NaCl, 50 mM glucose, 1 mM hypoxanthine, pH 7.8). The 
trypanosome-infected blood was diluted with an equal volume of sterile PSG and added to 
the column. The red blood cells were allowed to settle for 30 min. PSG was then used to 
elute unbound parasites and four 15 ml samples were collected. The parasites within the 
collected eluates were obtained by centrifugation (3500 x g, 15 min, 4oC) and resuspended 
in 1 ml PSG containing 20% (v/v) glycerol. The final number of parasites was counted using 
a haemocytometer and the samples were stored at -80oC until used. 
The parasites were pelleted (2000 x g, 10 min, RT) and resuspended in PBS (150 µl) 
followed by centrifugation (2000 x g, 5 min, RT). This was repeated twice. The parasite cell 
pellet was resuspended in lysis buffer (20 mM Tris-HCl, 10 mM EDTA, 1% Triton™  X-100, 
10 µM E64 at pH 7.2) and an equal volume of Laemmli’s reducing treatment buffer (Section 
4.2.7) was added followed by boiling for 10 min. A sample of this was subjected to 
SDS-PAGE and western blot as described in Chapter 4, Section 4.2.8. The western blot was 
probed with 5 µg/ml of primary antibody and 1:2500 rabbit anti-chicken secondary antibody 
conjugated to HRPO. The gel was visualised by ECL (Pierce, USA) using the Syngene, 
G:BOX (Vacutec, USA). 
3.3 Results 
3.3.1 Peptide Design 
Of the MSPs, classes MSP-B and -C were used to select peptides for the production of 
anti-peptide antibodies. These two classes were selected because MSP-B is known to be 
anchored to the surface (LaCount et al., 2003; Shimogawa et al., 2015) while MSP-C is 
expected to be secreted by the parasite. Since MSP-A and -E resemble MSP-B while 
MSP-D resembles MSP-C, none of the other classes were used for this study. MSP-B and 
-C sequences from T. brucei, T. congolense and T. vivax were analysed and conserved and 
nonconserved regions were selected to undergo epitope prediction. The Predict7 software 
(Cármenes et al., 1989) was used to determine which regions of the protein sequences are 
likely to be epitopes and, therefore, would be able to induce an immune response. 
The program incorporates a number of prediction algorithms and four were selected: 
hydrophilicity (Kyte and Doolittle, 1982), surface probability (Chothia and Janin, 1975), 
flexibility (Karplus and Schulz, 1985) and antigenicity (Welling et al., 1985). The latter 
prediction algorithm was developed using data from a small group of proteins for which 
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epitopes have been confirmed which leaves this parameter the least reliable out of the four. 
Regions that have these characteristics would be on the surface of the proteins in contact 
with the surrounding environment and, therefore, the immune system, forming epitopes.  
Three peptides were selected for antibody production and the Predict7 plots are shown in 
Figure 3.4. The peptide, Tb/TcoMSP:303-314, was selected from the T. congolense MSP-B 
sequence and there are regions where the prediction characteristics peak above zero 
(Figure 3.4 A) which is suggestive of an immunogenic region. Comparison of the selected 
peptide region to leishmanolysin’s tertiary structure shows that this peptide is likely to occur 
on the surface of the protein and is exposed to the surrounding environment (in yellow 
Figure 3.4 A). Figure 3.5 shows that peptide Tb/TcoMSP:303-314 shares 100% identity with 
TcoMSP-B and 77% identity with TbMSP-B, but less than 45% identity with all MSP-Cs. This 
peptide was designed to detect both T. brucei and T. congolense MSP-B. 
TbMSP:400-412 was chosen from the TbMSP-C sequences and the Predict7 plot again 
shows regions where all the epitope characteristics peak above zero (Figure 3.4 B), 
therefore, suggesting an immunogenic region. Comparison of the peptide region with the 
same region in leishmanolysin’s tertiary structure shows it on the surface (in yellow, Figure 
3.4 B) which supports the possibility that the peptide could have interacted with the immune 
system. TbMSP:400-412 shows 100% identity with TbMSP-C and 54% with TbMSP-B, 
while, less than 50% identity with TcoMSP-B, TcoMSP-C and TvMSP-C (Figure 3.5). This 
peptide was designed to detect TbMSP-C only with a low possibility of detecting other 
MSP-B and -C. 
The last peptide selected came from the C-terminal tail region seen in TvMSP-C (Figure 2.5, 
p. 48) which has little sequence identity with other MSPs. The Predict7 plot of 
TvMSP:686-697 shows a peak above zero for all epitope characteristics which is indicative 
of an immunogenic region. Again, the peptide was compared to leishmanolysin’s tertiary 
structure; however, since the peptide selected is from a region not seen in leishmanolysin, 
the region could not be visualised on the leishmanolysin structure. There was a peptide 
within leishmanolysin which showed similarity to TvMSP:686-697 and is shown in the tertiary 
structure in Figure 3.4 (C) in yellow. The sequence identity of TvMSP:686-697 to TvMSP-C 
was 100% while for the other MSP-B and -C it was less than 10%. This peptide was 
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Figure 3.4: Predict7 plots of selected MSP peptides and their predicted positions in a 
homologous protease. (A) Tb/TcoMSP:303-314 is an interspecies peptide designed to detect both 
T. congolense and T. brucei MSP-B, (B) TbMSP:400-412 peptide was designed to detect TbMSP-C 
and (C) TvMSP:686-697 peptide was designed to detect TvMSP-C only. Hydrophilicity ( ), flexibility 
( ), surface probability ( ) and antigenicity ( ) are shown. Arrows indicate the coupling terminus. 
Three dimensional representation of the predicted position of each peptide within the homolog, 
leishmanolysin (Schlagenhauf et al., 1998), is shown on the right (yellow). 
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Figure 3.5: Sequence alignment of each peptide with full length MSP-B and –C from T. brucei 
(Tb), T. congolense (Tco) and T. vivax (Tv). The table shows corresponding sequence identity. 
From the sequence identity, anti-Tb/TcoMSP:303-314 peptide antibodies (IgY or scFv) should detect 
both TbMSP-B and TcoMSP-B; anti-TbMSP:400-412 should detect only TbMSP-C and 











TbMSP-B 77% 54% 8% 
TbMSP-C 42% 100% 8% 
TcoMSP-B1 100% 46% 8% 
TcoMSP-C 42% 38% 0% 
TvMSP-C 42% 38% 100% 
20Figure 3.5: Sequence 
alignment of each peptide 
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–C from T. brucei (Tb), T. 












































3.3.2 Chicken Anti-Peptide Antibody Production 
The peptides selected were used to produce antibodies in chickens. Since the peptide is 
only 12-14 residues long, it is too small to induce an immune response on its own which 
means it needs to be conjugated to a carrier protein. The carrier protein used here was 
rabbit serum albumin (RSA) because of its relatively large size (69 kDa) and its evolutionary 
distance from chickens (using a mammalian protein not an avian protein). MBS was used as 
the linker molecule via a lysine on RSA and a cysteine residue in the peptide. 
For peptide Tb/TcoMSP:303-314, the flexibility is below zero from residue 303-307 which 
means it was conjugated was done to the N-terminus leaving the more immunogenic C-
terminus available for immune system reaction (Figure 3.4, arrow). A cysteine residue was 
added to the N-terminus of the peptide to allow for conjugation. For TbMSP:400-412 it was 
decided to conjugate to the N-terminus because there is a cysteine residue already available 
while the most immunogenic sequences are in the middle of the plot (Figure 3.4, arrow). 
Lastly, for TvMSP:686-697, a cysteine was added to the C-terminus for conjugation; since, 
flexibility is lowest at this point (Figure 3.4, arrow). 
To determine when antibody production peaks, a single representative egg from each 
chicken was collected each week and used. Total IgY purified from each egg and an 
enzyme-linked immunosorbent assay (ELISA) with the peptide antigen coated ELISA plate 
was conducted (Figure 3.6). Antibody production for all three peptides peaked from week 4 
to 12 and the eggs that were laid in this peak period were used to batch purify IgY antibodies 
(Figure 3.6 grey area). The 200 µg/ml total IgY antibody gave higher signal compared to the 
100 µg/ml, as expected. 
Large scale IgY purification was done for eggs collected from weeks 4-7 and 8-12. Affinity 
chromatography was used to purify specific anti-peptide antibodies from total IgY. The eluted 
antibody fractions were analysed using absorbance at 280 nm (Figure 3.7). Affinity purified 
anti-Tb/TcoMSP:303-314 peptide antibodies produced and purified from eggs from both 
chickens to give a final yield of ~8.3 mg (calculated using the Beer-Lambert law; Figure 3.7). 
For the affinity purified anti-TbMSP:400-412 peptide antibodies, four main absorbance peaks 
were seen for the two chickens used (Figure 3.7). The final yield of this antibody was ~7.4 
mg. Affinity purified anti-TvMSP:686-697 peptide antibodies gave only one prominent peak 



























































































Figure 3.6: Analysis of antibody production in chickens against Tb/TcoMSP:303-314, 
TbMSP:400-412 and TvMSP:686-697 peptides by ELISA. Individual microtitre plates were coated 
with 1 µg/ml (Tb/TcoMSP:303-314 and TbMSP:400-412) or 5 µg/ml (TvMSP:686-697) of peptide. The 
primary antibody was total IgY isolated from single representative eggs collected from weeks 0-16 at 
the concentrations indicated. Immunisations were conducted at week 0, 2, 4 and 6. The secondary 
antibody was rabbit anti-chicken-conjugated to HRPO and the substrate ABTS/H2O2. Absorbance 
readings were recorded at 405 nm using the Optima spectro-fluorometer after 1 h corrected by 
subtracting negative controls. Grey represents peak selected for batch purification. Chicken 1: 100 
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Figure 3.7: Elution profiles of anti-peptide antibodies from peptide-SulfoLink
®
 affinity columns. 
Total IgY isolated from eggs collected during weeks 4-7 and 8-12 (unless otherwise indicated) was 
used to affinity purify antibodies on SulfoLink
®
 resin coupled with specific peptide. Bound antibodies 
were eluted by decreasing the pH and 10 x 1 ml fractions were collected. Absorbance was read at 
280 nm using the Nanodrop spectrophotometer. 
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To confirm that affinity purified anti-peptide antibodies detect the corresponding peptide, 
ELISAs were conducted (Figures 3.8-3.10). Purified antibody was compared to non-immune 
control, total IgY and non-specific antibodies that did not bind to the affinity column. All 
non-immune IgY fractions gave low absorbance values in the ELISA (Figures 3.8-3.10) and 
these were comparable to the signal when only PBS was used (results not shown). 
Affinity purified Anti-Tb/TcoMSP:303-314 peptide antibodies gave higher absorbance values 
than total IgY before affinity purification and IgY that did not interact with the affinity column 
(Figure 3.8). There was little difference in the absorbance values for the different antibody 
concentrations used in the assay [(25-100 µ/ml); (Figure 3.8)], suggesting a wider range of 
antibody concentrations in the lower range (0.01-10 µg/ml) should have been tested. These 
results showed that specific anti-Tb/TcoMSP:303-314 peptide antibodies bound the column 
and were successfully purified. Colourimetric development of the signals for affinity purified 
antibodies was compared to total IgY antibodies over time. From Figure 3.8, absorbance 
after 15 min of total and purified antibody remained relatively constant; however, from 
30-60 min the absorbances for purified antibody increased while total IgY stayed relatively 
the same. This is indicative of purified antibody binding antigen in a more efficient manner as 
compared to the total, non-affinity purified antibody mixture.  
The purification of anti-TbMSP:400-412 peptide antibodies (Figure 3.9) shows a similar trend 
to the purification of anti-Tb/TcoMSP:303-314 (Figure 3.8). A higher absorbance signal was 
obtained for the affinity purified antibodies when compared to the total IgY and IgY that did 
not interact with the column (Figure 3.9). Again, no titration of this antibody occurred the 
25-100 µg/ml concentration range suggesting a prozone effect (Figure 3.9). Colourimetric 
development is more efficient by the purified antibodies when compared to total IgY (Figure 
3.9). 
Lastly, the purification process and antibody efficiency was studied for anti-TvMSP:686-697 
peptide antibodies (Figure 3.10). The affinity purified antibodies showed little difference in 
signal when compared to total IgY but higher signal when compared to the IgY that did not 
bind the column (Figure 3.10). Again, little difference in the absorbance values for the 
different antibody concentrations (25-100 µg/ml) was seen. Colourimetric development of 





































































Figure 3.8: Recognition of Tb/TcoMSP:303-314 peptide by corresponding affinity purified 
chicken anti-peptide antibody in an ELISA. IgY isolated from eggs collected during weeks 4-7 
(solid line) and weeks 8-12 (dotted line). Microtitre plates were coated with 5 µg/ml peptide and 
incubated with primary antibodies: non-immune control ( ), total IgY ( ; ), affinity column unbound 
fraction ( ; ) and purified antibody ( ; ), for 2 h. The secondary antibody was rabbit anti-chicken-
conjugated to HRPO and the substrate ABTS/H2O2. A) Increasing primary antibody concentration 
(25-100 µg/ml) after 1 h in substrate and B) colourimetric development (25 µg/ml primary antibody) 
after 15, 30 and 60 min in substrate. Absorbance readings were recorded at 405 nm using an Optima 
spectro-fluorometer. Similar absorbance values to those of non-immune control were recorded when 
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Figure 3.9: Recognition of TbMSP:400-412 peptide by corresponding affinity purified chicken 
anti-peptide antibody in an ELISA. IgY isolated from eggs collected during weeks 4-7 (solid line) 
and weeks 8-12 (dotted line). Microtitre plates were coated with 5 µg/ml peptide and incubated with 
primary antibodies: non-immune control ( ), total IgY ( ; ), affinity column unbound fraction ( ; ) 
and purified antibody ( ; ), for 2 h. The secondary antibody was rabbit anti-chicken-conjugated to 
HRPO and the substrate ABTS/H2O2. A) Increasing primary antibody concentration (25-100 µg/ml) 
after 1 h in substrate and B) colourimetric development (25 µg/ml primary antibody) after 15, 30 and 
60 min in substrate. Absorbance readings were recorded at 405 nm using an Optima spectro-
fluorometer. Similar absorbance values to those of non-immune control were recorded when the 
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Figure 3.10: Recognition of TvMSP:686-697 peptide by corresponding affinity purified chicken 
anti-peptide antibody in an ELISA. For chicken 1, IgY isolated from eggs collected during weeks 4-7 
(solid line) and weeks 8-12 (dotted line). For chicken 2, IgY was isolated for weeks 6-9 (solid line). 
Microtitre plates were coated with 5 µg/ml peptide and incubated with primary antibodies: non-
immune control ( ), total IgY ( ; ), affinity column unbound fraction ( ; ) and specific purified 
antibody ( ; ), for 2 h. The secondary antibody was rabbit anti-chicken-conjugated to HRPO and the 
substrate ABTS/H2O2. A) Increasing primary antibody concentration (25-100 µg/ml) after 1 h in 
substrate and B) colourimetric development (25 µg/ml primary antibody) after 15, 30 and 60 min in 
substrate. Absorbance readings were recorded at 405 nm using an Optima spectro-fluorometer. 
Similar absorbance values to those of non-immune control were recorded when the primary antibody 
was replaced with PBS (not shown). 
 
 
In all cases, peptide-specific antibodies were successfully produced by the immunised 
chickens and purified using affinity chromatography. These antibodies showed efficient 
binding of the respective antigens. Tb/TcoMSP:303-314 (8.3 mg) and TbMSP:400-412 
(7.4 mg) produced more antibodies, when compared to TvMSP:686-697 (1.7 mg) and 
anti-TvMSP:686-697 peptide antibodies showed the lowest sensitivity for detecting the 
peptide antigen. These purified antibodies were used to detect MSP in parasite lysate and in 
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3.3.3 scFv Anti-Peptide Antibody Production  
Single chain variable regions (scFvs), from the Nkuku® library (Van Wyngaardt et al., 2004), 
were also produced in this study. Biopanning was performed under stringent selection and 
washing conditions to select phagemids expressing scFv specific antibody scaffolds. Once 
panning was completed, a polyclonal ELISA was conducted on the phagemids isolated from 
each round as compared to the full phagemid Nkuku® library (Figure 3.11). Overall, an 
increase in signal is seen, after each round of panning, which shows the enrichment of 
specific scFvs and the removal of non-specific scFvs. The full Nkuku® library gave low 
absorbance readings against each MSP peptide as expected. scFvs selected to recognise 
Tb/TcoMSP:303-314 gave peak signals after round one and four; while, TbMSP:400-412 
gave a peak signal at round four only. TvMSP:686-697 gave peak signals after round two 












Figure 3.11: Polyclonal phagemid ELISA of panning rounds 1 to 4. Microtitre plates were coated 
with 10 µg/ml peptide and incubated with 1:10 dilution of phagemid stock isolated after each round of 
panning. Primary mouse anti-M13 antibody (1:8000) and secondary goat anti-mouse IgG antibody 
(1:10000) conjugated to HRPO were used. The substrate ABTS/H2O2 was added and readings were 
recorded at 405 nm using an Optima spectro-fluorometer. 
Since a general trend of increasing signal over each panning round was seen, round four 
was used for the selection of monocolony scFvs. This is done to select the best signal 
producing clone for further scFv expression and purification.  
Round 4 phagemid, selected for reactivity in ELISA tested against each peptide, was 
allowed to infect E. coli TG1 cells and titered to produce single colonies that can be 





































colonies that contain phagemid enriched to detect Tb/TcoMSP:303-314 were selected. After 
being cultured and rescued, soluble phagemid was allowed to react with antigen in an ELISA 
(Figure 3.12). A number of individual colonies gave strong signals which correspond to 
successful development and selection of single scFv phenotype producing clones that are 
able to detect the antigen. Colonies A1, A12, D2, D12, G1, G12, H1 and H12 gave the 
highest signal and could have been used to express and purify specific 
anti-Tb/TcoMSP:303-314 peptide scFvs (Figure 3.12).  
Similar results were obtained from the 96 colonies selected to recognise TbMSP:400-412 
(Figure 3.13). Again, columns 1 and 12 gave the highest overall signal and colonies A1, A12, 
D5, G1, G12, H1, and H12 gave the highest signal (Figure 3.13). These colonies could have 
been selected for the expression and purification of phenotypically unique anti-
TbMSP:400-412 peptide scFvs. 
The 96 colonies selected to detect TvMSP:686-697 gave low absorbance readings (Figure 
3.14). Only colonies F1, G1 and H11 gave a slight increase in signal over the others (Figure 
3.14). This result was unexpected because in polyclonal environments the anti-TvMSP:686-
697 peptide scFvs performed well giving an adequate signal. It is possible that the colonies 
selected did not express the scFvs that bind TvMSP:686-697 best or individual colonies did 

















Figure 3.12: Monocolony scFv ELISA on 96 single colonies from round 4 of panning against 
Tb/TcoMSP:303-314. Single infected colonies cultured in a microtitre plate were rescued and 
phagemid isolated by centrifugation. Phagemid was allowed to react in a microtitre plate coated with 
10 µg/ml Tb/TcoMSP:303-314. Primary mouse anti-M13 antibody (1:8000) and secondary 
goat anti-mouse IgG antibody (1:10000) conjugated to HRPO were used. The substrate ABTS/H2O2 
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Figure 3.13: Monocolony scFv ELISA on 96 single colonies from round 4 of panning against 
TbMSP:400-412. Single infected colonies cultured in a microtitre plate were rescued and phagemid 
isolated by centrifugation. Phagemid was allowed to react in a microtitre plate coated with 10 µg/ml 
TbMSP:400-412. Primary mouse anti-M13 antibody (1:8000) and secondary goat anti-mouse IgG 
antibody (1:10000) conjugated to HRPO were used. The substrate ABTS/H2O2 was added and 



















Figure 3.14: Monocolony scFv ELISA on 96 single colonies from round 4 of panning against 
TvMSP:686-697. Single infected colonies cultured in a microtitre plate were rescued and phagemid 
isolated by centrifugation. Phagemid was allowed to react in a microtitre plate coated with 10 µg/ml 
MSP: 303-314. Primary mouse anti-M13 antibody (1:8000) and secondary goat anti-mouse IgG 
antibody (1:10000) conjugated to HRPO were used. The substrate ABTS/H2O2 was added and 
readings were recorded at 405 nm using an Optima spectro-fluorometer. 
From the Nkuku® library, scFv phagemids were selectively enriched to detect the three 
peptides designed from the amino acid sequences of MSP-B and -C. The successful 
selection of individual colonies which would allow for the expression of specific scFv 
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3.3.4 Detection of MSP in Parasite Lysate 
The detection ability of the respective anti-peptide antibodies to detect proteins in blood 
stage form (BSF) parasite lysates of both T. brucei and T. congolense were assessed. 
Anti-Tb/TcoMSP:303-314 peptide antibody was able to detect a 63 kDa protein found in both 
species of Trypanosoma (Figure 3.15, panel B). Since this antibody was designed to detect 
MSP-B, from T. brucei and T. congolense, and the theoretical size of MSP-B is on average 
63 kDa, it is evident that the protein detected here may be native MSP-B.  
Detection of a 53 kDa protein by anti-TbMSP:400-412 peptide antibody in lysate of both 
parasite species is also present (Figure 3.15, Panel C). Since, this peptide was designed to 
detect TbMSP-C; the detection of a protein in the T. congolense lysate was unexpected. The 
size of this protein was smaller than the expected size of TbMSP-B of 64 kDa, and that of 
TbMSP-C of 66 kDa. Since these proteases have a proregion, which have to be removed for 
the protease to be active, it is suspected that the smaller size represents the active form of 
MSP. Anti-TbMSP:400-412 showed no detection of the larger 63 kDa protein expected to be 
MSP-B. Therefore, it is suspected that the protein of 53 kDa is MSP-C. Furthermore, 
TbMSP:400-412 shares a 100% identity with TbMSP-C while only 53% identity with 
TbMSP-B. The detection of 53 kDa protein in the T. congolense lysate was also observed, 
even though, the TbMSP:400-412 peptide only shares 38% identity with TcoMSP-C. 
Anti-TbMSP:400-412 also detected smaller unknown products of 38 kDa in both parasite 
lysates (Figure 3.15, Panel C, lane 1 and 2) and a 27 kDa protein in the T. brucei lysate. It 
could be possible that the 38 kDa protein is an active form of MSP while the smaller 27 kDa 
protein is the proregion of the protein (38 + 27 = 65 kDa). However, at residues 400-412, the 
peptide selected for antibody production is not present within the predicted proregion 
although, the predicted proregion is based on leishmanolysin and variations may occur.  
Anti-TvMSP:686-697 showed no detection of any protein in either parasite lysates (Figure 
3.15, Panel D). TvMSP:686-697 shares less than 8% identity with MSP-B and -C from 
















Figure 3.15: Detection of MSPs in parasite lysate, using anti-peptide antibodies. (A) 10% SDS-
PAGE gel and western blots with (B) anti-Tb/TcoMSP:303-314, (C) anti-TbMSP:400-412 or (D) anti-
TvMSP:686-697 peptide antibody (5 µg/ml) as indicated. Rabbit anti-chicken secondary antibody 
conjugated to HRPO (1:2500) and visualised by ECL luminescence using the syngene G:BOX. 
Lane M, ThermoScientific pre-stained marker; lane 1, BSF T. brucei parasite lysate; lane 2, BSF 
T. congolense parasite lysate. Arrows indicate detection of 63 kDa MSP-B, 53 kDa active MSP-C and 
38 kDa and 27 kDa unknown products (?). 
 
3.4 Discussion  
To allow for the detection of specific MSPs and also assess the possible use of these 
proteases as diagnostic targets, peptides were designed that either detect the MSPs from 
more than one species or select a specific homologue of MSP. The results shown here 
indicated that these peptides can induce the production of anti-peptide detection molecules 
using both chickens (full antibody) and Nkuku® phagemid library (scFvs). Both methods gave 
successful production of detection molecules with the ability to detect the peptide antigens. 
Furthermore, native MSP was detected in parasite lysate using chicken anti-peptide 
antibodies. 
In general, high homology in primary structure results in the production of antibodies with the 
ability to cross-react with different antigens (Aalberse et al., 2001). An antibody’s paratope 
bound to an antigen epitope covers about 15 amino acid residues (Benjamin and Perdue, 
1996; Dougan et al., 1998). It has been shown that five key residues can be responsible for 
the binding energy of the epitope (Benjamin and Perdue, 1996; Dougan et al., 1998). This 
means that only 33% of an epitope region is responsible for recognition by the antibody. For 
this reason, peptides were designed based on both their predicted immunogenicity and their 
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Sequence identity of over 50% between peptide and protein sequences was suspected to 
produce anti-peptide antibodies that have the ability to cross-react. Tb/TcoMSP:303-314 
showed high sequence identity with both TcoMSP-B (100%) and TbMSP-B (77%) and was 
chosen to produce antibodies to detect both species. The other two peptides were designed 
to detect specific species. TbMSP:400-412 was designed to produce antibodies to detect 
only T. brucei. However, due the moderate identity between the peptide and TcoMSP-B and 
-C (46% and 38%), anti-TbMSP:400-412 peptide antibodies may also be able to detect 
T. congolense (peptide may contain the important amino acids required for binding). 
TvMSP:686-697 shows little sequence identity with any other protease species other than 
T. vivax and antibodies produced against this peptide should detect this species’ MSP-C.  
Phage display was used to isolate colonies expressing scFvs with the ability to detect 
Tb/TcoMSP:303-314 and TbMSP:400-412, only. The TvMSP:686-697 polyclonal ELISA 
results also gave a high signal after round two. Similarly, the scFvs selected against 
Tb/TcoMSP:303-314 also gave a signal after round one. This suggests that the original 
assumption that as selection rounds for specific scFvs continue the more specific the scFvs 
become and the higher the signal will be (Griep et al., 2000; Van Wyngaardt et al., 2004), 
may be incorrect. Therefore, to have the best monocolony scFv that gives the highest signal, 
clones should be selected from each round. 
A nanobody library against T. congolense was recently developed that is able, in vitro, to 
detect experimental infection and can be used as a test of cure (Odongo et al., 2016). 
Furthermore, an scFv library panned against the p24 HIV capsid protein resulted in highly 
specific antibody fragments which may be used in the diagnosis of viral load in HIV patients 
(de Haard et al., 1998) and scFvs raised against Infectious Bursal Disease Virus (IBDV) 
antigens were reported to be able to distinguish between three strains of IBDV and even 
neutralise the virus (Sapats et al., 2003). These reports of the use of a phagemid library in 
the diagnosis of Trypanosoma and other diseases highlight the benefits of this technology in 
diagnostics and even treatment.  
The chicken anti-MSP peptide antibodies showed cross-reactivity during the detection of 
native MSP in parasite lysate. These proteases show different levels of conservation across 
species possibly resulting in this cross-reactivity. The anti-Tb/TcoMSP:303-314 peptide 
antibody was expected to cross-react. However, unexpectedly anti-TbMSP:400-412 cross 
reacted with TcoMSP-C which only shared 38% identity with the peptide. This was, 




Anti-TvMSP:686-697 showed no cross reactivity being unable to detect MSP in parasite 
lysates. Either the design of the peptide needs to be reassessed to ensure identity is 10% or 
less or these proteases would have more potential as a pan species detection system.  
The work described in this chapter showed that peptide epitopes were successfully used to 
produce antibody detection molecules. The specificity of the chicken anti-peptide antibodies 
was further assessed using T. brucei and T. congolense parasite lysate and a high level of 
cross-reactivity between the two species was seen. It is suggested that these MSPs can be 
used as a novel diagnostic marker for cross-trypanosomal species detection. These 
antibodies were used to further characterise recombinant MSP-C from both T. brucei and 
T. congolense as described in Chapter 4. 
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 Chapter 4  
Cloning of T. brucei MSP-C and Expression and Characterisation of 
T. brucei and T. congolense MSP-C 
4.1 Introduction 
Proteases within parasitic protozoa have been identified to play an important role in the life 
cycle of these organisms. Identifying different proteases and understanding the way they 
function have given insight into approaches for vaccine development and diagnostics for 
parasitic diseases (Klemba and Goldberg, 2002). The identification of the papain-like 
cysteine proteases and serine proteases within trypanosome species is a case in point 
(Grellier et al., 2001; Lalmanach et al., 2002; Bastos et al., 2013). Some of these proteases 
are pathogenic factors which break down host proteins and contribute to the manifestation of 
disease symptoms (Bastos et al., 2010).  
The Major Surface Proteases (MSPs), novel metalloproteases which reside on the surface of 
parasites, have been identified in the kinetoplastid Leishmania  (Etges, 1992). It functions to 
help these parasites to evade the host’s immune system, invade host macrophages and help 
in the survival of parasites within these organelles (Wilson and Hardin, 1988; Brittingham et 
al., 1995; Kulkarni et al., 2006; Matte et al., 2016). A number of MSPs have been identified 
in Trypanosoma species as well, including T. brucei and T. congolense. Since Leishmania is 
an intracellular parasite, some of the functions of these proteases do not apply to the African 
Trypanosoma homologues. These trypanosome populations have a highly evolved 
mechanism of evading the host immune system, which involves changing their VSG coat in 
a process called antigenic variation (Pays et al., 2004). These parasites are also 
extracellular and, therefore, they do not invade any host organelles. So the question arises: 
why do trypanosomes express these proteases and what are their functions?   
T  brucei and T. congolense have several forms of these proteases (El-Sayed and Donelson, 
1997a; Marcoux et al., 2010). Even though little is known regarding their function, it is 
suspected that each class has unique functions due to their differential expression within the 
parasite life cycle (LaCount et al., 2003). It has been shown that MSP-C is expressed in the 
blood stage form of T  brucei parasites (LaCount et al., 2003). It has also been predicted that 
TcoMSP-C is unlikely to be GPI-anchored to the surface of the parasite (Marcoux et al., 
2010). Studies have indicated that leishmanial species contain forms of the protease that are 
secreted (Jaffe and Dwyer, 2003). Therefore, it would be foreseeable if Trypanosoma 
species also contained forms of the protease that are secreted. It was deduced that MSP-C 
might be such a protease. If this was the case, it would be secreted straight into the blood 
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stream of its host where it may function as a pathogenic factor like the serine proteases 
prolyl oligopeptidase and oligopeptidase B [POP and OPB; Morty et al. (1998); Morty et al. 
(1999); Grellier et al. (2001)]. MSPs from Leishmania have been shown to cleave collagen 
and fibronectin (McGwire et al., 2003a), uniformly to Trypanosoma POP and OPB which 
cleaves components of the extracellular matrix as well (Bastos et al., 2013). If this protease 
is secreted into the host’s blood stream, it may be available for detection and be a novel 
cross-species trypanosomal diagnostic marker. Alternatively, it may induce an immune 
response which could allow for the detection of serum antibodies as seen for other 
Trypanosoma diagnostic tests (Büscher et al., 2014; Birhanu et al., 2015; Fleming et al., 
2016).  
Leishmanolysin, MSP from Leishmania major, has been shown to catalytically cleave the 
substrate N-Ala-Tyr↓Leu-Lys-Lys-C (Bouvier et al., 1990; Schlagenhauf et al., 1998). Using 
Schechter and Berger (1968) schematic layout of peptide substrate and active site 
interaction: P1 has a 35% chance of being Tyr while P2 can be either Ala and Leu (25% 
chance). P1′ also has a 35% chance of being Leu and P2′ and P3′ have a 45% chance of 
being Lys (Schomburg and Stephan, 2012). It has been shown in the analyses reported in 
this dissertation that each MSP contains key characteristics which would indicate that they 
have similar substrate specificities (Chapters 1 and 2). It was, therefore, viable to use the 
leishmanolysin substrate specificity and the possibility percentages of each residue within 
each P-site to select a peptide substrate for MSP-C cleavage.  
In the work reported in this chapter, T. brucei LiTat 1.3 parasites were successfully purified 
and genomic DNA extracted. PCR was performed using primers designed to amplify 
TbMSP-C which was subsequently cloned into a pGEM®-T vector and subcloned into a 
pGEX 4T-1 expression vector. The T. brucei MSP-C protease was recombinantly expressed 
in E. coli and the anti-peptide antibody (Chapter 3) detection specificity assessed. However, 
due to significant mutations within the cloned insert and presence of a number of truncated 
products during expression, TbMSP-C and TcoMSP-C gene constructs were synthesised 
and respective recombinant protein successfully purified. These enzymes were also used to 
assess the detection specificity of the anti-peptide antibodies. Furthermore, they were 
characterised under non-denaturing conditions, analysed enzymatically and assessed for 




4.2 Materials and Methods   
4.2.1 Materials 
All general reagents were of the highest purity and purchased from Merck (RSA).  
Molecular Biology: The pGEM® T-vector was purchased from Promega (USA) and the 
pGEX 4T-1 expression vector from Sigma-Aldrich (Germany). RNase, DreamTM Taq Enzyme 
Mix, High Fidelity PCR Enzyme Mix, dATP, dTTP, dGTP, dCTP, T4 DNA ligase Enzyme 
Mix, TransformAidTM cloning kit, GeneJet plasmid DNA isolation kit, EcoRI, NotI, 10 x ‘O’ 
buffer, Fast Alkaline Phosphatase (AP) enzyme mix, isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) were all from Life 
Technologies/ThermoScientific (Gauteng, RSA). Ethidium bromide was from Boehringer 
Mannheim/Roche (USA). O'GeneRuler 1 kb DNA Ladder and 6 x orange DNA loading dye 
were from Separation Scientific (USA). peqGOLD gel extraction kit was from PEQLAB 
biotechnologie (Germany) and Clean and Concentrate DNA Kit was purchased from 
ZymoResearch (USA).  
E. coli cell lines: Escherichia coli (E. coli) strains JM109 and BL21 (DE3) were purchased 
from New England Biolabs (USA).  
Constructs: Two MSP-C (T. brucei and T. congolense) constructs within the pET-100D 
vector were synthesised by GeneArt (ThermoFisher, Germany) with codon optimisation for 
expression in E. coli. The expressed proteins were referred to as rTbMSP-C and rTcoMSP-C 
Expression: Lysozyme was from ThermoFisher (USA). 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blot analyses: H2O2 and 2-mercaptoethanol were purchased from Merck (RSA) and 
ammonium persulfate from BioRad (USA). Rabbit anti-chicken IgY horse radish peroxidase 
(HRPO) and 4-chloro-1-naphthol were purchased from Sigma-Aldrich (USA). PageRuler pre-
stained marker was purchased from Separation Scientific (USA) and BioTrace™ 
nitrocellulose was from PALL Life Sciences (USA). ECL reagent was from Pierce (USA). 
Anti-GST antibodies were made previously in chickens.  
Purification: UltraLink® Hydrazide Resin was purchased from Separation Scientific (USA) 
and the Zeba™ desalting spin column was from Pierce (USA). Centricon® centrifugal 





Protease activity: 1,10 phenanthroline and porcine gelatin were purchased from 
Sigma-Aldrich (USA). H-Suc-Leu-Tyr-AMC peptide substrate was purchased from Bachem 
(Switzerland) and Nunc® Black 96 well plates were from ThermoFisher (USA).  
ELISA: Sera from infected (+28) and non-infected cattle (-7) were obtained from ClinVet 
International (PTY) LTD (Bloemfontein, South Africa). Rabbit anti-bovine IgG-HRPO (A8917) 
conjugate was purchased from Sigma Aldrich (USA).  
4.2.2 Parasite Purification  
This was done as described in Section 3.2.7 (Chapter 3). 
4.2.3 Genomic DNA Isolation  
T. brucei genomic DNA was isolated from both the procyclic Lister 427 and blood stage LiTat 
1.3 strains. The purified parasites were pelleted by centrifugation (3000 x g, 10 min, 4oC). 
The parasites were washed in 10 ml PBS and centrifuged again (3000 x g, 10 min, 4oC). The 
supernatant was discarded and the pelleted parasites were gently resuspended in 2 x 150 µl 
TELT lysis buffer (50 mM Tris-HCl, pH 8 containing 62.5 mM EDTA and 2.5 mM LiCl). The 
resuspended pellet was incubated at room temperature (RT) for 5 min. Phenol:chloroform 
(ratio 1:1) was added (2 x 150 µl) and incubated for another 5 min at RT.  
The sample was centrifuged (17000 x g, 10 min, 4oC) to separate the solution into three 
distinct phases. The top aqueous phase, containing nucleic acids, was removed and the 
volume determined. To the top aqueous phase an equal volume of ice cold 
100% (v/v) ethanol was added. This solution was incubated overnight at -20oC. The 
precipitated nucleic acid was pelleted by centrifugation (17000 x g, 15 min, 4oC), washed 
with 500 µl 100% (v/v) ethanol and dried by incubation at 37oC for 10 min. The pellet was 
dissolved in 100 µl TE buffer (10 mM Tris-HCl -HCl, 1 mM EDTA, pH 8.0) containing 1 µg/ml 
RNase and incubated at 37oC for 45 min to allow for the degradation of RNA. The genomic 
DNA sample was analysed for purity on a 1% (w/v) agarose gel containing 0.5 µg/ml 
ethidium bromide in 1 x TAE buffer (40 mM Tris-HCl , 20 mM acetate, 1 mM EDTA) and 
concentration determined using the Nanodrop 6000 spectrophotometer. The final purified 
genomic DNA from both T. brucei strains was stored at -20oC until needed.  
4.2.4 Primer Design and Polymerase Chain Reaction (PCR) of TbMSP-C 
The nucleotide sequence coding for T. brucei MSP-C was obtained from NCBI (accession 
number: AAO72980.1) and used to design the primers shown in Table 4.1.  
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The primers were designed to amplify the full length 1773 bp TbMSP-C gene and to 
introduce the EcoRI [ECoRI (Roberts et al., 2003)] and NotI site within the amplified product. 
The primers were synthesised by the University of Cape Town (South Africa).  
1Table 4.1: Primers designed for amplification of TbMSP-C. 
Primer Tm (oC) %GC 












NotI) and start codon is indicated in bold.  
 
The TbMSP-C gene was amplified from T. brucei Lister 427 genomic DNA using Dream™ 
Taq polymerase (1 U) in 1 x Dream™ Taq buffer (2 mM MgCl2), 0.8 µM dNTP mix, 0.5 µM 
forward and reverse primers and 1 ng genomic DNA made up to 20 µl reaction volume with 
MilliQ® deionised water.  
The TbMSP-C gene was amplified from T. brucei LiTat 1.3 from genomic DNA using High 
Fidelity Taq polymerase (0.5 U) in 1 x HF buffer, 2 mM MgCl2, 0.32 µM dNTP mix, 0.5 µM 
forward and reverse primers and 1 ng genomic DNA made up to 20 µl reaction volume with 
MilliQ® deionised water. 
Both PCR reactions followed the same cycling conditions, using the T100TM Thermocycler 
(BioRad, USA), as indicated in Figure 4.1 and the products analysed on a 1% (w/v) agarose 
gel as before. The concentration of the insert was determined using the G:BOX imaging 




























































4.2.5 Cloning of TbMSP-C into pGEM®-T and pGEX 4T-1 Vectors 
Amplified TbMSP-C was ligated into the pGEM® T-vector (Appendix 7, Figure A7.1). This 
was done using T4 DNA ligase (1 U) in 1 x ligation buffer with 50 ng vector DNA and   ng 
insert DNA to a final volume of 10 µl. The insert DNA was used at a ratio of 4:1 with vector 
DNA. The amount of insert added was calculated using the following equation:  
      
                                                   
                      





Ligation was performed at 4oC overnight and transformation into E. coli JM109 cells 
completed the next day. The TransformAid™ kit was used according to the manufacturer’s 
instructions (ThermoScientific) and the 40 µl final competent cell-ligation mixture was plated 
onto 2xYT media containing agar (1.5% (w/v) bacteriological agar) with 100 µg/ml ampicillin, 
20 µg/ml X-gal and 0.1 mM IPTG for blue-white colony selection. The transformed cells were 
grown overnight at 37oC.  
Once a white recombinant colony was obtained, the vector was tested to ensure the 
TbMSP-C insert was present. This was done by growing the white colony in 2xYT liquid 
medium containing 200 µg/ml ampicillin overnight at 37oC with shaking. From the overnight 
culture, plasmid DNA was isolated using the GeneJet plasmid DNA isolation kit 
(ThermoScientific) following the manufacturer’s instructions. PCR using specific gene 
primers was performed, as described in Section 4.2.4, to determine if the correct gene was 
present.  
Restriction digestion using EcoRI (1 U) and NotI (1 U) in 1 x ‘O’ buffer in a final volume of 
10 µl was also done to excise the insert from the vector for analysis. Both the PCR and 
restriction digestion products was analysed on a 1% (w/v) agarose gel as before. Once the 
MSP-C gene was present within the pGEM® T-vector glycerol stocks were made by adding 
25% (w/v) glycerol to an overnight culture and stored at -80oC.  
Before cloning into a pGEX 4T-1 expression vector (Appendix 7, Figure A7.2), large scale 
restriction digestion was done on both the recombinant TbMSP-C-pGEM® T-vector and the 
pGEX 4T-1 expression vector and analysed on a 1% (w/v) agarose gel as before. The 
excised insert (containing EcoRI and NotI ‘sticky ends’) was gel extracted from a 1% (w/v) 
agarose gel containing 10 µg/ml crystal violet strain (Rand, 1996) using a peqGOLD Gel 
extraction kit (PEQLAB biotechnologie) following the manufacturer’s instructions.  
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The concentration of extracted insert was determined using the Nanodrop 6000. After the 
digestion of the pGEX 4T-1 vector, it was dephosphorylated using Fast AP (1 U) in 1 x Fast 
AP buffer and 25 µl digested vector DNA made up to 30 µl with MilliQ® deionised water.  
The enzyme was allowed to react for 10 min at 37oC and the reaction stopped by heat 
inactivation at 65oC for 15 min. The digested desphosphorylated pGEX 4T-1 vector was 
cleaned and concentrated using the ZymoResearch clean and concentrate kit as per the 
manufacturer’s instructions. Concentration of pGEX 4T-1 vector was determined using the 
Nanodrop 6000.  
Once both insert and expression vector contained EcoRI and NotI ‘sticky ends’, they were 
ligated using T4 DNA ligase as before. The ligation mix was transformed into BL21 (DE3) 
E. coli cells using the TransformAid™ kit according to the manufacturer’s instructions and 
the 40 µl final competent cell-ligation mixture was plated onto 2xYT media containing agar 
supplemented with 100 µg/ml ampicillin. The plated cells were grown overnight at 37oC. 
Colonies that showed ampicillin resistance were tested for the presence of the insert by PCR 
and restriction digestion as before. Glycerol stocks of recombinant E. coli cells were made 
as described before. The recombinant pGEX 4T-1 vector was sequenced (University of 
Stellenbosch, South Africa) to ensure that the MSP-C gene was cloned and that no 
mutations occurred.  
4.2.6 Transformation and Restriction Digestion of Recombinant (r)TbMSP-C 
and rTcoMSP-C Constructs 
The synthesised construct DNA (based on the TbMSP-C sequence: AAO72980.1 and 
TcoMSP-C sequence: CCC93446.1) was resuspended in 50 µl MilliQ® dH2O according to 
manufacturer’s instructions. The construct DNA was transformed into BL21 (DE3) E. coli 
cells using CaCl2 transformation (Sambrook et al., 2001). Briefly, a non-recombinant BL21 
(DE3) E. coli colony was inoculated into 10 ml of 2xYT liquid medium and grown overnight, 
with shaking at 37oC. The overnight culture was diluted 1:100 with 90 ml 2xYT medium and 
grown until the OD at 600 nm was 0.3-0.4. The culture was transferred into ice cold, sterile 
centrifuge tubes and incubated on ice for 10 min. The cells were pelleted by centrifugation 
(5000 x g, 10 min, 4oC), resuspended in 40 ml of sterile CaCl2 (60 mM CaCl2, 10 mM 
HEPES, pH 7.0) and pelleted again (5000 x g, 10 min, 4oC). This was followed by 
resuspension in CaCl2 solution (2 ml). The now competent cells (20 µl) were added to the 
construct preparation (1 µl) and incubated on ice for 30 min. Heat shock was performed by 
incubating cells at 42oC for 90 s followed by incubation on ice for 2 min.  
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The cells were added to 80 µl pre-warmed super optimal cataboliser with catabolite 
repression (SOC) medium [2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose] and incubated at 37
oC for 1 h with 
gentle shaking. The resulting mixture (100 µl) was plated onto 2xYT agar plates 
(supplemented with 100 µg/ml ampicillin) and cells grown overnight at 37oC.  
The resulting colonies were selected (five from each) and grown overnight with shaking at 
37oC in 2xYT medium containing 200 µg/ml ampicillin (10 ml). The overnight culture was 
used to prepare glycerol stocks [750 µl culture with 750 µl 50% (v/v) sterile glycerol] and the 
remainder used to perform plasmid DNA isolation using the GeneJet plasmid DNA isolation 
kit (ThermoScientific, USA), following the manufacturer’s instructions. Restriction digestion of 
the rTbMSP-C construct, using EcoRI (1 U) and NotI (1 U) in 1 x ‘O’ buffer in a final volume 
of 10 µl, was done to excise the insert from the vector and ensure its correct size (1800 bp). 
Similarly, restriction digestion of the rTcoMSP-C construct, using BamHI (1 U) and NotI (1 U) 
in 2 x tango buffer in a final volume of 10 µl, was also performed. 
4.2.7 Recombinant Expression of TbMSP-C, rTbMSP-C and rTcoMSP-C.  
The recombinant BL21 (DE3) E. coli cells were used to express TbMSP-C within the 
pGEX 4T-1 vector with an N-terminal GST tag (Appendix 7, Figure A7.2)and rTbMSP-C and 
rTcoMSP-C within the pET100-D vector with an N-terminal His tag (Appendix 7, Figure 
A7.3). Two methods were used in an attempt to express the proteins: (1) IPTG induction and 
(2) autoinduction. Recombinant E. coli cells were streaked on 2xYT agar containing 
100 µg/ml ampicillin and incubated overnight at 37oC. All E. coli culture work was performed 
in a sterile environment.  
(1) A single TbMSP-C colony was inoculated in 2xYT liquid medium (containing 100 µg/ml 
ampicillin) overnight at 37oC. The overnight culture was used to perform a 1:100 dilution in 
fresh 2xYT medium (containing 100 µg/ml ampicillin) and the culture grown at 37oC until an 
OD at 600 nm of 0.5-0.7 was reached. Expression was induced with 1 mM IPTG, 
supplemented with 100 µg/ml ampicillin and the culture grown for a further 4 h at 37oC. 
Overnight culture (1 ml) was used as an uninduced control. Expressed culture (2 ml) was 
used as an induced sample. Cells were pelleted by centrifugation (5000 x g, 2 min, RT) and 
resuspended in 50 µl PBS and 50 µl reducing treatment buffer [125 mM Tris-HCl, pH 6.8 
with 4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol with bromophenol 




(2) A single rTbMSP-C or rTcoMSP-C colony was used to inoculate Terrific Broth 
autoinduction medium [1.2% (w/v) tryptone, 2.4% (w/v) yeast extract, 0.17 M KH2PO4, 0.72 
M K2HPO4] and the culture grown at 30
oC overnight. Cells were pelleted by centrifugation 
(5000 x g, 2 min, RT) and resuspended in 50 µl PBS and 50 µl reducing treatment buffer. 
Samples were stored at -20oC and boiled for 2 min before being used. 
4.2.8 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
and Western Blot Analyses. 
Samples were analysed by SDS-PAGE as described by Laemmli (1970) under reducing and 
non-reducing conditions. A 4% stacking and 10% running gel were used and gels 
electrophoresed  at 20 mA in tank buffer [250 mM Tris-HCl , 192 mM glycine, 0.1% (m/v) 
SDS, pH 8.3] using a BioRad casting system (USA). Gels were either stained with 
Coomassie blue [0.125% (m/v) Coomassie blue R-250, 50% (v/v) methanol, 10% (v/v) acetic 
acid], silver stained (Blum et al., 1987) or transferred to nitrocellulose for analyses by 
western blot.  
Proteins from the polyacrylamide gel were transferred to nitrocellulose using a Semi-phor® 
Semi-Dry blotter (Sigma, USA) at 20 V for 50 min or using a Biorad overnight transfer 
system (USA), at 20 mA, in blotting buffer [25 mM Tris-HCl, 190 mM glycine, 20% (v/v) 
methanol with 0.1% (w/v) SDS]. Transfer success was determined by staining with 
Ponceau S [0.1% (w/v) Ponceau S, 15% (v/v) acetic acid]. Stain was removed with a 0.5 M 
NaOH solution and protein free areas blocked using 5% (w/v) non-fat milk powder in Tris 
buffered saline (TBS; 20 mM Tris-HCl, 200 mM NaCl, pH 7.4) for 1 h. Primary antibody in 
blocking solution was added and the blot incubated at 4oC, overnight with gentle mixing. 
Anti-peptide antibody was used at 2 µg/ml, anti-GST antibody at 0.75 µg/ml and anti-His 
antibody (Sigma, USA) at 1:1500, unless otherwise indicated. The blot was washed 
3 x 5 min with TBS (washing). Rabbit anti-chicken IgY conjugated to horse radish peroxidase 
(HRPO) antibody [1:5000 dilution in 0.5% (w/v) bovine serum albumin (BSA) in TBS] was 
added and the blot incubated for 1 h. Following the washing step, protein bands were either 
visualised using 4-chloro-1-naphthol substrate solution [0.06% (m/v) 4-chloro-1-naphthol, 
0.0015% (v/v) H2O2 in TBS] or using ECL with luminal substrate solution [Pierce, USA]. All 
SDS-PAGE gels and western blots were visualised using the Syngene G:BOX (Vacutec, UK)  
4.2.9 Purification of Truncated (t)TbMSP-C, rTbMSP-C and rTcoMSP-C 
Large scale expression of tTbMSP-C was performed in 1000 ml 2xYT media induced with 
1 mM IPTG for 4 hours at 37oC. Large scale expression of both rTbMSP-C and rTcoMSP-C 
was performed in 250 ml Terrific Broth overnight at 30oC.  
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The cells were pelleted (6000 x g, 10 min) and resuspended in equilibration buffer (50 mM 
NaH2PO4, 300 mM NaCl, pH 7.0) containing 1 mg/ml lysozyme and 1 % (v/v) Triton™ X-100 
and incubated at RT for 1 hour. The cells were sonicated 10 x on ice (30 s sonication, 30 s 
rest) and centrifuged (10000 x g, 15 min) to obtain the soluble and insoluble fractions. The 
insoluble tTbMSP-C expression fraction was used to solubilise the protein by resuspending 
the pellet in PBS with 300 mM NaCl of the same volume as the supernatant and the solution 
was sonicated 10 x on ice (1 min sonication, 1 min rest). The solubilised protein was 
obtained by centrifugation (10000 x g, 5 min, 4oC) and the supernatant was filtered twice 
through Whatman no. 1 filter paper before purification. The soluble fractions from the 
rTbMSP-C and rTcoMSP-C expressions were clarified by filtering through 0.45 µm filter 
before purification. 
Purification of tTbMSP-C was performed using anti-TbMSP:400-412 peptide antibodies 
(2 mg) specific for TbMSP-C (Chapter 3) linked to UltraLink® Hydrazide resin. Purification of 
rTbMSP-C and rTcoMSP-C was performed using UltraLink® Hydrazide resin linked to 
anti-Tb/TcoMSP:303-314 (4 mg) cross-species anti-peptide antibodies (Chapter 3).  
The anti-peptide antibodies were linked to the resin following the manufacturer’s instructions. 
Firstly, the antibody was incubated with 10 mM meta-periodate in the dark for 30 min at RT. 
The Zebu™ spin desalting column (1  ml, ThermoFisher) was prepared following the 
manufacturer’s instruction. The column containing the resin was centrifuged (1000 x g, 2 
min, 4oC) and washed 3 x with coupling buffer (0.1 M NaH2PO4, pH 7.0) by centrifugation 
(1000 x g, 2 min, 4oC). The oxidised antibody preparation was added to the desalting column 
and desalted oxidised antibody recovered by centrifugation (1000 x g, 2 min, 4oC). The 
absorbance at 280 nm was recorded for this sample. 
Secondly, UltraLink® Hydrazide resin (2 mg antibody per 1 ml) was added to a plastic 
column and allowed to settle for 15 min. The liquid was drained and resin washed with 5 
column volumes coupling buffer. Finally, the oxidized antibody was added to the resin. The 
solution was mixed into the resin by gentle inversion and coupling was completed by 
incubating the column overnight at 4oC using an end-over-end rotator. The resin was 
allowed to settle for 15 min and the liquid drained. It was washed with one column volume 
coupling buffer and the absorbance at 280 nm recorded. The resin was washed with 5 
column volumes 1 M NaCl followed by 5 column volumes of phosphate storage buffer [0.1 M 
NaH2PO4 with 0.1% (w/v) NaN3] and was stored at 4
oC until used.  
The respective anti-peptide antibody affinity columns were equilibrated with 5 column 


























added. The columns were incubated overnight at 4oC on an end-over-end rotator to allow for 
antibody-antigen interaction.  
The resin was allowed to settle for 15 min and the liquid drained. The flow-through was 
cycled over the column once more followed by washing with equilibration buffer until the 
absorbance at 280 nm was less than 0.02. The bound antigen was eluted by decreasing the 
pH with elution buffer [100 mM glycine-HCl, 0.02% (w/v) NaN3, pH 2.8] and 10 x 1 ml 
fractions, containing 100 µl of neutralisation buffer [1 M Na2HPO4, 0.02% (w/v) NaN3, pH 
8.5], were collected and stored at -20oC until use. Samples (10 µl) were combined with 10 µl 
reducing treatment buffer and boiled for 2 min before analysis using SDS-PAGE and 
western blot.  
4.2.10 Protein Concentration Determination 
All fractions eluted from the hydrazide immunoaffinity resin were pooled and concentrated 
using Centricon® centrifugal concentrators (6000 x g, 5 min, 4oC). The Bradford protein 
assay was performed to determine the protein concentration as described by Bradford 
(1976). In order to obtain a standard curve (Figure 4.2), 1 mg/ml ovalbumin stock was used 
to prepare protein standards (1000 µg/ml - 125 µg/ml) in triplicate. Protein standards (10 µl) 
were mixed with an equal volume of Bradford reagent [10 µl; 0.12 % (w/v) Coomassie 
brilliant blue G-250 dissolved in 500 ml of a 2 % (v/v) perchloric acid solution]. The 












Figure 4.2 Bradford standard curve used for protein quantification. Triplicate ovalbumin 
standards (1000 µg/ml - 125 µg/ml) were added to Bradford reagent and the resulting absorbances 
read at 595 nm using a Nanodrop 6000 spectrophotometer. The equation of the fitted line is 









4.2.11 Gelatin Zymography of tTbMSP-C 
Enzyme activity of tTbMSP-C was visualised using zymography (substrate SDS-PAGE) 
according to Heussen and Dowdle (1980). Gelatin [0.1% (w/v)] was incorporated into a 
10% running gel and SDS-PAGE completed as normal. The samples were prepared under 
non-reducing conditions (mixed with non-reducing treatment buffer ([125 mM Tris-HCl -HCl, 
pH 6.8 with 4% (w/v) SDS, 20% (v/v) glycerol with bromophenol blue] and were not boiled).  
The gel was washed with assay buffer (50 mM Tris-HCl , 5 mM CaCl2, 1 µM ZnCl2, pH 7.4) 
containing 2.5% Triton™  X-100 for 2 x 30 min at RT, briefly rinsed with dH2O and incubated 
in assay buffer (50 mM Tris-HCl , 5 mM CaCl2, 1 µM ZnCl2, pH 7.4) for 6 h or overnight at 
37oC and stained with Coomassie blue as described by Hassani et al. (2014). 
4.2.12 Molecular Exclusion Chromatography of rTbMSP-C and rTcoMSP-C 
Purified rTbMSP-C and rTcoMSP-C were subjected to molecular exclusion using the 
HiPrep™ 16/16 Sephacryl™ S200 HR resin (16 x 600 mm) with the ÄKTA purifier®. The 
packed and calibrated column was equilibrated with 60 ml MilliQ dH2O at 1 ml/min and, 
thereafter, with 180 ml MEC buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) at 1 ml/min. 
After equilibration, rTbMSP-C and rTcoMSP-C were added, in separate experiments, to the 
column and eluted with MEC buffer in 2 ml fractions. The elution profile was compared to 
that obtained by separating standard proteins of known molecular weight to determine the 
size of MSP-C under non-denaturing conditions. Absorbance peaks were subjected to 
analysis by SDS-PAGE under reducing conditions.  
4.2.13 Hydrolysis of H-Suc-Leu-Tyr-AMC Peptide Substrate by rTbMSP-C and 
rTcoMSP-C  
The activity of rTbMSP-C and rTcoMSP-C was assessed by measuring its hydrolysis of the 
fluorogenic peptide substrate H-Suc-Leu-Tyr-AMC. Protein, diluted in assay buffer 
(0.5-1.5 µg/ml), was preincubated at 37oC for 10 min before addition of substrate 
(7.5-10 µM) within a black NUNC® microtitre plate. The plate was incubated at 37oC for 
10 min intervals and free 7-amino-4 methylcoumarin (AMC) excited at 360 nm and emission 
read at 460 nm using the FLUOstar Optima spectro-fluorometer (BMG Labtech, Germany).  
4.2.14 Inhibition of rTbMSP-C and rTcoMSP-C 
Recombinant protein in assay buffer (0.5 ug/ml) was incubated with EDTA or 
1,10 phenanthroline (0.01-1 mM) at 37oC for 10 minutes within a black NUNC® microtitre 
plate, after which the H-Suc-Leu-Tyr-AMC peptide substrate (7.5 µM) was added. 
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This reaction mix was incubation for 10 min at 37oC with substrate before free 7-amino-4 
methylcoumarin (AMC) was excited at 360 nm and fluorescence emission at 460 nm read 
using the FLUOstar Optima spectro-fluorometer (BMG Labtech, Germany). 
4.2.15 pH Profile of rTbMSP and rTcoMSP-C 
Protein (0.5 µg/ml) was preincubated with constant ionic strength buffer AMT [acetic acidic 
(100 mM), MES (100 mM) and Tris (200 mM), pH 2-11] buffer at 37oC for 10 min, after 
which, 7.5 µM of H-Suc-Leu-Tyr-AMC substrate was added within black NUNC® microtitre 
plates. Plates were incubated at 37oC for 10 min and free AMC excited at 360 nm and 
emission read at 460 nm using a FLUOstar Optima spectro-fluorometer. 
4.2.16 Detection of antibodies against rTcoMSP-C with Infected Cattle Sera  
T. congolense infected (CVB 151 +28) and non-infected (CVB 186 -7) cattle sera were used 
to detect rTcoMSP-C antigen, using ELISA (Section 3.2.5). NUNC® Maxisorb 96 well 
microtitre plates were coated with rTcoMSP-C (10-50 µg/ml) overnight at 4oC. The plates 
were blocked with 0.5% (w/v) BSA in PBS for 1 h at 37oC, followed by washing 3 x 300 µl 
with PBS Tween-20 using the Biotek ELx50 plate washer. Infected or non-infected sera, 
diluted with 0.5% (w/v) BSA-PBS (1:200), were added to the microtitre plate (100 µl/well) 
and incubated for 2.5 h at 37oC, followed by washing with PBS Tween-20 (3 x 300 µl). 
Secondary rabbit anti-bovine IgG conjugated to HRPO (1:5000 in BSA-PBS) was added 
(100 µl/well) and incubated for 1 h at 37oC after which the plate was washed 3 x 300 µl with 
PBS Tween-20. Addition of ABTS/H2O2 substrate solution (Section 3.2.5; 150 µl/well) was 
followed by absorbance readings at 405 nm every 15 min for 1 h using the FLUOstar Optima 
spectro-fluorometer (BMG Labtach, Germany). 
4.3 Results  
4.3.1 Genomic DNA Isolation 
Genomic DNA was isolated from both procyclic Lister 427 and blood stage LiTat 1.3 
T. brucei strains using phenol:chloroform followed by standard ethanol precipitation 
(Figure 4.3). Genomic DNA from both T. brucei strains was detected at a size larger  than 












Figure 4.3: Genomic DNA extraction from procyclic (Lister 427) and blood stage (LiTat 1.3) 
T. brucei strains, evaluated on 1% (w/v) agarose gels. Gels were stained with ethidium bromide 
and viewed under ultra-violet light. Lane M, O’GeneRuler 1 kb DNA ladder. Genomic DNA from (A) 
procyclic (lane 1-2) and (B) blood stage form (lane 3-4) parasites are shown. Arrows indicates 
presence of genomic DNA at >10000 bp. 
 
4.3.2 PCR of TbMSP-C and Cloning into pGEM®-T and pGEX 4T-1 Vectors  
Polymerase chain reaction (PCR) was conducted on the genomic DNA from both parasite 
forms. Figure 4.4 shows the successful amplification of a DNA product of 1800 bp in size 
which corresponds to the calculated size of the TbMSP-C gene. Other DNA products at 
3300 bp and 1400 bp were also present. Band intensity was used to calculate the 
concentration of the DNA for the three bands shown in lane 7 (Figure 4.4). For the bands at 
1400 bp and 3300 bp, the concentration was less than 10 ng/µl, while the 1800 bp band had 
a concentration of 293 ng/µl. The concentration ratio of the expected TbMSP-C gene 
(1800 bp band) to non-specific DNA products (1400 bp and 3300 bp bands) is ~29:3:1 







Figure 4.4: Polymerase chain-reaction of TbMSP-C on both procyclic and blood stage form 
T. brucei genomic DNA, evaluated on 1% (w/v) agarose gels. Lane M, O’GeneRuler 1kb DNA 
ladder. PCR performed on (A) procyclic form (lanes 1-4) or (B) blood stage form (lanes 5-7) genomic 
DNA. Arrows indicate sizes of DNA bands obtained.  
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Once a substantial amount of amplified TbMSP-C DNA was obtained, it was cloned into the 
pGEM®-T vector and transformed into E. coli JM109 cells. Analysis of the recombinant 
T-vector (Figure 4.5, lane 1) showed at least three forms of DNA i.e. linear, nicked and 
supercoiled (Lodge et al., 2007). The tightly compacted, smaller, supercoiled form is most 
abundant as reported in the literature (Lodge et al., 2007). In comparison, digestion of 
recombinant pGEM®-T-TbMSP-C with the restriction enzymes, EcoRI and NotI, shows the 
excised insert of 1800 bp (lane 2). The band at 3000 bp represents the linear 
pGEM®-T vector, while the larger band at 4750 bp represents undigested T-vector. The 
undigested pGEX 4T-1 expression vector appeared at a size 3000 bp (Figure 4.5, lane 3). 
However, on digestion, with EcoRI and NotI, linearisation occurred resulting in a 4900 bp 







Figure 4.5: Undigested and digested pGEM
®
-T-TbMSP-C and expression vector pGEX 4T-1 
using EcoRI and NotI, analysed on 1% (w/v) agarose gel. Lane M, O’GeneRuler 1kb DNA ladder; 
lane 1, undigested recombinant pGEM
®
-T-TbMSP-C; lane 2, digested recombinant 
pGEM
®
-T-TbMSP-C; lane 3, undigested pGEX 4T-1; lane 4, digested pGEX 4T-1. Arrows show sizes 
of linear pGEX 4T-1 (4900 bp) and TbMSP-C (1800 bp). 
 
The digested TbMSP-C gene was sub-cloned into the pGEX 4T-1 expression vector and 
transformed into E. coli BL21 (DE3) cells. Analysis of a recombinant colony by PCR shows 
the amplification of a gene at 1800 bp (Figure 4.6, lane 1). Restriction digestion of 
recombinant pGEX 4T-1, with EcoRI and NotI, shows the release of the insert (1800 bp) 
from the vector (4900 bp; lane 3), in comparison with the undigested vector (lane 2). It was 
concluded that the TbMSP-C gene was successfully ligated into the expression vector and 













































Figure 4.6: Determining whether the expression vector is recombinant as analysed on 1% (w/v) 
agarose gel. Lane M, O’GeneRuler 1kb DNA ladder; lane 1, PCR using T. brucei MSP-C specific 
primers on pGEX 4T-1; lane 2, undigested recombinant pGEX 4T-1-TbMSP-C DNA; lane 3, restriction 
digestion of recombinant pGEX 4T-1-TbMSP-C DNA using EcoRI and NotI. Arrows show linear pGEX 
4T-1 (4900 bp) and TbMSP-C (1800 bp). 
 
4.3.3 Expression of TbMSP-C (tTbMSP-C) in E. coli 
Taking into account the GST tag of 26 kDa, TbMSP-C would be expressed at 92 kDa. Over 
expression, using IPTG, of E. coli cells containing the recombinant pGEX 4T-1 vector was 
compared to expression of E. coli cells containing the non-recombinant pGEX 4T-1 vector. 
The expressed proteins were resolved on SDS-PAGE and western blotted using anti-GST 
antibodies (Figure 4.7). The E. coli lysate of uninduced cells showed no induced proteins 
(panel B, lanes U1 and U2). Expression of the E. coli cells containing non-recombinant 
pGEX 4T-1 vector resulted in a single protein of 26 kDa corresponding to the GST tag 
(panel B, lane 1). Expression of the E. coli cells containing recombinant pGEX 4T-1-TbMSP-
C vector resulted in numerous protein bands and the four main bands are labelled (panel B, 
lane 2). The smallest 26 kDa band is suspected to be GST. The bands at 54 kDa and 
39 kDa are suspected to be truncated forms of the fusion protein, while the 92 kDa band 
would correspond to full length GST-TbMSP-C fusion protein.  
The detection of a single 26 kDa band after non-recombinant pGEX 4T-1 expression 
suggests that the numerous bands detected in the western blot with anti-GST antibodies, 
after recombinant TbMSP-C expression, are due to the presence of the TbMSP-C gene and 
are likely truncated forms of the protein. Since there are these unexpected truncated forms 
of the protein present during expression in E. coli, the expressed protein from cloned 
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Figure 4.7: Expression of (t)TbMSP-C (recombinant pGEX 4T-1) in comparison with 
non-recombinant pGEX 4T-1. (A) 10% SDS-PAGE gel and (B) western blot using chicken anti-GST 
primary antibody, rabbit anti-chicken secondary antibody conjugated to horseradish peroxidase and 
addition of 4-chloro-1-naphthol/H2O2 chromogenic substrate. Lane M, ThermoScientific pre-stained 
marker; lane U1 and U2, uninduced non-recombinant and recombinant pGEX 4T-1; lane 1, induced 
non-recombinant pGEX 4T-1; lane 2, induced recombinant pGEX 4T-1. Arrows indicate full length and 
truncated forms of TbMSP-C. 
 
4.3.4 Gene Sequencing Analyses 
Gene sequencing and translated amino acid sequence alignments are shown in Appendix 6. 
Four point mutations which caused the translated protein sequence to change occurred 
during the cloning procedure. Mutations one (F10-L10), three (N207-S207) and four (V226-I226) do 
not result in a change in amino acid class. However, mutation two (H27-L27) results in a 
change from a positively charged amino acid to a hydrophobic amino acid. Mutations that 
result in a change in amino acid class can result in a change in final tertiary structure and 
therefore enzyme activity (Lodish et al., 2000). A deletion also occurred within the 
recombinant TbMSP-C sequence which resulted in a frameshift at amino acid residue 504 
and a premature stop codon at amino acid residue 520 (Appendix 6).  
4.3.5 Anti-Peptide Antibody Specificity against tTbMSP-C 
The recombinantly expressed protein was shown to be detected with the anti-peptide 
antibodies (Figure 4.8) produced as described in Chapter 3. Anti-TbMSP:400-412 peptide 
antibodies designed to detect TbMSP-C were able to detect full length tTbMSP-C, at 92 kDa. 
However, they were unable to detect the truncated forms (Figure 4.8, panel C, lane 1 and 3). 
Furthermore, a protein band at 80 kDa was also seen, which is detected by anti-GST 
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Figure 4.8: Detection of tTbMSP-C with anti-peptide antibodies. (A) 10% SDS-PAGE gel and 
western blots with (B) anti-Tb/TcoMSP:303-314, (C) anti-TbMSP:400-412 or (D) anti-TvMSP:686-697 
peptide antibodies as indicated. Rabbit anti-chicken secondary antibody conjugated to horseradish 
peroxidase was used and addition of 4-chloro-1-naphthol/H2O2 chromogenic substrate. Lane M, 
ThermoScientific pre-stained marker; lane U, uninduced control; lane 1, IPTG induced culture; lane 2, 
soluble fraction; lane 3, insoluble fraction. Arrow indicates tTbMSP-C.  
 
The tTbMSP-C protein was detected in inclusion bodies in the insoluble fraction (Figure 4.8, 
lane 3). Unexpectedly, detection of full length tTbMSP-C by anti-Tb/TcoMSP:303-314 
peptide antibodies was also seen (panel B, lane 3). No protein was detected by anti-
TvMSP:686-697 peptide antibodies (panel B) which was expected. The fact that the 
expressed tTbMSP-C protein was detected by anti-TbMSP:400-412 peptide antibodies, 
infers that the protein being expressed is TbMSP-C. These antibodies were used to purify 
tTbMSP-C in the hope of diminishing the presence of truncated forms of the protein. 
4.3.6 Purification and Activity of tTbMSP-C 
Detection of tTbMSP-C in the insoluble fraction meant the protein had to be solubilised 
before purification. After solubilisation, the 92 kDa tTbMSP-C from the insoluble fraction 
(Figure 4.8, lane 1) moved to the soluble fractions (Figure 4.9, lanes 2-4). This fraction was 
then used to purify tTbMSP-C using anti-TbMSP:400-412 peptide antibodies (Figure 4.10).  
The soluble 92 kDa tTbMSP-C is seen in both the soluble and unbound fractions 
(Figure 4.10, lanes 1-2) with purification of a smaller 70 kDa protein seen (lanes 3-12). Small 
amounts of full length tTbMSP-C are, however, seen (Figure 4.10, panel A, lanes 5-9) and a 
number of lower molecular weight contaminating proteins are also present. No protein of 
70 kDa is seen or detected in the soluble fraction used for purification (Figure 4.10, panel B, 
lane 1) and so it is suspected that the protein underwent degradation or enzymatic 
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pH used when eluting the protein from the resin. Since the protein was purified using specific 









Figure 4.9: Solubilisation of tTbMSP-C as analysed on a 10% SDS-PAGE gel. Lane M, 
ThermoScientific pre-stained marker; lane 1, insoluble fraction; lane 2, solubilised fraction; lane 3 and 











Figure 4.10: Purification of recombinantly expressed and solubilised tTbMSP-C. (A) 10% 
SDS-PAGE and (B) western blot using chicken anti-TbMSP:400-412 peptide antibody, rabbit 
anti-chicken secondary antibody conjugated to HRPO with addition of 4-chloro-1-naphthol/H2O2 
chromogenic substrate. Lane M, ThermoScientific pre-stained marker; lane 1, solubilised fusion 
protein loaded onto the column; lane 2, unbound protein from the column; lane 3-12, purified protein 
fractions 1-10 (1 ml each). Arrow indicates purified tTbMSP-C. 
 
To ensure that the purified protein was an active protease, gelatin zymography was 
performed (Figure 4.11). When low amounts of purified tTbMSP-C (0.25 µg) were present a 
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was present smear of digestion was seen at ~55 kDa and digestion products were also seen 








Figure 4.11: Protease activity of purified tTbMSP-C as analysed on a 0.1% (w/v) gelatin 
zymogram stained with Coomassie blue. (A) 0.25 µg protein and (B) 1 µg protein. Lane M, 
ThermoScientific pre-stained marker; lane 1, purified tTbMSP-C. Arrow at 55 kDa indicates active 
tTbMSP-C and at 70 and 92 kDa latently active tTbMSP-C. 
 
This smaller 55 kDa protein is present in small quantities in the purification of tTbMSP-C 
(Figure 4.10, panel A and B, lanes 6-9) and may represent a fully active TbMSP-C, without 
the proregion. The larger 70 kDa and 92 kDa protein showed little activity and could 
represent a latently active enzyme in the presence of the proregion. This 55 kDa active 
protein is probably present due to the numerous truncations seen when tTbMSP-C is 
expressed in E. coli (Figure 4.7). 
Due to the presence of numerous truncations of the tTbMSP-C protein, the mutations 
present in the cloned gene, the unexplained reduction of size during purification and the 
presence of an active smaller 55 kDa protein, it was decided to have full length TbMSP-C 
and TcoMSP-C constructs synthesised and optimised for expression in E. coli. These will be 
called recombinant (r) TbMSP-C and TcoMSP-C. 
4.3.7 Transformation of Synthesised Constructs: rTbMSP-C and rTcoMSP-C 
The construct plasmid rTbMSP-C and rTcoMSP-C, obtained from GeneArt, were 
transformed into E. coli BL21 (DE3) cells. Recombinant cells were used to obtain plasmid 
DNA and restriction digestion performed to ensure the correct size gene product was 
present. Undigested rTbMSP-C and rTcoMSP-C DNA again showed the presence of three 
main bands of DNA i.e. linear, nicked and supercoiled (Figure 4.12, lane 1 and 3). 









































































product indicative of the MSP-C gene (Figure 4.12, lane 2 and 4), comparable to the PCR 








Figure 4.12: Restriction digestion of rTbMSP-C and rTcoMSP-C plasmid DNA obtained from 
recombinant E. coli cells as analysed on 1% (w/v) agarose gel. Lane M, O’GeneRuler 1kb DNA 
ladder; lane 1 and 3, undigested plasmid DNA from TbMSP-C and TcoMSP-C, respectively; lane 2, 
digested TbMSP-C construct with NotI and EcoRI; lane 4, digested TcoMSP-C construct with NotI 
and BamHI. Arrow shows presence of MSP-C gene (1800 bp). 
 
4.3.8 Expression of rTbMSP-C and rTcoMSP-C 
Recombinant E. coli BL21 (DE3) cells were used to express rTbMSP-C and rTcoMSP-C 
protein in Terrific Broth overnight and the solubility of each expressed protein was assessed. 
The theoretical size of TbMSP-C is 70 kDa while TcoMSP-C is slightly smaller at 68 kDa. 
Expression was assessed by SDS-PAGE and western blot (Figure 4.13, lane 1) and a 
71 kDa protein was observed for both plasmids as detected with both 
anti-Tb/TcoMSP:303-314 peptide antibodies [(Figure 4.13, panels B1 and B2); (designed to 
detect Tb and TcoMSP-B)] and anti-His antibodies (Figure 4.14, panels C1 and C2). The 
detection of MSP-C by the anti-Tb/TcoMSP:303-314 peptide antibody was unexpected 
since, the peptide only shared 42% identity with the protein (Figure 3.5, Section 3.3.1; see 
Section 4.3.11 for more information). The expressed proteins contained the N-terminal 
His-tag as evidenced by their detection with anti-His tag antibodies (Figure 4.13, panels C1 
and C2).  
The presence of smaller protein products was also unexpectedly observed and may be 
truncated protein. The rTbMSP-C construct expressed a smaller 60 kDa protein 
(Figure 4.13, panel B1), while, the rTcoMSP-C construct expressed two smaller proteins of 
65 and 43 kDa (Figure 4.13, panel B2). In the case of rTcoMSP-C expression, smaller 
protein products were only detected with anti-Tb/TcoMSP:303-314 peptide antibodies and 
not anti-His antibodies which suggests the loss of size occurred at the N-terminus of the 
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anti-Tb/TcoMSP:303-314 and anti-His antibodies indicating that the reduction in size 
occurred at the C-terminus. The theoretical size of active MSP-C, without the proregion, is 
53-55 kDa and, therefore, these unexpected products are not the active form of the protein. 
The protein was shown to be soluble (Figure 4.13, lane 2) with low amounts of protein 
detected in the insoluble fraction (lane 3). The soluble fraction was used for the purification 










Figure 4.13: Expression and solubility of rTbMSP-C (1) and rTcoMSP-C (2). Protein expression 
was performed overnight at 30
o
C in Terrific Broth and analysed using a 10% SDS-PAGE gel (A1 and 
2) and western blot with anti-Tb/TcoMSP:303-314 (B1 and 2) and anti-His (C1 and 2) primary 
antibody, rabbit anti-chicken secondary antibody conjugated to HRPO and visualised by ECL 
luminescence using the Syngene G:BOX. Lane M, ThermoScientific pre-stained marker; lane 1, 
overnight culture; lane 2, soluble supernatant fraction and lane 3, insoluble pellet fraction. Arrows 
indicate detection of 71 kDa MSP-C, and smaller protein bands. 
 
4.3.9 Purification of rTbMSP-C and rTcoMSP-C 
Recombinantly expressed rTbMSP-C and rTcoMSP-C was successfully detected by 
anti-Tb/TcoMSP:303-314 peptide antibodies. It was decided to use these antibodies, 
coupled to hydrazide resin, to purify the recombinant protein as metal chelate affinity 
purification proved to be inefficient (data not shown). The soluble fraction obtained after 
expression was loaded onto the antibody conjugated resin after which bound antigen was 
eluted. The successful purification of a 71 kDa protein, of both proteins, as detected by both 
anti-Tb/TcoMSP:303-314 peptide (Figure 4.14, panels C and D, lanes 2-11) and anti-His 
antibodies (Figure 4.14, panels E and F, lanes 2-11). was achieved. No protein was detected 
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Figure 4.14: Purification of rTbMSP-C (A, C and E) and rTcoMSP-C (B, D and F). (A and B) 10% 
SDS-PAGE gel and western blot using (C and D) anti-Tb/TcoMSP:303-314 peptide antibody and (E 
and F) anti-His antibody with rabbit anti-chicken secondary antibody conjugated to HRPO and 
visualised by ECL luminescence using the Syngene G:BOX. Lane M, ThermoScientific pre-stained 
marker; lane 1, unbound protein; lane 2-11, purified protein fractions 1-10 (1 ml each). 
 
 
45Figure 4.14: Purification of rTbMSP-
C and rTcoMSP-C. 
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Purification of a smaller 30 kDa protein was also seen (Figure 4.14, panels, A, B, C, D, E 
and F, lane 2-11). This 30 kDa product was not observed in expression samples (Figure 
4.13) and may be degradation of the smaller protein bands observed; however, a similar 
27 kDa protein was detected in T. brucei parasite lysate (Figure 3.15, section 3.3.4). Since 
the purification was done using specific antibody-antigen interaction, it is suspected that the 
smaller product is some part of the full length MSP-C protein. The successful purification of 
MSP-C, from both species, allowed for further analysis of its multimerisation and its 
enzymatic properties 
4.3.10 Analysis of the Multimerisation of rTbMSP-C and rTcoMSP-C.  
To assess the possible multimerisation of MSP-C from the two trypanosomal species, the 
protein was studied under non-denaturing conditions using non-reducing SDS-PAGE and 
molecular exclusion chromatography. Under non-reducing conditions, rTbMSP-C and 
rTcoMSP-C appear as protein multimers of larger than 170 kDa (Figure 4.15, panel A). This 
larger protein was detected by the anti-Tb/TcoMSP:303-314 antibodies confirming its identity 









Figure 4.15 Analysis of rTbMSP-C and rTcoMSP-C under non-denaturing conditions. 
(A) Non-reducing SDS-PAGE (10%) and (B) western blot using anti-Tb/TcoMSP:303-314 peptide 
antibodies, rabbit anti-chicken secondary antibody conjugated to HRPO and visualised by ECL 
luminescence using the Syngene G:BOX. Lane M, ThermoScientific pre-stained marker; lane 1, 
rTbMSP-C and lane 2, rTcoMSP-C. Arrows show multimerisation of protein.  
 
To confirm this data, molecular exclusion chromatography was performed and showed that 
these proteins aggregate and elute at the void volume of the column (Figure 4.16, panel A 
and C). The elution peak from molecular exclusion chromatography was subjected to 





































































































































































and D). There were, however, smaller degradation products present in the sample as well 
(Figure 4.16, panel B and D). The Sephacryl S200 column has a separation range of 
5-250 kDa, therefore, the enzyme aggregate is expected to be greater than 250 kDa. Since 
the multimerisation of the protein was disrupted by denaturation, it suggests that the 
















Figure 4.16: Molecular exclusion chromatography of rTbMSP-C (A and B) and rTcoMSP-C (C 
and D). (A and C) Elution profile of rTbMSP-C (blue) and rTcoMSP-C (orange) from an S200 
sephacryl molecular exclusion chromatography column. Elution profile of calibration proteins is 
included (grey). (B and D) Reducing SDS-PAGE (10%) showing the presence of 71 kDa protein 
(arrow). Smaller degradation products are also present (square box). 
 
4.3.11 Hydrolysis of H-Suc-Leu-Tyr-AMC Peptide Substrate 
The enzyme activity of rTbMSP-C and rTcoMSP-C was determined by assessing the 

























































leishmanolysin recognises -Leu/Ala-Tyr↓Leu-Lys-Lys- and a similar recognition site was 
used here.  
Both rTbMSP-C and rTcoMSP-C proteins were able to hydrolyse the peptide substrate as 
evidenced by the release of fluorescence over time (Figure 4.17). A maximum fluorescence 
signal, of 30000-40000, was seen for lower concentration of protein (0.5 and 1 µg/ml) after 
30 min incubation with the substrate. In contrast, a lower fluorescence of 15000-25000 was 
observed at higher protein concentration (5 µg/ml). This is likely due to enzymatic 
competition for the small amount of substrate in the presence of large amount of enzyme. 
The fluorescence released by 0.5 µg/ml of protein showed an increase in fluorescent 
intensity from 20000 after 20 min to 30000 after 30 min. A similar trend is observed for 1 
µg/ml and 5 µg/ml of protein with maximum overall fluorescence obtained from rTcoMSP-C, 








Figure 4.17: Hydrolysis of peptide substrate H-Suc-Leu-Tyr-AMC by rTbMSP-C and 
rTcoMSP-C.  Varying concentrations (0.5 µg/ml, 1 µg/ml, 5 µg/ml) of rTbMSP-C (green and blue) and 
rTcoMSP-C (purple and orange) were used to assess the hydrolysis of 10 µM substrate by measuring 
fluorescence released (Ex360 nm and Em460 nm) after incubation at 37
o
C for 20 (green and purple) and 
30 min (blue and orange) incubation times, using an Optima spectro-fluorometer. Results are the 
mean of duplicate readings with standard deviation.  
 
The activity of both rTbMSP-C and rTcoMSP-C were shown to be inhibited by the two 
metalloprotease inhibitors, EDTA and 1,10 phenanthroline. The fluorescent signal measured 
was shown to decrease as the concentration of inhibitor increased (Figure 4.18). The activity 
of rTbMSP-C and rTcoMSP-C was inhibited by 1,10 phenanthroline best, with a larger 
reduction in fluorescent signal when comparing 10 µM to 1 mM. The fluorescent intensity 
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Figure 4.18: Inhibition of rTbMSP-C and rTcoMSP-C by metalloprotease inhibitors, EDTA and 
1,10 phenanthroline. rTbMSP-C and rTcoMSP-C (0.5 µg/ml) was incubated with varying 
concentrations (0.01-1 mM) of metalloprotease inhibitor (EDTA and 1,10 phenanthroline) for 10 min at 
37
o
C, after which, 7.5 µM H-Suc-Leu-Tyr-AMC peptide substrate was added. Fluorescence intensity 
(Ex360 nm and Em460 nm), after incubation at 37
o
C for 10 min, was read using an Optima spectro-
fluorometer. Results are the mean of duplicate readings with standard deviation. 
 
To assess the pH optimum of rTbMSP-C and rTcoMSP-C, activity was determined from 
pH 2 to pH 11 (Figure 4.19). It can be seen that both rTbMSP-C and rTcoMSP-C enzymes 
prefer an acidic pH to that of a neutral one and basal signal is detected in alkaline pH of less 
than 20000. rTcoMSP-C favoured a more acidic pH of 4.5 (Figure 4.19, panel B), compared 








Figure 4.19: pH profile of rTbMSP-C (A) and rTcoMSP-C (B). Protein (0.5 µg/ml) was incubated 
with AMT buffer (pH 2-11) at 37
o
C for 10 min before addition of H-Suc-Leu-Tyr-AMC peptide 
substrate (7.5 µM). Enzyme activity was determined by measuring fluorescence released (Ex360 nm 
and Em460 nm) after 10 min at 37
o
C, using an Optima spectro-fluorometer. Results are the mean of 

























































































4.3.12 Anti-peptide Antibody Specificity against rTcoMSP-C 
To assess the detection ability of the anti-peptide antibodies against rTcoMSP-C, as was 
done for tTbMSP-C (Section 4.3.5); purified rTcoMSP-C was probed with each antibody 











Figure 4.20: Detection of rTcoMSP-C with anti-peptide antibodies. (A) SDS-PAGE (10%) and 
western blots with (B) anti-Tb/TcoMSP:303-314, (C) anti-TbMSP:400-412 or (D) anti-TvMSP:686-697 
peptide antibodies (2 µg/ml) as indicated. Rabbit anti-chicken secondary antibody conjugated to 
HRPO was used and visualised by ECL luminescence using the Syngene G:BOX. Lane M, 
ThermoScientific pre-stained marker; lane 1, purified rTcoMSP-C. Arrow indicates rTcoMSP-C.  
 
 
rTcoMSP-C was detected by anti-Tb/TcoMSP:303-314 antibodies (designed to detect Tb 
and TcoMSP-B), at 71 kDa (Figure 4.20, panel B). The detection of rTcoMSP-C by this 
antibody was unexpected, since it only shares 42% identity with the peptide selected for 
antibody production. By comparison, tTbMSP-C (Figure 4.8, panel B) and rTbMSP-C (Figure 
4.13, panel B1) were also detected by the antibody and also shares 42% identity with the 
peptide (Section 3.3.1, Figure 3.5). Anti-TbMSP:400-412 antibodies (designed to detect 
TbMSP-C) showed faint detection of rTcoMSP-C (Figure 4.20, panel C), while no detection 
was seen by anti-TvMSP:686-697 antibodies (Figure 4.20, panel D). TcoMSP-C shares 38% 
identity with the TbMSP:400-412 peptide and 0% identity with the TvMSP:686-697 peptide 
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4.3.13 Detection of rTcoMSP-C with Infected Cattle Sera 
To determine whether MSP-C induces an immune response in cattle, T. congolense infected 
cattle sera were used to detect rTcoMSP-C in an ELISA format (Figure 4.21). Increasing 
concentrations of rTcoMSP-C as coating antigen resulted in an increase in absorbance 
signal with time, with 50 µg/ml protein giving the highest signal of 0.75 after 60 min. 
However, high absorbance signal was obtained for the non-infected sera control (Figure 
4.21, orange), comparable with the infected sera (green). A comparison of the different 
protein concentrations with the signal released after 60 min shows higher signal in the 
presence of more protein (compare blue, red and green). The signal increases from 0.45 for 
10 µg/ml of protein to 0.55 for 25 µg/ml of protein to 0.75 for 50 µg/ml of protein. This result 
suggests that there are serum antibodies present that detect rTcoMSP-C in infected sera 








Figure 4.21: Detection of rTcoMSP-C with infected cattle sera. Decreasing protein concentration 
(50, 25 and 10 µg/ml) were used to coat a 96 well microtitre plate and infected or non-infected cattle 
sera (1:200) were used to detect the protein. Secondary anti-bovine IgG (1:5000) conjugated to 
HRPO was used to visualise detected protein in the presence of substrate ABTS/H2O2. Absorbance 
was read at 405 nm at 15 min intervals for one hour using an Optima spectro-fluorometer. Results are 
the mean of duplicate readings with standard deviation. Controls are shown in grey. 
 
4.4 Discussion  
The results in this chapter reported the analyses of the MSP-C protease from both T. brucei 
and T. congolense. The TbMSP-C gene was detected in both Lister 427 and LiTat 1.3 
strains of T. brucei confirming previous results that showed that these proteases are 
conserved across species, genera and families of parasite protozoa [(Etges, 1992; El-Sayed 
and Donelson, 1997a; Cuevas et al., 2003; Jesudhasan et al., 2007; Marcoux et al., 2010; 












































After the PCR, cloning and expression of the TbMSP-C gene, numerous truncated protein 
products resulted. It is known that when expressing eukaryotic genes within prokaryotes, 
codon bias may result. Codon bias is caused when a codon present within the cloned gene 
is used by E. coli at a rate of 1% or less [rare codon; (Kane, 1995)]. This may result in 
truncation of the expressed protein or incorrect amino acid incorporation (Rosano and 
Ceccarelli, 2014), due to the fact that tRNA of their amino acid are less abundant (Buchan 
and Stansfield, 2007). During protein synthesis, if many rare codons are present within the 
cloned gene, the tRNA molecules can become depleted, thus resulting in ribosomal pausing 
and subsequent disconnection of the RNA strand (Buchan and Stansfield, 2007). By using 
rare codon predictors (http://nihserver.mbi.ucla.edu/RACC/; http://www.genscript.com/cgi-
bin/tools/rare_codon_analysis), the TbMSP-C gene was analysed for the presence of rare 
codons. Both predictors revealed between 11-38 rare codons. This is substantial evidence 
that explains the presence of the numerous truncated forms of the protein seen during 
expression. 
It was because of this truncated expressed protein as well as the presence of mutations 
within the cloned gene, the unexplained purification of a smaller 70 kDa protein (expected a 
92 kDa fusion protein) and the activity of a 55 kDa protein, that the synthesis of TbMSP-C 
and TcoMSP-C constructs with E. coli optimised genes were considered. These constructs 
were used to express and purify full-length MSP-C, of 71 kDa, from both species. The 
purified protein still contained the proregion; hence the larger size than when compared to 
MSP-C in parasite lysate (Figure 3.15, Section 3.3.4). Purification of the protein was 
performed using anti-Tb/TcoMSP:303-314 peptide antibodies coupled to a hydrazide resin. It 
was unexpectedly seen that both rTbMSP-C and rTcoMSP-C were detected and further 
purified with this antibody. As mentioned in chapter 3 (Section 3.4), it was accepted that 33% 
identity in the selected MSP peptide epitopes would be the minimum requirement for cross-
reactivity (Benjamin and Perdue, 1996; Dougan et al., 1998). Similarly, TbMSP-C and 
TcoMSP-C share 42% identity with Tb/TcoMSP:303-314 peptide and the cross-reactivity of 
this antibody was not unforeseen. Furthermore, TvMSP-C also shares 42% identity with the 
peptide; therefore, this anti-peptide antibody would be expected to detect the T. vivax 
species as well. However, this antibody was unable to detect native MSP-C in neither 
T. brucei nor T. congolense parasite lysates (Figure 3.15, section 3.3.4).  
The anti-TbMSP:400-412 peptide antibody showed a low level detection of rTcoMSP-C (with 
ECL only) but a high level of detection of tTbMSP-C, although this cross-reactivity was 
expected, since this antibody showed detection of both native TbMSP-C and TcoMSP-C in 
parasite lysate (Figure 3.15, section 3.3.4). Anti-TvMSP:686-697 peptide antibodies showed 
no detection of either tTbMSP-C or rTcoMSP-C, and remains a T. vivax specific antibody.  
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The possible multimerisation of MSP-C was assessed and it was found that the enzyme 
from both T. brucei and T. congolense was shown to be greater than 170 kDa on a non-
reducing SDS-PAGE and greater than 250 kDa in molecular exclusion chromatography. This 
is evidence that the protein forms multimeric complexes. At a size of ~70 kDa for each 
monomer, the multimer comprises of 3.5 monomers or greater. Since the multimer could be 
visualised within a non-reducing SDS-PAGE gel and there is evidence that the range for a 
10% bis-Tris polyacrylamide gel is 20-300 kDa (Spectra Multicolor High Range Protein 
Ladder example), this suggests that MSP-C is present as a tetramer (280 kDa) or pentamer 
(350 kDa) but is unlikely larger than this. Leishmanolysin has been shown to be active as a 
monomer or dimer while oligomeric forms have been detected in parasite membranes 
(Soteriadou et al., 1988). Furthermore, other metalloproteases like meprin and 
aminopeptidase, have been detected as multimers as well (Bertenshaw et al., 2003; 
Appolaire et al., 2014). Interestingly, GPI-PLC, an enzyme that has a similar function to 
MSP-B in Trypanosoma, has been shown to form tetramers (Armah and Mensa-Wilmot, 
2000). 
The MSP-C enzyme showed activity using the H-Suc-Leu-Tyr-AMC peptide substrate and 
this activity was inhibited by the metalloprotease inhibitors: EDTA and 1,10 phenanthroline 
as expected (Chaudhuri et al., 1989; Bangs et al., 1997; Cuevas et al., 2003; Grandgenett et 
al., 2007). The detection of enzyme activity, in the presence of the proregion, was not 
unexpected since leishmanolysin was shown to have latent activity in the presence of its 
proregion (Macdonald et al., 1995) and it was shown here that tTbMSP-C had both a fully 
active 55 kDa form and a latently active 70 kDa form. Further work to assess the effects of 
the removal of the proregion is required. The removal of the proregion is possible with 
chemicals such as APMA (4-Aminophenylmercuric acetate) or organomercurials (Stricklin et 
al., 1983; Van Wart and Birkedal-Hansen, 1990; Macdonald et al., 1995; Shapiro et al., 
1995; Galazka et al., 1996), which, disrupt the cysteine switch mechanism suspected to be 
employed by these surface metalloproteases for inhibition (Macdonald et al., 1995). The 
testing of different peptide substrates to determine P-site preference of these enzymes will 
also be considered in future studies.  
The pH optimum for rTcoMSP-C was pH 4.5 while for rTbMSP-C was pH 5. It has been 
reported that leishmanolysin is an acidic protease (Chaudhuri and Chang, 1988; Chaudhuri 
et al., 1989). Conversely, literature has shown that this enzyme possesses neutral to alkaline 
pH optima (Etges et al., 1986; Ip et al., 1990). Later, it was shown that the pH optimum for 
leishmanolysin is substrate dependent (Tzinia and Soteriadou, 1991). Furthermore, the 
soluble form of leishmanolysin was also shown to be active at acidic pH as well (Ilg et al., 
1993), similar to MSP-C.  
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Further assessment of trypanosomal MSP-C activity with different substrates is required to 
determine whether this enzyme has a pH optimum at a neutral pH as well. However, 
considering the possibility that the enzyme may be secreted into the host blood stream 
(Marcoux et al., 2010), activity at physiological pH (7.2-7.4), for certain substrates, is 
probable. Substrates found within the host such as extracellular matrix components like 
collagen and fibronectin should be assessed for hydrolysis by MSP-C at a range of pH-
values.  
To assess the possibility that TcoMSP-C induces an immune response in cattle infected with 
T. congolense, infected cattle sera were used to detect rTcoMSP-C in an ELISA, as was 
done before for other trypanosomal proteases (Mendoza-Palomares et al., 2008; Pillay et al., 
2013; Mo et al., 2014; Fleming et al., 2016). Successful detection of the recombinant protein 
by sera was seen. However, non-infected sera showed high levels of non-specific detection 
as well. Whether this is due to the presence of high concentrations of protein and antibodies 
that resulted in protein-protein interaction or due to the presence of anti-TcoMSP-C IgG 
within non-infected sera is uncertain. Further optimisation of the ELISA is required to 
maximise antigen detection but minimise non-specific background detection before 
determining the sensitivity and specificity of the MSP-C antigen as a diagnostic target. 
However, the requirement for diagnostic tests against trypanosomiasis, to be able to 
distinguish between current and post infection is a necessity. It would, therefore, be more 
beneficial to focus on an antigen detecting test rather than an antibody detecting test as is 
already available for different trypanosomiasis infections (Büscher et al., 2014; Birhanu et 
al., 2015; Jamonneau et al., 2015).  
In conclusion, MSP-C from both T. brucei and T. congolense, were successfully expressed 
and purified and were subjected to further analyses. The enzymes were shown to form 
multimers under non-denaturing conditions and were shown to have acidic pH optima. 
Furthermore, it is suspected that MSP-C is able to induce an immune response during 
trypanosome infection in cattle. A number of additional analyses are required to further 





Human African trypanosomiasis (HAT) and animal African trypanosomiasis (AAT) are two of 
the many neglected tropical diseases on the continent negatively affecting health, agriculture 
and the economy. These diseases are caused by protozoan parasites particularly 
Trypanosoma brucei, T. congolense and T. vivax. Trypanosomal parasites have a dual life 
cycle: within a mammalian host and within the tsetse fly vector (Glossina spp). Within its 
host, it is an extracellular parasite which multiplies in the blood causing disease symptoms 
and eventually death, if untreated.  
The number of HAT cases are declining, which suggests that disease transmission is under 
control (Tiberti et al., 2013). As infected populations decline; more sensitive diagnosis is 
required to accurately diagnose HAT and eradicate it from the continent. On the other hand, 
bovine trypanosomiasis (a form of AAT) control has been less effective as the parasites 
have spread to previously trypanosome free areas (Majekodunmi et al., 2013; 
Abdoulmoumini et al., 2015; Odeyemi et al., 2015).  
Diagnostic tests are often required to follow the WHO ASSURED criteria [(Affordable, 
Sensitive, Specific, User‐friendly, Rapid and robust, Equipment‐free and Deliverable to 
end‐users); (Peeling et al., 2006)] to be viable which is particularly applicable for HAT and 
AAT due to the environments where the diseases occur. Often these types of tests involve 
immunochemical reactions for the detection of antibodies (Büscher et al., 2014; Birhanu et 
al., 2015; Jamonneau et al., 2015). Diagnostic tests that can distinguish between post and 
current infection are still necessary. Both diseases are still treated with drugs that have been 
on the market for over 25 years and are becoming ineffective with increasing drug resistance 
(Barrett et al., 2007; Alsford et al., 2013; Munday et al., 2015). Therefore, there is a need to 
identify novel virulence factors and diagnostic targets to help in the fight against HAT and 
AAT. 
Good diagnostic targets are those that are expressed in the host blood stage form of the 
parasite. These targets either need to be expressed at high enough levels to be detected or 
need to be immunogenic enough to induce an immune response in the host to allow 
detection of the resulting antibodies. Proteases from these parasites are often virulence 
factors (Grellier et al., 2001; Lalmanach et al., 2002; LaCount et al., 2003; Marcoux et al., 
2010) that elicit high levels of antibodies.  
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One such factor may be the MSPs of trypanosomes. These zinc M8 metalloproteases were 
first found in leishmanial parasites (Russell and Wilhelm, 1986). Later, a number of putative 
gene and protein sequences of these MSPs were identified in trypanosome species, 
including T. brucei and T. congolense (El-Sayed and Donelson, 1997a; Marcoux et al., 
2010). MSPs are separated into five classes (-A, -B, -C, -D and -E) within trypanosome 
species. It has been shown by mRNA northern blot analyses that T. brucei contain classes 
A, B and C only (LaCount et al., 2003), while, T. congolense contains all five classes 
(Marcoux et al., 2010). These proteases are expressed in both the procyclic and blood stage 
form of the parasites where they have been identified as a virulence factor (LaCount et al., 
2003; Grandgenett et al., 2007; Marcoux et al., 2010). Some of these MSP genes are 
present as tandem repeats. (El-Sayed and Donelson, 1997a; LaCount et al., 2003) which 
may indicate that they are required in high levels by the parasite while others are expected 
to be secreted.  
This study set out to investigate MSPs from the African trypanosomes: T. brucei, 
T. congolense and T. vivax to determine their potential as diagnostic markers and highlight 
characteristics of the enzyme to deduce possible novel functions. The sequenced T. vivax 
genome was examined and putative MSP sequences were used to perform a number of 
bioinfomatic analyses. This subsequently allowed for the identification of conserved and 
non-conserved regions from the two MSP classes, MSP-B and -C, from the three 
trypanosome species. Epitope prediction software was used to select three immunogenic 
peptides from protein sequences of MSPs for the production of two forms of anti-peptide 
detection molecules: full IgY antibody and single chain variable fragments (scFvs). The 
anti-peptide antibodies, raised in chickens, were used to detect native MSP in parasite 
lysates. Furthermore, the TbMSP-C gene was cloned and expressed in E. coli. However, 
due the numerous truncated proteins present during expression (tTbMSP-C), rTbMSP-C and 
rTcoMSP-C constructs were commercially synthesised. Both rMSP-C proteases were 
recombinantly expressed and purified and it was determined that these proteases form 
multimers under non-denaturing conditions and are optimally active at acidic pH. The sera of 
T. congolense infected cattle were shown to detect rTcoMSP-C in an ELISA format. 
Before assessing these MSPs as diagnostic markers, various analyses of T. vivax MSPs 
were performed. Putative M8 metalloprotease genes were identified previously within the 
T. vivax genome (Jackson et al., 2012). In the present study, nine putative metalloprotease 
sequences for T. vivax were found which were then phylogenetically classed into MSP-A, -C, 
-D and -E, based on their identity with other MSPs from T. brucei, T. congolense, T. cruzi 
and leishmanolysin from L. major (using BLASTp). The absence of a sequence resembling 
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MSP-B was unforeseen. These sequences were subjected to bioinfomatic analyses as a 
parallel to the work done by Marcoux et al. (2010) for T. congolense. 
All the MSP gene sequences identified contained the HEXXHXXGF truncated active site 
motif unique to M8 metalloprotease and the third histidine ligand required for zinc binding 
~60 amino acid residues downstream. TvMSP-A and -E were predicted to be GPI-anchored 
to the surface of the parasite while TvMSP-D is unlikely to be GPI-anchored as seen in other 
trypanosome species (Cuevas et al., 2003; LaCount et al., 2003; Marcoux et al., 2010). It 
was unexpected that TvMSP-C was predicted to be GPI-anchored to the surface of the 
parasite, unlike other MSP-C proteases (Marcoux et al., 2010). There were a number of 
putative T. vivax MSP-C sequences identified during phylogenetic classification and one 
sequence was selected to represent TvMSP-C. These putative sequences may represent a 
tandemly repeated gene within the T. vivax genome. However, no other MSP-Cs were 
tandemly repeated and all appeared as a single gene within the species’ genome (Voth et 
al., 1998; LaCount et al., 2003; Marcoux et al., 2010). GPI-anchor prediction 
(http://gpcr.biocomp.unibo.it/predgpi/) was done on the unused sequences (CCD18122.1, 
CCD19977.1, CCD21328.1, CCD20103.1) from the T. vivax genome and it was found that 
two were weakly probable and two were highly probable (like TvMSP-C) to have an anchor. 
These characteristics of TvMSP-C (and sequences CCD20103.1 and CCD21328.1) 
resemble MSP-Bs from other species and so it was hypothesised that ‘TvMSP-B’ may have 
higher identity with MSP-Cs from other species, rather than MSP-Bs as assumed. 
Sequences CCD18122.1 and CCD19977.1 would then represent the true MSP-C class from 
T. vivax which lacks the GPI-anchor as expected. Nevertheless, this is speculative and it is 
possible that T. vivax lost the MSP-B gene and uses MSP-A and -E as a replacement. 
These forms have been shown to have similar properties to MSP-B [work done here and 
(Marcoux et al., 2010)]. To date, the TvMSP-B gene remained unidentified. 
Three-dimensional modelling of the four putative sequences was done to identify key 
characteristics that MSPs may have, in comparison to leishmanolysin. It was found that all 
T. vivax MSPs have three domains. The N-terminal domain contained helix A and helix B 
with the active site motif. The central domain contained a Met-turn, helix C and the third 
histidine ligand while the C-terminal domain contained two anti-parallel β-sheets leading into 
a β-sheet sandwich. All these structural elements are present in leishmanolysin 
(Schlagenhauf et al., 1998), as well as a number of metzincin metalloproteases (Stocker et 
al., 1993).  
The three histidines were in optimal position for zinc binding. TvMSP-A and -E were 
predicted to be compact enzymes with a conformation closely resembling that of 
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leishmanolysin, while TvMSP-C and -D contain extra regions making their conformations 
unique. The propeptide region was also included during modelling to assess the possible 
mechanism of enzyme inhibition. TvMSP-A and -E show propeptide folding as a lid over the 
active site as expected by analogy with leishmanolysin which would explain the latent activity 
seen for leishmanolysin in the presence of its proregion (Macdonald et al., 1995). On the 
other hand, TvMSP-C and -D proregion showed little active site interference which was 
attributed to the method the three-dimensional modelling software uses. This bioinformatic 
study reinforced what was known previously i.e. that these proteases are highly conserved 
across species, genera and families which indicates that they must have some significant 
function within all these protozoan parasites (Chaudhuri and Chang, 1988; Etges, 1992; 
Ramamoorthy et al., 1992; El-Sayed and Donelson, 1997a; Cuevas et al., 2003; Jesudhasan 
et al., 2007; Marcoux et al., 2010; Oladiran and Belosevic, 2012).  
To establish whether these MSPs could be novel diagnostic markers, a number of 
preliminary studies were done. The first was the production of anti-peptide antibodies (whole 
IgY and scFvs) which were assessed for specificity against different MSPs from different 
trypanosomal species. The production of antibodies that can detect parasitic antigen is the 
basis for an antigen detection diagnostic test.  
This was done by determining conserved and non-conserved regions within T. brucei, 
T. congolense and T. vivax MSP sequences. These regions were subjected to epitope 
prediction, using Predict7 software (Cármenes et al., 1989), to determine peptides with high 
immunogenicity for their use in anti-peptide antibody production. Three peptides were 
selected to produce antibodies to detect 1) TbMSP-B and TcoMSP-B (peptide 
Tb/TcoMSP:303-314; cross-species), 2) detect only TbMSP-C (peptide TbMSP:400-412) 
and 3) detect only TvMSP-C (peptide TvMSP:686-697). They were used to generate two-
types of detection molecules; complete IgY anti-peptide antibodies and scFvs, with the 
capability of detecting their respective peptide in an ELISA format.  
The ability of the IgY anti-peptide antibodies to detect native MSP was assessed by probing 
blood stage form T. brucei and T. congolense parasite lysate, in a western blot. Their 
specificity was further assessed on recombinantly expressed tTbMSP-C, rTbMSP-C and 
rTcoMSP-C. The anti-Tb/TcoMSP:303-314 peptide antibody was shown to detect a 63 kDa 
protein, in both T. brucei and T. congolense lysate, expected to be native MSP-B. 
Furthermore, these antibodies were able to detect tTbMSP-C, rTbMSP-C and rTcoMSP-C.  
By comparison TvMSP-C, like TbMSP-C and TcoMSP-C, shares 42% sequence identity with 
the peptide and may also be detected with this antibody. This evidence suggests that the 
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anti-Tb/TcoMSP:303-314 peptide antibody is a true cross-trypanosomal species detecting 
antibody allowing detection of all three African Trypanosome species.  
Anti-TbMSP:400-412 showed detection of a smaller 53 kDa protein in both T. brucei and 
T. congolense parasite lysates expected to be active MSP-C with the proregion removed. As 
expected tTbMSP-C was detected with anti-TbMSP:400-412 peptide antibodies as well. But, 
this antibody also detected rTcoMSP-C. The cross-reactivity seen here was not expected 
since the peptide only shares 38% identity with the corresponding TcoMSP-C sequence. 
However, detection of rTcoMSP-C was only seen using ECL, which is a highly sensitive 
technique and, therefore, the antibody showed preference for tTbMSP-C. This cross-
reactivity of the anti-TbMSP:400-412 peptide antibody implies that it is not species specific 
as originally suspected and the high level of identity between the MSPs made finding 
species specific antibodies difficult. 
Anti-TvMSP:686-697 peptide antibody detected no protein in either species lysate nor for 
tTbMSP-C or rTcoMSP-C, as expected. Although the specificity of this antibody against 
T. vivax proteins remains to be tested, it appears to be T. vivax specific, showing no 
cross-reactivity with T. brucei or T. congolense proteins. It shares less than 10% identity with 
the TbMSP and TcoMSPs. Therefore, for further species specific peptide design, percentage 
identity of 10% or less should be considered. A peptide specific for T. brucei MSPs needs to 
be redesigned and a peptide designed for T. congolense MSPs needs to be selected from 
the unique regions already identified. 
The development of scFvs using the Nkuku® phage display library against each peptide was 
also done. It was possible to produce individual colonies using this technology that express 
scFvs that can detect the peptide antigen. However, further work to express and purify 
individual scFvs needs to be done (Van Wyngaardt et al., 2004). The detection abilities and 
specificity of these scFvs also needs to be tested, as was done for the IgY anti-peptide 
antibodies. Similarly, a nanobody library was developed against T. congolense that is able, 
in vitro, to detect experimental infection and can be used as a test of cure (Odongo et al., 
2016). These antibody molecules can also be selected to produce detection fragments with 
improved thermal stability (Brockmann et al., 2005; Miller et al., 2010). Thermal stability 
studies, comparing IgY antibodies to scFvs, will be done to identify a better detection system 
in hot semi-arid climate, where trypanosomiasis is prevalent.  
An alternative diagnostic test detects host antibodies within infected blood or sera (Büscher 
et al., 2014; Birhanu et al., 2015; Jamonneau et al., 2015). To establish whether MSP 
antigens could be used as a diagnostic marker in this diagnostic test, T. congolense infected 
cattle sera were used to detect rTcoMSP-C in an ELISA format. The sera were able to detect 
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rTcoMSP-C, however, high background signal was obtained from the non-infected sera as 
well. This showed that TcoMSP-C induces an immune response during a trypanosome 
infection. Further optimisation of this assay is required before assessing the specificity and 
sensitivity of this antigen as a diagnostic target, as was done previously for TcoMSP-D, 
Tc38630, GM6 and p310 antigens (Marcoux et al., 2010; Mochabo et al., 2013; Pillay et al., 
2013; Fleming et al., 2016). The ability of T. congolense infected sera to detect rTbMSP-C 
will also be assessed, however, due to the high cross-reactivity seen for the anti-peptide 
antibodies, it is expected that cross-reactivity will occur here too.  
Although, the potential of MSPs to be novel diagnostic markers has been shown in 
preliminary studies, further work as highlighted here, needs to be done. The highly 
conserved nature of these proteases, within Trypanosoma, makes them more suited as a 
cross-trypanosomal species detecting agent. More analyses to determine the possibility of 
species-specific detection is required, although anti-peptide antibodies against T. vivax 
MSP-C showed no cross reactivity with other species’ MSPs.  
These proteases have been identified as virulence factors, however, little is known about 
their function within trypanosome parasites, especially the MSP-C class. The latter class of 
protease remains of particular interest, since it is not detected on the surface of the parasite 
(Shimogawa et al., 2015), but has been suggested to be secreted (Marcoux et al., 2010) and 
gene expression of TbMSP-C is only present within the blood stage form of the parasite 
(LaCount et al., 2003). It was for these reasons that research into this class of MSP was 
done by performing initial characterisation on the recombinantly expressed protein. 
The cloning and expression of TbMSP-C yielded numerous truncated forms of the protein 
thought to result from the presence of rare codons within the sequence (Rosano and 
Ceccarelli, 2014). Therefore, in the present study it was called truncated (t)TbMSP-C. Most 
importantly, expression of the cloned gene resulted in a full length fusion protein of 92 kDa 
(26 kDa GST tag + 66 kDa TbMSP-C). However, after immunoaffinity purification using 
anti-TbMSP:400-412 peptide antibodies, a 70 kDa protein was purified. Additionally, 
full-length 92 kDa and smaller protein products were also present. This purified tTbMSP-C 
was assessed for activity using gelatin zymography. It was interesting to observe both 
latently active 70 kDa and fully active 55 kDa protein in the zymogram.  
This is expected when the enzyme is in the presence or absence of its proregion, 
respectively, as seen for leishmanolysin previously (Macdonald et al., 1995). The active form 
of the protein is expected to be present due to the numerous truncated proteins formed 
during expression and is unlikely due to an autocatalytic activity of this enzyme. 
Leishmanolysin shows no autocatalytic activity (in cis or in trans) and is believed to be 
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inhibited by its proregion via the cysteine switch mechanism (Macdonald et al., 1995). This is 
where a conserved cysteine’s sulfhydryl group binds the zinc cofactor, blocking the active 
site. All MSPs have a conserved cysteine residue (except TcoMSP-B1) and are suspected to 
be inhibited in a similar manner.  
Due to a number of shortcomings in the expression and purification of tTbMSP-C that could 
not be explained, TbMSP-C and TcoMSP-C constructs were commercially synthesised for 
expression in E. coli. These two enzymes (recombinant (r)TbMSP-C and rTcoMSP-C) were 
successfully expressed and purified and additional characterisation was done. Unexpectedly 
both rTbMSP-C and rTcoMSP-C formed multimers in non-reducing conditions which were 
deduced to be tetramers or pentamers. Older literature reports the identification of oligomeric 
forms of leishmanolysin (Soteriadou et al., 1988), but no other evidence exists that this 
protease forms multimeric complexes. Further studies on the native protease are required to 
determine whether these multimeric complexes form naturally or whether this assembly of 
protein complexes is due to the recombinant expression environment of the proteases. 
Prokaryotic expression systems lack the ability to perform glycosylation which may be 
required for proper protein folding. This may result in soluble or insoluble protein aggregates 
(De Marco et al., 2005). 
These multimers did not affect the activity of the enzyme as both rTbMSP-C and rTcoMSP-C 
were able to hydrolyse the H-Suc-Leu-Tyr-AMC peptide substrate. The selection of this 
substrate was based on the P-site preferences determined for leishmanolysin (Bouvier et al., 
1990). This activity was shown to decrease in the presence of increasing concentrations of 
metalloprotease inhibitors, EDTA and 1,10 phenanthroline. These activity assays were 
preliminary and further enzymes kinetics will be done. This includes the hydrolysis of a range 
of peptide substrates (H-Tyr-AMC, H-Leu-AMC, H-Ala-AMC, H-Phe-AMC, H-Arg-AMC, H-
Met-AMC) to determine the P1 site preference for each enzyme and inhibition studies using 
a range of inhibitors (E64, AEBSF, pepstatin A, leupeptin, phosphoromidon, EDTA, 1,10 
phenanthroline) specific for each protease family. The observed activity of rTbMSP-C and 
rTcoMSP-C was in the presence of the proregion and is expected to be latent activity, as 
observed for leishmanolysin (Macdonald et al., 1995) and tTbMSP-C. Further work on 
enzyme activity of each protease without the proregion, is required. The employment of the 
cysteine switch mechanism of inhibition by MSPs can be disrupted by chemicals such as 
APMA and organomercurials (Stricklin et al., 1983; Van Wart and Birkedal-Hansen, 1990; 
Macdonald et al., 1995; Shapiro et al., 1995; Galazka et al., 1996).  
The pH optimum for rTbMSP-C was found to be pH 5, while, that of rTcoMSP-C was pH 4.5. 
This favouring of acidic pH was seen for leishmanolysin (Chaudhuri and Chang, 1988; 
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Chaudhuri et al., 1989), however, was found to be substrate dependent (Tzinia and 
Soteriadou, 1991). This enzyme is also active at neutral to basic pH (Etges et al., 1986; Ip et 
al., 1990). It is suspected that these differences in pH optima are a regulatory mechanism of 
leishmanolysin which allows it to select for certain substrates in certain environments (Tzinia 
and Soteriadou, 1991; Ilg et al., 1993). Assessment of the ability of rTbMSP-C and 
rTcoMSP-C to cleave different substrates at different pH-values still needs to be done. 
However, activity at physiological pH is expected considering that MSP-C might be secreted 
into the host blood stream. The cleavage of substrates that may be present within the host, 
such as extracellular matrix components, will be assessed. This may help deduce possible 
functions of MSP-C, since other proteases within Trypanosoma also function to cleave 
extracellular matrix components (Bastos et al., 2010; de Sousa et al., 2010). 
The MSP-C proteases from both T. brucei and T. congolense were shown to have similar 
characteristics. The multimerisation of the proteases was unique in that this has only been 
reported for MSP once before (Soteriadou et al., 1988). Furthermore, the pH optimum at 
acidic pH suggests activity in a non-physiological environment although, the pH optimum of 
these proteases has been shown to be uniquely substrate dependent (Tzinia and 
Soteriadou, 1991). Further analyses on the activity of these proteases from T. brucei and 
T. congolense still need to be done, however, the detection of the smaller active form of 
native MSP-C, in parasite lysate in the present study, has provided evidence that these 
proteases are active within the parasite. 
Additional studies that could be done on these proteases are described below. These 
include determining the cellular localisation of Trypanosoma MSP-B using confocal 
microscopy as was done previously with leishmanolysin from L. braziliensis (Cuervo et al., 
2008). Furthermore, the identification of MSP-C in the parasite culture medium would give 
evidence of a secreted protein as was shown for other secreted matrix metalloproteases 
within mouse and human cell lines (Lewis et al., 2000; Duellman et al., 2015). The 
identification of a secreted MSP-C protease has significant benefits since the diagnostic 
capability of these MSPs would benefit from a secreted antigen and the function of this 
protease within the host blood would be of interest.  
To assess whether these proteases could be possible drug targets and, therefore, treatment 
options, they need to be essential genes required for parasite survival and life cycle 
progression. RNA interference (RNAi) studies have the ability to diminish mRNA levels of a 
specific targeted gene and hence protein levels within a cell.  
Therefore, this method would be useful to assess whether MSP-B and -C are essential for 
the parasite as was demonstrated for TbMSP-B (Grandgenett et al., 2007). This study 
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showed that TbMSP-B, as well as GPI-phospholipase C, are both essential for parasite 
differentiation from blood stage to procyclic forms within the host (Grandgenett et al., 2007). 
The absence of these proteins within parasites also showed diminished parasite 
proliferation. Furthermore, immunisation of mice with rMSP-B or -C before parasite infection 
could give insight into the necessity of these proteases as was done before for TcoMSP-D 
(Marcoux et al., 2010). Unexpectedly, the study showed increased susceptibility to 
parasitaemia of previously immunised mice. A better outcome to such a study would be 
increased mouse survival after parasite infection which would indicate the possible use of 
MSPs for treatment.  
In conclusion, the MSPs from African trypanosomes are an interesting group of proteases 
which have been shown to possess unique characteristics as a group of proteases and 
across species and genera. They were shown to be novel diagnostic targets. However, the 
high level of identity between species MSPS resulted in cross-reactivity in their detection by 
anti-peptide antibodies and further work to produce species-specific detection molecules is 
required. Additionally, detection of the native antigen was shown in parasite lysate. The 
native antigen must be detected in infected sera or blood as well, to be useful for the 
development of a diagnostic test. The detection of active native MSP-C, from both T. brucei 
and T. congolense, was reported for the first time. The function of MSP-C remains significant 
due to their expected secretion by these parasites, directly into the mammalian host. We 
have shown that rTbMSP-C and rTcoMSP-C form high molecular weight multimers and have 
acidic pH optima. Further assessment of their activity is required to determine possible 





Sequence Identities and Alignments 




TbMSP TcoMSP TvMSP 
TcMSP 
(gp63)  








TbMSP A ID 31% 26% 48% 31% 32% 24% 22% 28% 36% 25% 19% 32% 36% 36% 29% 24% 
B 31% ID 27% 32% 53% 56% 29% 19% 32% 31% 23% 18% 34% 44% 44% 34% 27% 
C 26% 27% ID 29% 27% 28% 48% 19% 25% 25% 30% 17% 27% 28% 30% 32% 22% 
TcoMSP A 48% 32% 29% ID 33% 33% 27% 23% 29% 32% 25% 20% 33% 36% 36% 33% 27% 
B1 31% 53% 27% 33% ID 87% 27% 19% 31% 30% 24% 18% 35% 47% 46% 33% 28% 
B2 32% 56% 28% 33% 87% ID 27% 20% 32% 32% 24% 19% 35% 49% 48% 33% 30% 
C 24% 29% 48% 27% 27% 27% ID 19% 27% 24% 31% 17% 27% 28% 28% 33% 22% 
D 22% 19% 19% 23% 19% 20% 19% ID 18% 21% 17% 42% 20% 21% 20% 20% 20% 
E 28% 32% 25% 29% 31% 32% 27% 18% ID 25% 23% 18% 43% 35% 34% 29% 24% 
TvMSP A 36% 31% 25% 32% 30% 32% 24% 21% 25% ID 22% 19% 28% 32% 33% 29% 24% 
C 25% 23% 30% 25% 24% 24% 31% 17% 23% 22% ID 15% 21% 25% 25% 26% 20% 
D 19% 18% 17% 20% 18% 19% 17% 42% 18% 19% 15% ID 18% 19% 19% 18% 20% 
E 32% 34% 27% 33% 35% 35% 27% 20% 43% 28% 21% 18% ID 37% 37% 32% 24% 
TcMSP 
(gp63) 
B1 (Ia) 36% 44% 28% 36% 47% 49% 28% 21% 35% 32% 25% 19% 37% ID 92% 35% 28% 
B2 (Ib) 36% 44% 30% 36% 46% 48% 28% 20% 34% 33% 25% 19% 37% 92% ID 35% 28% 
C    (II) 29% 34% 32% 33% 33% 33% 33% 20% 29% 29% 26% 18% 32% 35% 35% ID 25% 
 Lmgp63 24% 27% 22% 27% 28% 30% 22% 20% 24% 24% 20% 20% 24% 28% 28% 25% ID 
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Figure A1: Amino acid sequence alignment of all Major Surface 
Proteases from T. brucei, T. congolense, T. vivax, T. cruzi and 
leishmanolysin. # denotes almost conserved cysteine with in the 
propeptide. ^ denotes 18 fully conserved cysteines. * denotes 12 
semi-conserved prolines (11 or more sequences contain a proline at 
that position). Black line indicates truncated zinc binding motif 
HEXXHXXGF. Dotted line represents the Met-turn. Sequences 
obtained from NCBI and accession numbers are as follows; TbMSP-A1 
(AAB61263.1), TbMSP-B (AAX79769.1), TbMSP-C (AAO72980.1), TcoMSP-
A (CCC95375.1), TcoMSP-B1 (CCD15541.1), TcoMSP-B2 (CCD15540.1), 
TcoMSP-C (CCC93446.1), TcoMSP-D (CCC95354.1), TcoMSP-E 
(CCC95375.1), TcMSP-B1 (AAP22090.1), TcMSP-B2 (AAP22091.1), 
TcMSP-C (AAP22092.1) and Lmgp63 (AAC39120.1). T. vivax sequences 
included but discussed in chapter 2 TvMSP-A (CCC52269.1), TvMSP-C 
(CCD18177.1), TvMSP-D (CCC53317.1), TvMSP-E (CCC53338.1). 
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Primary Structural Analyses 
3Table A2: Total number of amino acid residues and size of various Major Surface 
Proteases from T. brucei, T. congolense, T. vivax, T. cruzi and leishmanolysin. 
 
Protein 
Total number of 
amino acid residues 
Size 
(kDa)  
TbMSP-A1 622 68 
TbMSP-B 587 64 
TbMSP-C 591 66 
TcoMSP-A 572 63 
TcoMSP-B1 558 60 
TcoMSP-B2 540 58 
TcoMSP-C 580 64 
TcoMSP-D 678 75 
TcoMSP-E 580 63 
TvMSP-A 608 68 
TvMSP-C 706 77 
TvMSP-D 695 75 
TvMSP-E 545 60 
TcMSP-B1 543 59 
TcMSP-B2 543 60 
TcMSP-C 566 62 












Figure A2: Comparison of sizes (kDa) of various MSP protein, between different species (A) or 










































1,4 Met-turn  
55Figure A3: Secondary 
structure prediction of 





PredGPI and DAS-TMfilter programmes analyses 
4Table A4: MSPs predicted to be GPI-anchored or contain a transmembrane domain. 
Familiy of MSP Accession Number Probability of GPI-Anchor* Trans-membrane Domain** 
TbMSP-A1 AAB61263.1 Highly Probable Unlikely 
TbMSP-B AAX79769.1 Probable Likely 
TbMSP-C AAO72980.1 Not GPI-Anchored Unlikely 
TcoMSP-A CCC95375.1 Probable Likely 
TcoMSP-B1 CCD15541.1 Highly Probable Likely 
TcoMSP-B2 CCD15540.1 Highly Probable Likely 
TcoMSP-C CCC93446.1 Not GPI-Anchored Likely 
TcoMSP-D CCC95354.1 Not GPI-Anchored Unlikely 
TcoMSP-E CCC95375.1 Probable Likely 
TcMSP-B1 AAP22090.1 Highly Probable Likely 
TcMSP-B2 AAP22091.1 Highly Probable Likely 
TcMSP-C AAP22092.1 Not GPI-anchored Likely 
*Using PredGPI: http://gpcr2.biocomp.unibo.it/gpipe/pred.htm  





TvMSP Bioinfomatical Analyses: raw data 
5Table A5.1 Secondary structural analyses on identified TvMSP classes: comparison between four bioinformatical databases. 
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6Table A5.2: Secondary Structure Analysis: PredGPI and DAS-TMfilter programs. 




TvMSP-A CCC52269.1 Highly Probable Likely 
TvMSP-C CCD18177.1 Highly Probable Likely 
TvMSP-D CCC53317.1 Not GPI-anchored Unlikely 
TvMSP-E CCC53338.1 Probable Likely 
 











TvMSP-A 1 92 109 TvMSP-D 1 115 132 
2 157 195 2 12 27 
3 380 390 3 410 420 
4 349 359 4 176 213 
5 421 432 5 657 668 
6 451 470 6 451 462 
7 512 519 7 525 548 
8 475 493 8 598 604 
9 21 33 9 382 400 
TvMSP-C 1 245 284 
 10 615 630 
2 180 197  11 484 508 
3 456 477 
TvMSP-E 1 160 199 
4 537 554 2 382 392 
5 7 16 3 519 538 
6 559 576 4 94 111 
7 23 28 5 476 494 
8 507 518 6 435 471 
9 424 436 7 352 359 
10 597 609 8 424 454 
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Figure A6: Cloned TbMSP-C gene sequencing compared to actual sequence including 
translated protein sequence. Sequencing done using specific gene primers and edited using the 
BioEdit. Black arrows indicate mutation in protein sequence and black line indicated deletion and 
frameshift. Stars indicate stop codons.  Black circle indicates where expressed protein would 



































-T vector map. Going anticlockwise around the 
plasmid, Amp
r
, ampicillin resistance; ori, origin of replication of double 
stranded DNA; thymidine overhang; multiple cloning site (MCS); lacZ, 
gene that codes for β-galactosidase which cleaves X-gal (5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside) into blue chromogenic product; f1 
ori, origin of replication of single stranded DNA. The vector also contains 
















Figure A7.2: pGEX 4T-1 vector map. Going clockwise around the 
plasmid, Amp
r
, ampicillin resistance; ori, origin of replication of double 
stranded DNA; lac I
q
, lac repression; Ptac, Taq promoter which induces 
expression in the presence of IPTG; glutathione S-transferase (GST) 
gene, GST and results in the expression of fusion protein; multiple cloning 
site (MCS) containing the thrombin cleavage site.   
 
57Figure A7.1: pGEM®-T vector map. 











Figure A7.3: pET100/D-TOPO vector map. Going clockwise around the 
plasmid; lac I
q
, lac repression; ampicillin resistance; ori, origin of replication 
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